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Abstract: 
Mitochondrial dysfunction is implicated in many diverse diseases, including 
cancer, diabetes, neurodegeneration (i.e. Glaucoma, Alzheimer’s and 
Parkison’s disease) and autoimmune diseases. Although a lot of common 
diseases are associated with mitochondrial dysfunction, only a very limited 
number of approved therapeutics are currently available on the market that 
directly target and normalize mitochondrial function. 
One of the most frequent inherited mitochondrial diseases is Leber’s 
Heriditary Optic Neuropahthy (LHON) that is characterized by acute vision 
loss. As first-in-class, the short chain benzoquinone idebenone was approved 
only recently by the European Medicine Agency (EMA) to treat LHON 
patients. Despite its clinical activity, this molecule has several drawbacks. 
First and foremost, idebenone displays a very short half-life in vivo, due to a 
rapid first-pass metabolism. Furthermore, idebenone depends on a single 
enzyme for its bioactivation called NQO1 (NAD(P)H:quinone oxidoreductase 
1) that reduces the quinioid core by a two-electron mechanism. However, a
large section of the general population carry a polymorphic form of the NQO1
gene (C609T) that inactivates the resulting protein. Failure to reduce
idebenone to the benzoquinol form not only results in a loss of therapeutic
activity but could also increase levels of reactive oxygen species (ROS) and
may lead to toxicity and cell death.
Using idebenone as a lead compound, a suite of analogues were 
synthesized with the aim to establish a structure activity relationship (SAR). A 
large library of analogues containing a 3-methyl-naphthoquinone core was 
prepared. The functionality and physical properties of the side chain were 
investigated and optimisation based on polarity was employed to identify the 
highest level of cytoprotection against mitochondrial dysfunction. Under these 
conditions, the ability to restore adenosine triphosphate (ATP) levels and 
provide cytoprotection was achieved by attaching an amino alcohol or 
equivalent amine to the quinone core via a four-carbon linker that utilised 
amide coupling. Restoring ATP levels is essential, as insufficient ATP levels 
may result in cell death. 
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After significant optimisation of the side chain, core optimisation was 
undertaken. The importance of the methyl substituent at the C3-position of 
the naphthoquinone core was identified. Removal of this substituent resulted 
in a drop in cytoprotection and the ability to restore ATP levels. This effect is 
proposed to be due to conjugation with glutathione that prevents the 
analogues to shuttle in and out of the mitochondria. Also a comparative 
analysis of naphthoquinone, plastoquinone and benzoquinone cores was 
completed, when tested with a common side chain. The superiority of the 
naphthoquinone core over both plastoquinone and benzoquinone analogues 
was identified as these were unable to rescue ATP levels and provide 
cytoprotection under identical conditions. Using these optimised structural 
features, a redox active dye capable of sensing a reductive stimulus such as 
NQO1 was also developed.  
Therefore, the identified analogues that are superior to idebenone require a 
naphthoquinone core with a methyl substituent in the C3 position, a side-
chain containing a four-carbon linker and an amino alcohol or equivalent 
amine attached through an amide linkage. Biological analysis in vitro 
identified 34 analogues significantly superior to idebenone out of a total of 
131 synthesised compounds. This is a significant result, as currently 
idebenone is the only therapeutic approved to treat LHON. Two of those 
analogues (70 and 80) have advanced to in vivo studies in two different 
disease models. Both new idebenone analogues were highly efficient and 
were shown to restore mitochondrial-dysfunction-induced vision loss in a 
mouse model of LHON and a rat model of diabetic retinopathy. Therefore, 
this research significantly advances the development of new therapeutics to 
treat mitochondrial dysfunction. 
As a result of the research presented in this thesis, a provisional patent was 
filed in 2017. 
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Chapter 1: Introduction 
1.1 Quinones in nature and their role in mitochondria
Quinones represent an important class of molecules, which are ubiquitous in 
nature. Quinones are compounds that contain a 1,4-quinioid ring structure (1) 
but differ in the substitution on the quinone core and the length and 
functionalization of the carbon side chain substituent. Biologically active 
quinones have two key features which are referred to as the ‘head’ and ‘tail’, 
the polar quinone core is the head and the long aliphatic chain is referred to 
as the tail.1 Due to their reversible redox-characteristics, quinones are widely 
found in nature as co-factors, antioxidants, signalling molecules and vitamins, 
including vitamin K (2) and Coenzyme Q10 (CoQ10) (3) (Figure 1).2-5 
Quinones can be broken down into three subclasses; benzoquinones, 
plastoquinones and naphthoquinones.  
Figure 1: An example of the quinioid ring structure (1) and two naturally occurring 
quinones, Vitamin K (2) and CoQ10 (3). 
Vitamin K (2) is identified as a naphthoquinone (4) as it contains a bicyclic 
ring structure derived from naphthalene (Figure 2). Plastoquinones (5) 
feature three methyl substituents and are a subclass of benzoquinones, 
which are all remaining quinones (Figure 2). In comparison, CoQ10 (3) is 
classed as a benzoquinone as it contains two methoxy and one methyl 
substituent on the quinone core (6) (Figure 2). Unless otherwise stated, in 
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this thesis, benzoquinone will refer to a quinone moiety containing two 
methoxy and one methyl substituent. These particular classes of compound 
are responsible for the transfer of electrons in many biological processes, 
particularly within the mitochondria and a disruption to these processes is 
associated with many diseases.6  
 
Figure 2: Structures of the naphthoquinone (4), plastiquinone (5) and benzoquinone 
(6) moieties.  
Mitochondria play an essential role in the production of energy within cells; 
90 % of cellular energy is provided by the mitochondria through the electron 
transport chain.7 The electron transport chain consists of four multimeric 
protein complexes located in the inner mitochondrial membrane. Electrons 
are transported along the complexes to molecular oxygen to ultimately 
produce water. Simultaneously, protons are pumped out of the mitochondrial 
matrix across the mitochondrial inner membrane by complexes I, III and IV 
(Figure 3).8 This forms an electrochemical gradient (also called mitochondrial 
membrane potential) across the inner mitochondrial membrane, which is 
utilized by complex V (also called adenosine triphosphate (ATP) synthase) 
(Figure 3). This multimeric protein complex allows the protons to re-enter the 
mitochondrial matrix and in this process ADP is phosphorylated to ATP.8-10 
 
Figure 3: Schematic diagram of the mitochondria, illustrating the shuttle of electrons 
to Complex I, III and IV and the resulting proton gradient. 
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One of the best-known physiological quinones is CoQ10 (3), which belongs to 
the class of benzoquinones and features a hydrocarbon side-chain of ten 
isoprenyl units (Figure 1). CoQ10 (3) acts as a potent, physiological 
antioxidant in its reduced form and is essential for cellular energy production 
due to its role as an electron carrier. Because of its ability to undergo 
reversible redox reactions with enzyme complexes of the mitochondrial 
respiratory chain,11,12 CoQ10 (3), is responsible for the electron transport 
between mitochondrial complexes I, II and III (Figure 3).  
1.2 Mitochondrial Dysfunction 
Electron transport through mitochondria, which is aided by quinone 
compounds such as CoQ10 (3)(Figure 1), is responsible for supplying all 
higher organisms with carbohydrate-derived chemical energy in the form of 
ATP through oxidative phosphorylation.13 However, inadequate electron 
transfer within the respiratory chain can lead to the formation of reactive 
oxygen species (ROS), which results in oxidative damage to cellular 
macromolecules such as lipids, proteins and DNA that can potentially lead to 
cell death.14  
ROS can be generated within the mitochondria at several sites of the 
electron transport chain, particularly in complexes I and III. Here, electrons 
can be lost due to ineffective electron transfer within the respiratory 
complexes as a result of inherited mutations in complex subunits. This 
process can, in turn, lead to inadequate reduction of CoQ10 (3) to the 
semiquinone by a single electron transfer (Figure 4).11 This forms a phenolic 
radical, which is the most reactive form of cellular oxygen radicals and under 
physiological conditions is immediately detoxified to less reactive compounds 
such as hydrogen peroxide by mitochondrial enzymes. In addition, other 
enzymatic processes within the mitochondria also have the ability to produce 
smaller levels of ROS.13 Under ideal conditions, quinones are reduced by a 
two-electron transfer to prevent the formation of the semiquinone radical, 
which results in a ROS (Figure 4). 
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Figure 4: Schematic representation of quinone bioactivation by a two-electron 
transfer to produce the stable hydroquinone (top) compared to a single electron 
transfer that generates the unstable semiquinone (bottom). 
A break down in this mitochondrial electron transport process and a reduction 
in these high energy molecules can result in mitochondrial dysfunction and 
can be classified into primary and secondary dysfunction.15 Primary 
dysfunction results from a mutation in a gene encoded by mitochondrial DNA 
(mtDNA) or a nuclear-encoded gene for a mitochondrial protein that is 
maternally inherited as the mother is the sole contributor of mitochondria to 
their offspring.16 In contrast, secondary dysfunction is an acquired 
dysfunction and arises from pathological events, environmental factors or 
lifestyle, that occur outside the mitochondria such as in the case of cancer, 
diabetes, neurodegeneration (i.e. Alzheimer’s, Huntington’s and Parkison’s 
disease) and autoimmune diseases.6,15,16 Despite the large variation in 
disease types, they all share the common feature of defective cellular energy 
metabolism with diminished ATP levels, abnormal oxidation metabolism and 
a surplus production of free radicals.17  
Although a lot of common diseases are associated with mitochondrial 
dysfunction, there are very few approved therapeutics available on the 
market that intentionally target and treat mitochondrial dysfunction.18 Due to 
the need for therapeutics to transfer electrons through the respiratory 
transport chain, quinone analogues, which have the ability to undergo 
oxidation and reduction, are an obvious choice as potential therapeutics. 
Currently there are various quinone analogues under investigation as 
potential therapeutics, which share varied structural features with CoQ10 (3). 
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However, the highly lipophilic tail of CoQ10 significantly limits its effectiveness 
as a potential therapeutic. Indeed, the use of naturally occurring quinones is 
limited by their pharmaco-chemical characteristics such as poor solubility, 
limited bioavailability and their broad effects on a multitude of physiological 
processes.2 Furthermore, variation of their chemical and physiochemical 
properties can lead to significant differences in pharmacological effects often 
without clear structure-activity relationships (SAR).2 
1.3 Potential Therapeutics  
Over the past decade significant progress in the development of 
mitochondrial quinone therapeutics have been made. These all contain 
similar core motifs but possess different lengths and functionality of their 
side-chain to reduce hydrophobicity and ultimately produce better 
pharmacokinetic profiles.13,19 Typically, CoQ10 is administered orally and 
because it displays poor solubility in aqueous environments, intestinal 
adsorption of dietary CoQ10 is extremely limited.2,11,14,19 Only chronic 
ingestion of large doses increase CoQ10 concentrations within the body.11 
Thus, synthetic analogues of CoQ10 with enhanced pharmaco-chemical 
characteristics are required. A variety of currently developed quinone 
analogues will be discussed in detail below. 
EPI-743 
EPI-743 (α-tocotrienol quinone, 7) is a vitamin E analogue (Figure 5) and 
belongs to the class of plastoquinones that are characterised by three methyl 
substituents on the quinoid core (Figure 1). In addition, EPI-743 also contains 
a hydrocarbon side chain that is similar to CoQ10 but only contains four 
isoprenyl units with hydroxylation of the isoprenyl unit alpha to the quinone 
core. α-Tocotrienol quinone (EPI-743, 7) is described as a natural metabolite 
of α-tocotrienol, which is a naturally occurring compound that can be isolated 
from Elaeis guineensis, which is commonly referred to as the African oil 
palm. Like CoQ10 (3), EPI-743 (7) is an electron-acceptor, possesses 
antioxidant activity and was developed by Edison Pharmaceuticals to treat 
hereditary respiratory chain diseases.20 
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Figure 5: Structure of EPI-743 (7) featuring the plastoquinone moiety with one of 
the four isoprenyl hydroxylated. 
EPI-743 (7) is in clinical trials for a variety of mitochondrial diseases, 
including Friedreich ataxia, Leigh syndrome (LS), and Lebers hereditary optic 
neuropathy (LHON).21-23 EPI-743 (7) has been shown to restore 
mitochondrial redox balance in the mitochondria of patients genetically 
diagnosed with Leigh syndrome, which is characterised by impaired energy 
synthesis and increased oxidative stress. LS arises from defects in the 
mitochondrial, nuclear or X-linked genes.23 Although the results of this trial 
were promising, only a small sample size of ten children was treated. 
Patients received EPI-743 (7) three times daily for six weeks and levels of 
reduced, oxidised and protein-bound glutathione were analysed from blood 
samples.23 At the end of the study the children showed an apparent reversal 
of disease progression. However, due to the small number of patients in this 
trial these results have to be interpreted with caution.21 
In an open label study involving a small cohort of patients approaching end-
of-life care, EPI-743 (7) was reported to improve the quality of life of patients 
with various inherited mitochondrial diseases. Notably, no serious adverse 
effects (SAE) were observed. This indicated that although the patients were 
not cured, EPI-743 (7) might have had an effect on the progression of the 
various mitochondrial diseases.24 Similarly, some LHON patients showed a 
recovery of vision when receiving EPI-743 (100 – 400 mg per dose) orally, 
three times daily.22 The halt of disease progression and some reversal of 
vision loss were seen in four of the five patients within three months.22 
Although EPI-743 (7) showed promise as a potential therapeutic for a variety 
of inherited mitochondrial diseases, it should be noted that clinical trials and 
studies at present have only been performed on small sample sizes, in a 
relatively uncontrolled manner and therefore further investigation is required.  
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Mitoquinone (MitoQ) 
Mitoquinone (MitoQ, 8) is a benzoquinone analogue containing a lipophilic 
cation, which directly targets the molecule into the mitochondria by a 
mitochondrial membrane potential dependent mechanism. MitoQ features the 
same benzoquinone moiety of CoQ10 but has a triphenylphosphonium (TPP) 
cation attached to the quinone through a 10-carbon linker with a mesylate 
counter anion (Figure 6). 
 
Figure 6: MitoQ (8) features benzoquinone moiety attached via a 10-carbon linker 
to the TPP cation. 
MitoQ (8) is a positively-charged molecule that is orally available and is an 
antioxidant that can easily pass through biological membranes including the 
blood-brain barrier and muscle cells.19 Due to its positive charge MitoQ (8) 
accumulates several hundred-fold in the mitochondria as it requires no 
specific uptake mechanism to pass through the phospholipid bilayers.25 This 
is in contrast to other quinone analogues, which distribute into extracellular 
and intracellular compartments in addition to the mitochondria. This means 
MitoQ (8) provides exceptional protection against oxidative damage.19,26  
MitoQ (8) has been investigated for multiple hereditary mitochondrial 
diseases in vivo, including Alzheimer’s disease, multiple sclerosis (MS) and 
retinopathy.27-29 MitoQ (8) was found to reduce neurological disabilities 
associated with MS as well as the suppression of inflammatory markers and 
the reduction of neuronal cell loss, which is a key underlying factor of most 
motor disabilities.27 These protective effects, as well as the reduction of 
oxidative stress levels indicate that MitoQ could be a potential new candidate 
for MS.  
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However, further experiments with MitoQ (8) in other mitochondrial diseases 
did not have the same successful outcomes. In a mouse model designed to 
investigate inherited photoreceptor degeneration (IPD) with a major 
characteristic being increased oxidative stress, MitoQ (8) was unable to 
reduce oxidative stress, restore complex I activity and glutathione (GSH) 
levels or provide any protection against IPD.28 Similarly, a placebo-controlled 
study into Parkinson’s disease showed no effect on the progression of the 
disease over the treatment period of one year.30 These unsuccessful 
outcomes indicate the need to further analyse MitoQ (8) as a potential 
therapeutic for mitochondrial dysfunction before any further conclusions can 
be made. 
SkQ1 
SkQ1 (9) is an analogue of MitoQ (8) where the benzoquinone moiety has 
been replaced with a plastoquinone moiety, which contains two methyl 
substituents (Figure 7). SkQ1 (9) also features a ten-carbon linker and a 
triphenylphosphonium (TTP) cation with a bromine counteranion. SkQ1 (9) 
can readily accumulate within the mitochondria in a similar manner to MitoQ 
(8) at a several hundred-fold concentration gradient. This is because it also 
requires no specific uptake mechanism to pass through the phospholipid 
bilayer due to its positive charge.31  
 
Figure 7: Structure of SkQ1 (9) featuring a plastiquinone moiety attached via a 10-
carbon linker to the TPP cation. 
Although SkQ1 (9) was shown to be a prooxidant at micromolar 
concentrations, at sub-micromolar concentrations it displays antioxidant 
activity.31 SkQ1 has been studied in relation to treatment of senescence, 
retinopathy, dry eye syndrome and for prolonging life.31-34 In an animal study 
investigating retinopathy in rats, SkQ1 (9) prevented the onset of retinopathy 
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as well as reducing the severity of pre-existing pathological changes in the 
retina at nanomolar concentrations.32 SkQ1 (9) has also been shown to 
prolong the lifespan of crustaceans, fungus and mice and was particularly 
effective in the early to middle stages of ageing. In mammals, the effects of 
SkQ1 (9) on ageing were also accompanied by its ability to inhibit the onset 
of age related diseases and traits.31 TPP analogues have great potential as 
therapeutics but also face issues with concentration, as high accumulation of 
the lipophilic cations in the mitochondrial matrix can result in a disruption to 
the mitochondrial membrane potential and inhibit mitochondrial respiration 
and ATP production.35 
Szeto – Schiller Peptide (SS-31) 
SS-31 (10) differs from the above analogues in that it does not feature a 
quinone moiety. SS-31 (10) is a small water soluble tetra–peptide, featuring 
an aromatic-cationic sequence with alternating aromatic and basic residues 
(Figure 8). This enables it to enter cells without requiring an active form of 
uptake (i.e. peptide transporters).36,37 SS-31 (10) uptake is thought to be 
independent of the mitochondrial membrane potential but is reliant on 
selective binding to the inner membrane.6 SS-31 (10) is an antioxidant due to 
the presence of the dimethyl tyrosine moiety as it can readily scavenge a 
variety of ROS and inhibit lipid peroxidation.36 By analogy to the 
triphenylphosphonium analogues, SS-31 (10) can concentrate approximately 
1000 – 5000-fold in the inner mitochondrial membrane.38,39 
 
Figure 8: SS-31 (10) structure featuring the aromatic-cationic structure with Arg-
DMT-Lys-Phen-NH2 fragments. 
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The effectiveness of SS-31 (10) against varying diseases associated with 
elevated ROS production has been studied in animal models. The results of 
these studies indicate that SS-31 (10) reduced the symptoms associated with 
the elevated ROS levels, and appeared to have no toxic side-effects.36 In an 
animal model investigating diabetic retinopathy, SS-31 (10) was found to 
reverse visual decline without improving glycemic control or body weight.40 In 
comparison, progressive visual decline in the untreated animals occurred 
before obvious symptoms of metabolic and ophthalmic abnormalities were 
apparent, which was accompanied by compromised glucose clearance and 
elevated blood glucose and bodyweight.40 This indicates that treating with 
SS-31 (10) in the early stages of visual dysfunction in the course of diabetes 
could possibly prevent permanent vision loss. 
Similarly, in an animal model investigating Alzheimer’s disease, SS-31 
restored altered protein expression in mice and rescued memory and 
learning deficiencies.41 This indicates that SS-31 (10) could be a potential 
therapeutic to slow down cognitive decline.41 Similar positive results were 
obtained from ischemia-reperfusion injury, Parkinson’s disease, muscle 
atrophy and weakness and metabolic syndrome indicating the potential of 
SS-31 (10) as a therapeutic.39 However, further investigation is required. 
1.4 Leber’s Hereditary Optic Neuropathy and Idebenone  
Leber’s Hereditary Optic Neuropathy (LHON’s) 
A primary dysfunction of interest is Lebers hereditary optic neuropathy 
(LHON), which is caused by single point mutations within the mitochondrial 
DNA (mtDNA).22 LHON is a disease commonly found in young males of all 
ethnic groups, between 15 – 30 years of age resulting in acute loss of vision 
leading to permanent blindness with an incidence of approximately 
1:45,000.3,42 Vision loss is observed in 50 % of male carriers but only seen in 
10 % of female carriers.26 Disease onset is painless, rapid and after affecting 
the first eye, loss of vision in the second eye occurs typically within a few 
weeks to a couple of months.3,43 Vision loss is severe and LHON presents 
with severe unilateral, followed by bilateral, loss of central and colour vision, 
which finally leads to blindness.22  
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LHON is defined as an inherited respiratory chain disorder but differs from 
other respiratory chain diseases by its restriction to the retina, whereas most 
other mitochondrial diseases affect multiple tissues, i.e. the brain, heart, 
muscles. In contrast, the pathology of LHON is highly specific and only 
affects the retinal ganglion cells.22,44 One of three mtDNA mutations are 
responsible for the majority of LHON’s cases (90-95%),45 which affect the 
nicotinamide adenine dinucleotide (NADH) dehydrogenase (ND) subunit 
genes at positions ND4 (11778G > A), ND1 (3460G > A) or ND6 (14484T > 
C). These mutations result in the dysfunction of complex I of the 
mitochondrial respiratory chain, which prevents the transport of 
electrons.22,26,46 Vision loss is in most cases permanent with the ND4 (11778 
G>A) mutation being the most abundant.42 However, in the case of ND6 
(14484T > C), some patients have been described with partial or full 
spontaneously recovered vision 1–5 years after the onset of the disease 
without any treatment.22,47  
The three classical LHON mutations impair oxidative phosphorylation, reduce 
ATP production and increase oxidative stress.26 These features can be 
explained; as a mutation of a complex I subunit results in the failure to 
transfer electrons from NADH to CoQ10 (3), which subsequently prevents 
proton pumping and the formation of the proton gradient. This failure 
ultimately stops ATP production, increases oxidative stress and results in cell 
death.4 It should be noted that no particular mutation influences the timing or 
severity of the initial vision loss and although LHON’s is hereditary and 
maternal, up to 40 % of patients have no traceable family history.48 
It is proposed that environmental factors may increase visual failure and 
explain the incomplete penetrance observed in LHON, however, there is only 
limited data to support this hypothesis. A study in 2009 showed a strong and 
consistent association between vision loss and smoking, irrespective of 
gender and alcohol intake.49 However, there was also a slight correlation 
between vision failure and alcohol consumption but only with heavy alcohol 
intake.49 Further studies are required to support these findings before any 
definitive conclusions can be made. 
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Due to the fundamental activity of CoQ10 (3) in cellular energy production, 
short-chain quinone analogues have been proposed as a therapeutic option 
for LHON. Since 2015, a synthetic benzoquinone called idebenone (11) has 
been approved by the European Medicine Agency (EMA) for treatment of 
LHON.50 However, approval was granted under the category of exceptional 
circumstances requiring further investigation and analysis. Idebenone (11), 
like CoQ10, contains a benzoquinone moiety but differs in that it features a 
short ten-carbon side chain containing a terminal hydroxy group (Figure 9). 
 
Figure 9: Structure of Idebenone (11). 
Similar to other quinone analogues, idebenone (11) acts as an electron 
carrier in the electron transport chain and is also a potent antioxidant.2,4,26 
Idebenone (11) has been investigated for a variety of disorders associated 
with mitochondrial dysfunction such as Duchene muscular dystrophy 
(DMD),51-54 multiple sclerosis (MS),55 Parkinson’s and Huntington’s 
disease,56 Friedreich’s ataxia (FDRA).57-59 In addition, in depth studies have 
evaluated the potential of idebenone (11) in LHON patients.60-62 Idebenone 
(11) was found to have consistent tendencies towards visual recovery, with 
the therapeutic benefit of idebenone (11) shown in the acute phase of the 
disease.26 In an Expanded Access Program (EAP), higher rates of clinical 
recovery were observed than expected naturally in patients, which was 
consistent with other clinical trials.62 
Despite their structural similarities, CoQ10 (3) and idebenone (11) differ 
significantly in their physiochemical properties. Due to its highly lipophilic tail 
containing the 10 isoprenyl units (50 carbon atoms), CoQ10 (3) with a logD 
value of 19.12 is sparingly soluble in aqueous environments  (LogD is the 
distribution coefficient between octanol and water at physiological pH (pH = 
7.4) and is a measurement of solubility).11 This results in very limited oral 
absorption.11 In contrast, idebenone (11) contains a 10-carbon chain with a 
O
O
MeO
MeO
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OH
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terminal hydroxyl unit and a LogD value of 3.91. This provides greater 
polarity and increases its solubility in aqueous solutions, meaning it is much 
more readily available when administered as an oral formulation.11  
In contrast to CoQ10, idebenone (11) has been reported to undergo redox 
reactions outside the mitochondria. In the cytosol, idebenone (11) is reduced 
by NQO1 (recombinant NAD(P)H:quinone oxidoreductase) in a two-electron 
dependent reduction before re-entering the mitochondria and being oxidised 
by complex III. This process regenerates the mitochondrial respiratory chain, 
regenerates the proton gradient and restores ATP synthesis.4 By this 
mechanism, idebenone (11) can effectively bypass the Complex I inhibition 
inherent to LHON. Notably, this ability has not been observed for CoQ10 (3), 
which is a direct result of its poor solubility.2,4  
Although idebenone (11) was identified as the lead compound, 70 idebenone 
(11) analogues2 were also tested for their capacity to normalise ATP levels 
under conditions of complex I dysfunction. The ability to rescue ATP levels 
was correlated to the solubility of the compounds, expressed as LogD. 
Unless analogues had a solubility in the range of 2<LogD<7 they were 
unable to restore ATP levels, which is explained by their inability to shuttle in 
and out of the mitochondria.2 A high logD value will see a compound 
effectively restricted to the lipid bilayer (i.e. membrane) and are therefore 
unable to enter either the cytoplasm or the mitochondrial matrix. In an 
extension of this study, idebenone (11) was found to increase cell viability in 
vitro and normalise ATP levels.3 In a subsequent in vivo study, idebenone 
(11) was reported to protect against RGC cell loss, retinal pathology and 
restore visual acuity in a LHON mouse model.3  
It is known that the electron transport ability of idebenone (11) is solely due to 
the quinone motif,18 but its ability to pass through the membrane and its 
association with the membrane is due to the lipophilic portion of the 
molecule.4 Idebenone (11) has two significant issues due to its structure. The 
long side-chain of idebenone (11) is readily degraded by oxidation processes 
due to its analogous structure to lipids. In addition to this, idebenone (11) is 
activated solely by NQO1.4,63  
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However, a number of inactivating NQO1 polymorphisms are described in 
the general population such as 609C>T resulting in decreased or even 
absent enzymatic activity of NQO1.14,64,65 This implies that in these 
individuals bio-activation of quinones is reduced or even absent.14,64,65 
Prevention of the inactivation of the quinone moiety is of high importance as 
failure to reduce the quinone can lead to cytotoxicity.2 The prevention of 
quinone-mediated toxicity can be achieved through the development of 
molecules that are also bio-activated even in the absence of NQO1.  
If the quinone portion is not reduced by a two-electron transfer, these 
compounds will be metabolized by the cytochrome (CytP450) enzymes as an 
attempt to detoxify the compounds in the liver. This reaction results in a 
single electron transfer, which gives rise to the unstable semiquinone and 
generates superoxide, which leads to cellular damage and can ultimately kill 
the cells.2 It should be noted that only the reduced hydroquinone form of the 
molecule is active as an antioxidant and electron carrier.14 This indicates that 
this benzoquinone moiety is not ideal as a therapeutic and as a result 
requires optimisation due to the possibility that for some individuals these 
compounds could be ineffective or even toxic. Consequently, the efficient 
two-electron reduction of quinones has to be targeted to avoid cellular toxicity 
as well as for the compounds to be of therapeutic potential. 
Naphthoquinones, such as vitamin K (2), are a related group of quinones, 
which have a common 1,4-naphthoquinone core (4) containing an aromatic 
ring fused to the quinone moiety (Figure 10). Vitamin K plays well known 
roles in post transitional modifications of proteins required for blood 
coagulation and bone metabolism.66 There is evidence that vitamin K is 
involved in maintaining brain function,67 particularly in Alzheimer’s68 and 
Parkinson’s disease.69,70 A range of naphthoquinone derivatives with differing 
lengths of the aliphatic side chains in the C2 position and a methyl group at 
the C3-position have been reported to be highly neuroprotective agents.66 In 
an animal model for epilepsy, naphthoquinone derivatives were able to 
successfully supress seizures.71 The proposed mechanism for this 
naphthoquinone-dependent protection was based on their ability to maintain 
or restore energy (ATP) production.71 
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Figure 10: Structure of the naphthoquinone core (4) with C2 and C3 positions 
denoted. 
Similar to benzoquinones, naphthoquinones are thought to be protective in 
pre-clinical disease models by modulating mitochondrial function and 
reducing oxidative stress.66,69,70 However, in contrast to benzoquinones that 
are exclusively reduced by NQO1, naphthoquinones can be reduced to the 
hydroquinone by two different enzymes, vitamin K oxidoreductase 1 
(VKORC1)72,73 and vitamin K oxidoreductase 1 like 1 (VKORC1L1)74 in 
addition to NQO1. This suggests that in individuals carrying the inactivating 
NQO1 polymorphism, naphthoquinones can still be efficiently reduced by two 
enzymes (Figure 11). Thus, the risk of generating reactive semiquinones as 
well as the associated elevated ROS production and toxicity should therefore 
be minimized. 
 
Figure 11: When naphthoquinones are reduced to hydroquinones by VKORC1, 
VKORC1L1 and NQO1, only minimal amounts of the unstable semiquinones should 
be formed. 
In 2013, derivatives of menadione (3-methyl-1,4-naphthoquinone) (12) were 
synthesised in a preliminary study by the Smith/Gueven group at the 
University of Tasmania (UTAS) to investigate whether naphthoquinone 
analogues could provide greater protection against mitochondrial dysfunction 
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in the wider population.75 Biological testing for potential therapeutics that 
could alleviate the molecular problems associated with LHON was performed 
using a synthetic Complex I inhibitor called rotenone, which replicates the 
molecular defect associated with LHON. Combining rotenone and retinal 
ganglion or HepG2 (liver) cell lines it was possible for Woolley et al.75 to 
investigate the therapeutic potential of the naphthoquinone analogues.3,4 
1.5 Preliminary Information 
In 2013, a range of analogues by Woolley et al.75 were synthesised by two 
established synthetic methods exploiting the addition of an alkyl radical by 
decarboxylation of readily available carboxylic acids. In this way, 26 
naphthoquinone analogues containing different alkyl chains at the C2-
position of menadione (12) were synthesised (Table 1).  
Table 1: Naphthoquinone analogues 13 – 38 synthesised by Woolley et al.75 in the 
2013 preliminary study. 
 
Entry R = Entry R = Entry R= 
1 a 
 
10 a 
 
19 b 
 
2 a 
 
11 a 
 
20 b 
 
3 a 
 
12 a 
 
21 c 
 
4 a 
 
13 a 
 
22 a 
 
5 a 
 
14 a 
 
23 a 
 
O
O
O
O
R
R
12
Method A
or 
Method B
or 
Method C
OH
13
OH
22
OH
O
31
14
O
23
OH
O32
15 24
O
O33
O
16 25 34
17 O O26
35
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 6 a 
 
15 a 
 
24 c 
 
7 c 
 
16 a 
 
25 c 
 
8 c 
 
17 a 
 
26 c 
 
9 a 
 
18 a 
 
a Synthesised via silver mediated radical decarboxylation76 
b Synthesised via peroxide generated radical addition to the naphthoquinone77 
c Synthesised via fischer esterification of analogues 29 or 30 
 
Biological evaluation of preliminary analogues from 201375 
Initially, analogues were tested for toxicity, as incomplete reduction to the 
semiquinone is associated with ROS production and oxidative damage. 
Endogenous toxicity was assessed in two cell lines with either high (HepG2) 
or low (RGC5) reducing capacity (Figure 12). The significantly higher IC50 in 
the HepG2 cells compared to the low reducing cell line (RGC5), indicated 
lower toxicity as well as supporting the hypothesis that the cellular reducing 
capacity of the cell line determines cellular toxicity of the quinones.  
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Figure 12: Toxicity of individual naphthoquinones measured in RGC5 and HepG2 
cell lines. Concentrations are given as [µM]. IC50: defined as reduction of cellular survival by 
50%. Note: maximal concentration tested: 200 µM. *** IC50 analysis performed by Nuri 
Gueven at the University of Tasmania, unpublished results. 
However, the most significant information obtained from the toxicity data is 
the direct comparison between idebenone (11) and the idebenone-like 
naphthoquinone derivative 13. Besides the change from the benzoquinone 
core in 11 to the naphthoquinone core in 13, both compounds are structurally 
identical (Figure 13). In both cell lines the change in the quinone core 
doubled the IC50 value, which illustrated that in otherwise identical 
compounds, a naphthoquinone moiety reduces cytotoxicity when compared 
to a benzoquinone moiety. This effect can likely be attributed to the more 
efficient reduction of the naphthoquinone core by VKORC1, VKORC1L1 and 
NQO1. It is known that HepG2 cells express high levels of NQO1,4 while the 
level of expression of VKORC1 is currently unknown. 
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Figure 13: Direct comparison of structure and toxicity levels of idebenone (11) and 
idebenone-like analogue 13. 
The naphthoquinone analogues were then evaluated for cytoprotection 
against rotenone-induced mitochondrial dysfunction in the two different cell 
lines, HepG2 and RGC5. Evaluation of cytoprotection is a five day process. 
On day one, the cells are seeded and, on day two, the cells receive a two-
day pre-treatment with the desired analogue before being subjected to a six-
hour rotenone challenge on day four. One day later (day five), ATP levels are 
measured as a percentage of the control. In both cell lines several novel 
quinones provided increased protection compared to idebenone (11) (Figure 
14). However, no clear structure activity relationship (SAR) was detected 
within this suite of analogues. Nevertheless, it was noted that idebenone-like 
analogue 13 induced a high level of cytoprotection.  
Furthermore, there were two noticeable trends, with removal of the terminal 
hydroxyl substituent of the idebenone-like naphthoquinone derivative 13 as 
seen in 10-C alkene derivative 14 and 10-C alkane derivative 15, all 
protection was lost indicating the polarity of the hydroxyl substituent is 
important. Similarly, decreasing the aliphatic chain length to between four 
and eight carbons resulted in an increase in protection. Combining these two 
features and synthesising short chain- and oxygen-containing analogues 
provided a number of compounds exhibiting cytoprotection (22, 23, 33, 35) at 
levels equivalent to idebenone (11) (Figure 14a,b).  
In addition, cytoprotection was observed to be cell line specific, which is 
surprising given the previous data reported in the literature for 
benzoquinones which demonstrated no species or tissue dependency for 
biological activity.2 The highest level of protection against rotenone-induced 
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mitochondrial dysfunction for the RGC5 cells was the ethyl ester analogue 36 
(Figure 14b). In contrast, the HepG2 cell line exhibited very little protection by 
this analogue, with idebenone-like naphthoquinone derivative 13 and 
hydroxyl-butyl derivative 22 achieving the highest protection (Figure 14a).  
 
 
Figure 14: Cytoprotection against rotenone induced complex I dysfunction by 
quinones (13 – 38) at 10µM given as a relative percentage of cell survival compared 
to untreated HepG2 (a) and RGC5 (b) cell lines. Data represents the mean of n=3 
independent experiments with 6 replicates each. 
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In line with work performed on idebenone (11) by Erb et al.,2 analogues were 
investigated for their ability to restore ATP levels in HepG2 cells only. This 
was due to the lack of activity seen in the RGC5 cell line as a consequence 
of their low reducing ability. Evaluation of ATP requires a rapid two-hour 
assay; the cells are seeded and subjected to desired derivative for one hour 
before the addition of rotenone. One hour later, ATP levels are measured as 
a percentage of the control. Due to the proposed mode of action for 
idebenone (11) as a Complex I bypass agent that restores the electron 
transport chain and ultimately cellular ATP levels, the ability for an analogue 
to provide cytoprotection was thought to correlate to its ability to restore ATP. 
For idebenone (11) (Figure 15), ATP levels were restored from 15 % to 81 %. 
However, the remaining novel naphthoquinone derivatives failed to do so. In 
particular the idebenone-like naphthoquinone derivative 13, showed no ability 
to restore ATP levels at all, whereas analogue 22 (3-hydroxybutyl side-chain) 
showed a slight improvement to 47 % in ATP levels, although nowhere near 
as substantial as idebenone (11). However, both idebenone-like 
naphthoquinone derivative 13 and hydroxylbutyl derivative 22 provided 
cytoprotection equal to that of idebenone (11). This result was surprising, as 
it suggested that an alternative ATP-independent pathway was mediating the 
cytoprotective activities of short-chained quinones. 
 
Figure 15: ATP rescue by quinones (13 – 38) at 10µM in the presence of rotenone-
induced complex I dysfunction as percentage of untreated HepG2 cells. Data 
represents the mean of n=3 independent experiments with 6 replicates each. 
-20.0 
0.0 
20.0 
40.0 
60.0 
80.0 
100.0 
D
M
S
O
 
Vi
ta
m
in
 K
 (2
) 
Id
eb
en
on
e 
11
 
M
en
ad
io
ne
 1
2 13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
31
 
32
 
33
 
34
 
35
 
36
 
37
 
38
 AT
P 
R
es
cu
e 
(%
 C
on
tr
ol
) 
Chapter	1:	Introduction	
	 22	
Given the absence of any obvious SAR in either ATP rescue or 
cytoprotection assays, cytoprotection levels were plotted against cLogP 
(partition coefficient) to determine if the same correlation with compound 
solubility was observed as previously reported.2 Previously, it was reported 
that for benzoquinones a Log P/D value of 2<LogP/D<7 was required for 
activity. However, neither cell line provided any support for this hypothesis. 
For example, hydroxylbutyl derivative 22 exhibited the highest level of 
cytoprotection in the HepG2 cell line with a cLogP value of 1.57, which is 
slightly outside of the 2<LogP<7 area, while the majority of the remaining 
analogues fell between a clogP of 2 – 7 but provided varying levels of 
cytoprotection (Figure 16). 
  
Figure 16: Viability correlation to clogP in both HepG2 (a) and RGC5 (b) cell lines 
with idebenone (11) identified by darker colouring. 
Given the success of SS-31 (10) with the unique delivery mode to the 
mitochondria and desired solubility, it was proposed a peptide functionality 
attached to the quinone moiety might show significant activity. L- 
Phenylalanine methyl ester (39) was coupled to carboxylic acid analogue 32 
(Scheme 1) to provide L-phenylalanine methyl ester derivative 40 as a 
model. This process was carried out using an amide coupling technique, 
which can readily be used to generate a large library of compounds if 
required. 
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Scheme 1: Synthesis of analogue 40 via amide coupling. 
Initial testing of L-phenylalanine methyl ester derivative 40 showed the most 
promising result from the entire initial suite of analogues. In addition to 
idebenone (11) this represented the new lead compound. L-phenylalanine 
methyl ester derivative 40 rescued ATP levels and provided cytoprotection in 
a similar manner to idebenone (11) (Figure 17). Although L-phenylalanine 
methyl ester derivative 40 is not a simple hydrocarbon and now contains an 
amide and ester functionality, the side-chain is somewhat similar in size to 
the structure of idebenone (11) and possesses similar activity. 
 
Figure 17: ATP rescue and cytoprotection against rotenone-induced complex I 
dysfunction by analogue 40 at 10µM given as a relative percentage of cell survival 
compared to untreated HepG2. Data represents the mean of n=3 independent 
experiments with 6 replicates each. 
In addition to a similar size of the structure, if the solubility requirement is 
2<LogP<7, L-phenylalanine methyl ester derivative 40 is in that target range 
with a cLogP value of 2.74. The correlation between ATP rescue and 
cytoprotection as well as the correct cLogP value implies that L-
phenylalanine methyl ester derivative 40 as well as idebenone (11) are the 
new lead structures for further analogue development. However, with limited 
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SAR and only one successful structure, it is the basis for further investigation. 
The outcome of the preliminary study was essential to improve the specific 
cytoprotective characteristics of this class of compounds and to work towards 
the development of future therapeutics that can protect against mitochondrial 
dysfunction and oxidative stress. 
1.6 Project Aims  
Based upon the previous study by Woolley and co-workers75 a number of 
aims were proposed for future analogue development, these being: 
1. Investigate the redox properties of the previously synthesised quinone 
analogues. This will identify if there is a correlation between activity 
and the ability of an analogue to undergo oxidation and reduction. 
2. Synthesise and fully characterize multiple small libraries of 
naphthoquinone analogues based on L-phenylalanine methyl ester 
derivative 40 and idebenone (11) as lead compounds with continuous 
biological testing for rapid next generation development.  
3. Develop a structure activity relationship (SAR), to identify analogues 
that have both the ability to provide cytoprotection as well as restore 
ATP levels. These will then progress to animal models. 
4. Optimize the quinone core moiety for further SAR development, to 
allow for the comparison of activity between quinone moieties. 
5. Development of peptide targeting molecules based on Szeto–Schiller 
Peptide (SS-31) (7). The conjugation of these peptides with the 
quinone moiety would potentially enable the compound to be directly 
delivered to the mitochondria.  
6. Development of a redox active dye capable of sensing a reductive 
stimulus such as NQO1 .  
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Chapter 2: Development of Structure-Activity 
Relationship (SAR) of the side chain 
2.1 Investigation into Redox characteristics of preliminary 
compounds 
Prior to synthesising new compounds, the redox properties of the 
naphthoquinone derivatives from the preliminary study were investigated. 
The current hypothesis for quinone compounds as therapeutics for electron 
shuttling in mitochondrial dysfunction has resulted in a general conclusion. 
This being, that as long as the compound can adequately pass through the 
mitochondrial membrane, then the quinone moiety should be able to restore 
the electron transport chain.2 With no obvious structure activity correlations in 
the initial suite of 26 analogues by Woolley et al.75 in the preliminary study, it 
was proposed that the cytoprotective activity observed could be explained 
through the oxidation and reduction ability of the quinone. If particular 
analogues were more easily oxidised or reduced than others, then in theory, 
their ability to provide cytoprotection would be enhanced and this could 
potentially explain the differences seen within the preliminary study. 
Therefore the redox properties of all analogues (13 – 38) and idebenone (11) 
were analysed by performing cyclic voltammetry. Idebenone (11) had an 
oxidation potential of  –0.637 V and a reduction potential of –0.714 V. 
Similarly the idebenone-like naphthoquinone derivative 13 had an oxidation 
potential of –0.768 V and a reduction potential of –0.845 V (Figure 18). 
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a)	  b)  
Figure 18: Cyclic voltammograms of a) Idebenone (11) and b) the idebenone-like 
derivative 13. 
Although there was a slight difference, there was no significant information 
obtained from this analysis, nor from the naphthoquinone derivatives (14 – 
40). However, one exception to the redox characteristics was if a carboxylic 
acid or a functionality that could undergo oxidation separately to the quinone 
core was present. Specifically, carboxylic acid derivatives 31 and 32 
underwent irreversible oxidation, via Kolbe oxidation. Kolbe oxidation leads to 
oxidative decarboxylation of a carbonate anion to generate radical 
intermediates.78,79 Although this occurs during cyclic voltammetry, it is not 
possible in the assays and therefore is not of relevance to the comparison.  
Therefore, the cytoprotective ability of the current suite of analogues (13 – 
38), which were assayed in both the HepG2 and RGC5 cell lines, were 
plotted against both their oxidation and reduction potential. Intriguingly, 
despite substantial differences with regards to the cytoprotective abilities of 
these compounds, no correlation between the reduction or oxidation 
potentials of each analogue to its cytoprotective capacity was observed in 
both cell lines (Figure 19a – d). 
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Figure 19: Protection of viability by naphthoquinones (10 mM) versus their redox 
characteristics as determined by cyclic voltammetry in two cell lines RGC5 (a,b) and 
HepG2 (c,d). Each data point is the average of 3 independent experiments with 6 
replicates within each experiment for viability and 1 experiment for cyclic 
voltammetry. Error bars were omitted for clarity. 
This strongly suggests that the redox characteristics per se do not influence 
cytoprotective function in the naphthoquinone series. Similarly, when 
comparing the benzoquinone core to naphthoquinone core, no significant 
difference in the oxidation or reduction potentials were observed, which 
indicates that the cytoprotective activity is likely associated with the specific 
functionality of the alkyl side chain rather than the specific redox-
characteristics of the quinone. This conclusion is in agreement with earlier 
studies using a range of benzoquinones.2 
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2.2 Development of Structure Activity Relationships 
2.2.1 Synthesis of analogues via silver-mediated radical 
decarboxylation 
While initially waiting on further biological data to be obtained on the L-
phenylalanine methyl ester derivative 40, an investigation into the effects of 
analogues containing perfluorinated side chain was performed. Fluorinated 
analogues were desired to prevent metabolism of the alkyl side chain, as it 
was reported in the literature that the alkyl chain present in idebenone (11) 
undergoes rapid metabolism.4,63 Formation of these analogues utilises 
radical chemistry, which enables the introduction of the alkyl chains with 
relative ease on to the naphthoquinone (Scheme 2). The alkyl radical can be 
generated by a variety of methods depending on the reaction conditions. 
Examples include Barton esters (N-hydroxypyridin-2-thione),80 peroxy acids 
to generate the radical through thermal cleavage of the weak O–O bond77, as 
well as the formation of metal salts using MnIII acetate or CeIV ammonium 
nitrate81,82.   
However, in the case of naphthoquinones the most widely utilised method 
employs silver nitrate and ammonium persulfate to generate the carbon-
centred radical. Silver nitrate forms a AgI carboxylate salt that is oxidised by 
persulfate to produce AgII which decomposes with the release of carbon 
dioxide. This provides a carbon-centred nucleophilic radical, which attacks 
the electron-deficient naphthoquinone. Oxidation of the ensuing intermediate 
delivers the substituted quinone (Scheme 2).76 
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Scheme 2: Mechanism for the introduction of the alkyl chain via the silver-mediated 
radical decarboxylation. 
Trifluorobutyric acid and 3-(trifluoro)-3-hydroxybutyric acid were utilised to 
make the initial fluorinated derivatives due to their ready availability (Table 2). 
These two acids are also functionally similar to the desired characteristics 
identified in the previous data, which indicated oxygen containing short alkyl 
chains provided the high level of cytoprotection. These analogues were 
synthesised by the silver-mediated radical decarboxylation protocol and 
isolated using flash chromatography in low to moderate yields. It is worth 
noting, the low yields are a result of un-optimised reaction conditions.  
Table 2: Synthesis of fluorinated analogues 41 and 42. 
 
Entry  Carboxylic Acid Product Yield % 
1 
 
 
35 
2 
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The formation of the fluorinated naphthoquinone analogues were supported 
by 1H NMR spectroscopy with the absence of a singlet peak at 6.84 ppm 
indicating the loss of the proton attached to the C3-position of the 2-
methylnaphthoquinone (menadione, 12) along with the additional peaks in 
the aliphatic region. Both 1H NMR and 13C NMR analysis showed complex 
splitting patterns due to the presence of fluorine substituents (fluorine is a 
half spin nucleus). Very clear splitting of the three carbon resonances for the 
propyl side chain by the three fluorine atoms was observed in the 13C NMR 
spectra for both analogues (see, for example, Figure 20). 
  
Figure 20: 13C NMR spectrum for analogue 41 illustrating the fluorine splitting 
pattern. 
In addition to fluorinated derivatives, analogues containing two alkyl chains 
were desired. Di–alkylated analogues were synthesised following the same 
method described earlier. However, naphthoquinone (4) was reacted with 
excess carboxylic acid to allow for the addition of both alkyl chains. 
Formation of the di–alkylated species proceeded in exceptionally low yields 
(Table 3). It appears the first alkylation proceeds with yields comparable to 
what was previously observed with menadione (12). However, formation to 
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the di–alkylated species proceeds in very low yields and, only from 4-
methylpentanoic acid was a di–alkylated product in 10 % yield obtained.  
Table 3: Synthesis of mono– and di–alkylated analogues of naphthoquinone (4). 
 
Entry Carboxylic acid Product Yield % Product  Yield % 
1 
 
 
35 
 
10 
2 
 
 
0 
 
0 
 
Formation of analogue 43 was supported by NMR spectroscopic analysis. A 
signal shifted upfield in the 1H NMR spectra from 6.98 ppm to 6.78 ppm, for a 
singlet integrating for two to a triplet integrating for one with allylic coupling of 
J = 1.4 Hz indicating the loss of the proton in the C2 position of the 
naphthoquinone core (4) and the new attachment of a single alkyl chain. 
Comparison of the 1H NMR spectra of the mono-alkylation product to di–
alkylated analogue supported the introduction of the second alkyl chain. The 
highly characteristic triplet at 6.79 ppm for the proton attached to the C3 
position of the quinone core was absent and all signals in the aliphatic region 
responsible for the alkyl chain had doubled in integration values relative to 
the quinone core. 
Analogues 45 and 46 could not be synthesised, which it strongly indicates 
that there was an issue with the formation of the radical. This method proved 
to be insufficient for introducing di–alkyl chains on to the naphthoquinone (4). 
Particularly when to develop SAR, a large library of analogues is required. 
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Biological evaluation of molecules 42 and 43 was investigated before this 
group of analogues were investigated further. 
The capacity of the two new fluorinated analogues (41 and 42) and the 
mono- and di–alkylated analogues of 4-methylpentanoic acid (43 and 44) to 
promote cell viability (cytoprotection) and rescue ATP levels was investigated 
by colleagues in the School of Medicine. Biological evaluation in both assays 
illustrated that fluorination or mono– or di–alkylation has no positive impact 
on the biological activity (Figure 21). 
 
Figure 21: Protection of viability and acute rescue of ATP levels against rotenone 
induced complex I dysfunction by naphthoquinones. Both cytoprotection and ATP 
rescue in HepG2 cells by naphthoquinones (10mM) are displayed as percentage of 
untreated control (no rotenone). 
Analogues (41 – 44) performed poorly in one (ATP rescue) of the two 
assays. As previously discussed with the preliminary analogues, if the 
proposed mechanism for idebenone (11) is correct, there should be a 
correlation between ATP rescue and cytotoxicity. Optimisation of the 
analogues should result in therapeutics that exhibits high levels of both. 
Therefore the four new analogues were combined with the initial suite of 
preliminary analogues and were plotted against each other to identify 
correlations. Including the four new analogues, the compounds were divided 
into characteristic groups based on the structure of the side chain (aliphatic, 
slight polarity (with reference to the straight aliphatic chains, i.e. containing 
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oxygen), acids and aliphatic esters) in an attempt to identify structure activity 
relationships (SAR). As seen in Figure 22, neither the new fluorinated 
analogues, nor the di-alkylated analogues show any significant activity when 
compared to the initial suite of compounds.  
 
Figure 22: Protection of viability versus acute rescue of ATP levels against 
rotenone-induced complex I dysfunction by naphthoquinones. Both cytoprotection 
and ATP rescue in HepG2 cells by naphthoquinones (10mM) are displayed as 
percentage of untreated control (no rotenone) with error bars omitted for clarity.  
Data represents the mean of n=3 independent experiments with 6 replicates each. 
A general grouping was observed in aliphatic and aliphatic esters, whereas 
acids and the slightly polar analogues showed varied response in both 
assays (Figure 22). The aliphatic compounds were unable to rescue ATP 
levels in the presence of the mitochondrial inhibitor rotenone, whilst having a 
varied ability to provide cytoprotection. On the other hand, aliphatic esters 
are grouped tightly but did not protect viability or rescue ATP levels. With no 
significant data obtained from the recently synthesised analogues (41 – 44) 
as seen in Figure 21 or Figure 22, L-phenylalanine methyl ester derivative 40 
still remained the lead compound. L-phenylalanine methyl ester derivative 40 
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provided the highest level of cytoprotection and is within error of idebenone 
(11) with respect to the ability to rescue ATP levels, which has not been 
exceeded by the novel naphthoquinone analogues. With analogues of L-
phenylalanine methyl ester derivative 40 containing an amino fragment high 
priority, optimisation of the synthetic approach to the carboxylic acid 
precursor 32 was required. In the preliminary study, this analogue was 
synthesised following a literature procedure77 via thermal decarboxylation of 
a peroxyacid intermediate to generate the carbon-centred radical which 
underwent thermal cleavage before addition to the quinone as shown in 
Scheme 3.  
 
Scheme 3: Synthesis of analogues 31 and 32 via a peroxyacid intermediate to 
generate the carbon centred radical.75 
However, this method is not viable for a larger scale synthesis for a number 
of reasons. Firstly, this method is extremely low yielding particularly the first 
step involving the generation of the peroxyacid intermediate (48a/b) and, 
secondly, due to safety reasons the peroxyacid intermediate was not dried 
and was used immediately upon formation.75 With this in mind, a new method 
needed to be identified, and returning to the silver-mediated method seemed 
the most viable option as it typically proceeds efficiently with 
naphthoquinones.  
Unfortunately, synthesising an acid-containing naphthoquinone derivative via 
the silver-mediated method provides products (31 or 32) that are also 
susceptible to further decarboxylation. This results in a second radical 
intermediate causing a dimer formation (52) as seen in Scheme 4. As the 
protocol utilises carboxylic acids to generate the carbon-centred radical, once 
the carboxylic acid (32) is formed, it can undergo oxidative decarboxylation 
and dimerise with a second molecule of menadione (12), resulting in 
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undesired by-products.  Bisquinone (52) was subjected to biological 
evaluation and showed no ability to provide cytoprotection. 
 
Scheme 4: Potential formation of by-product 52 during the synthesis of carboxylic 
acid derivative 32 from menadione (12). 
Formation of the dimer is not ideal and could easily be prevented by 
protecting the acid as its methyl ester, which would be hydrolysed in a 
subsequent step. However, hydrolysis in the presence of a quinone normally 
results in decomposition.75 Therefore, the simplest option to synthesise 
analogue 32 via this method, was to optimise conditions and prevent 
formation of bisquinone 52. The literature method76 indicates that the addition 
of a ammonium persulfate solution in water occurs over a 2 h period. 
However, for the initial suite of analogues in the preliminary study it was 
found that the slow addition of ammonium persulfate over a 2 h period was 
not required, with comparative yields obtained over a 15 min addition time 
frame followed by a 2 h reaction. These conditions were used for all 
analogues in the initial suite.  
When attempting to synthesise carboxylic acid 32, optimisation of the 
reaction conditions was undertaken, with investigation into the addition time 
of the ammonium persulfate as well as the reaction time (Table 4). The very 
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slow addition over a 2 h period gave rise to carboxylic acid (32) and 
bisquinone (52) in very low yields with high levels of impurities. However, 
with the 15 min addition of ammonium persulfate only carboxylic acid 32 was 
obtained in reasonable yields. 
Table 4: Yield comparison of the two different methods for the synthesis of 32 from 
menadione 12.  
Entry 
Addition of Ammonium 
Persulfate (h) 
Reaction 
time (h) 
Yield % 
32 
Yield % 
52 
Impurity 
Present 
1 1.0 1.0 18 <1 Yes 
2# 0.25 0.5 10 0 No 
3# 0.25 1.0 15 0 No 
4# 0.25 1.5 15 0 Yes 
5# 0.25 2.0 15 0 Yes 
6* 0.25 1.0 62 0 No 
# Synthesis performed with what was identified post reaction as a decomposed bottle of 
ammonium persulfate, * is a repeat with new batch of ammonium persulfate. 
However, reaction time proved to be crucial. If the reaction time exceeded 1 
h the formation of an unidentified by-product occurred. Purification of the 
product from this intractable by-product was not possible by flash column 
chromatography. The impurity, a yellow oil, displayed a broad signal from 
1.00 – 4.50 ppm in the 1H NMR spectrum. Unfortunately, this meant that the 
reaction was quenched before complete consumption of menadione (12), as 
the reaction needed to be quenched prior the formation of the impurity.  
However, the starting material can easily be recovered after purification by 
column chromatography. The starting material menadione (12) was eluted 
with 100 % dichloromethane, while elution with 100 % ethyl acetate afforded 
the carboxylic acid product (32). Similarly, reaction scale was important to 
obtain high yields. When the scale exceeded one gram of menadione (12), 
formation of the product (32) dramatically decreased. Therefore, multiple 
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one-gram reactions were performed in parallel to provide multi-gram 
quantities of material. In this way, carboxylic acid 32 was synthesised rapidly 
and used in subsequent amide coupling reactions to generate a library of 
amide/peptide analogues.  
2.2.2 Synthesis of analogues via amide coupling 
Synthesis of the analogues via amide coupling represents a straightforward 
method to obtain a wide variety of analogues with diverse functionality. 
Analogues were synthesised via known methods for amide coupling. 
Formation of an amide bond, with an example being the peptide bond, is the 
formation of a bond between the carbon terminus of a carboxylic acid 
fragment and the nitrogen terminus of amine fragment with the use of a 
coupling agent (Scheme 5).  
  
Scheme 5: Formation of a peptide bond. 
Due to the nature of amide coupling, when coupling amino acids, protecting 
groups are selectively introduced and removed on the carboxylic acid group 
that is not required for coupling to ensure self-coupling does not occur. The 
carboxylic acid group of the amino acid is commonly protected as its methyl 
or ethyl ester. However, as demonstrated with carboxylic acid 32 in the 
preliminary study in 2013 by Woolley et al.,75 base hydrolysis, which is the 
common removal technique for these type of esters results in decomposition 
of the compound and therefore alternative protecting group was required. t-
Butyl esters are also common carboxylic acid protecting groups, due to their 
ease of deprotection under mild acidic conditions. For this reason, t-butyl 
groups were utilised to generate a library of amino acid derivatives.  
A large variety of amide coupling agents are now widely used in synthetic 
organic chemistry. Originally, dicyclohexylcarbodiimide (DCC) (56) (Figure 
23) was the first reagent used as a coupling agent due to its insensitivity to 
moisture and excellent yields. Its use was first reported by Sheehan and 
Hess in 1955.83 However, issues with racemisation of stereogenic centres 
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resulted in the use of additional additives such as 1-hydroxybenzatriazole 
(HOBt) (57) being added to supress these undesired processes and increase 
the reaction rate.84  
 
Figure 23: Structures of coupling agents DCC (56), EDCI (58), BOP (59), PyBOP 
(60) and additive HOBt (57). 
Over recent decades, many new coupling agents have been developed 
which are superior to DCC (56) meaning additives are no longer required and 
their use is aligned with substrate complexity. For this research, coupling 
agents EDCI (1-ethyl-3-3(3-dimethylaminopropyl-carbodiimide) (58), BOP, 
(benzotriazol-1-yloxy) tris(dimethylamino)phosphonium hexafluorophosphate, 
(59) and PyBOP (benzotriazol-1-yloxy)-tripyrrolidinophosphonium 
hexafluorophosphate (60) (Figure 23) were used depending on the substrate 
being synthesised. The reactions proceeded with EDCI (58) as the coupling 
agent unless otherwise stated; while reactions that contained hindered, 
precious or difficult to make substrates utilised the stronger coupling agents, 
BOP (59) or PyBOP (60) as a precaution.  
The polarity of idebenone (11) appears to be an important factor. This was 
also demonstrated by the naphthoquinone derivatives in the preliminary 
study, where the absence of the alcohol functionality in the 10-carbon alkene 
derivative 14 and the 10-carbon alkane derivative 15 showed a significant 
decrease in the cytoprotective capacity when compared to the idebenone-like 
analogue (13). The simplest way to modify L-phenylalanine methyl ester 
derivative 40 to obtain increased polarity in the side chain was to convert the 
amino ester to an amino acid derivative. With the use of the t-butyl ester this 
can be easily achieved. Therefore a variety of acid derivatives containing 
varying functionality were synthesised to prepare the next suite of 
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compounds for biological evaluation following the previously developed 
method (Table 5).75 
Table 5: Synthesis of t-butyl ester analogues 61 – 68. 
 
Entry Amino Ester  Structure Yield (%) 
1 L-phenylalanine t-butyl ester 
 
36 
2 L-proline t-butyl ester 
 
53 
3 L-norvaline t-butyl ester 
 
44 
4 glycine t-butyl ester 
 
36 
5 L-leucine t-butyl ester 
 
39 
6 L-tyrosine t-butyl ester	
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The successful formation of analogues (61 – 66) was consistent with 
spectroscopic data, particularly with 1H NMR and 13C NMR spectroscopy. 
The incorporation of the amide portion was supported by the 1H NMR 
spectrum with a doublet present in all analogues at ~6.15 ppm integrating for 
one proton. This was identified as the proton attached to the nitrogen, which 
was shifted upfield due to the formation of the amide. In addition, all 1H NMR 
spectra displayed characteristic singlets at ~1.40 ppm integrating for nine 
protons consistent with the presence of the t-butyl protecting group. In the 
13C NMR spectrum, the carbonyl of carboxylic acid derivative 32 experienced 
a shift from 179.3 to around ~172.0 ppm due to formation of the amide bond. 
However, in the case of analogue 66, a second compound was identified. 
This compound was identified to be 68, which was formed by coupling of a 
second equivalent of carboxylic acid 32 to the phenol of the tyrosine unit 
(Scheme 6).   
 
Scheme 6: Formation of analogues 66, 68 and 69.  
To prevent this occurrence, the phenol could have had a protecting group 
installed to avoid this unwanted side reaction. However, this issue was 
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overcome by performing a transesterification under mild conditions with 
potassium carbonate in methanol to cleave the ester group producing L-
tyrosine t-butyl ester derivative 66 and methyl ester (69). This provided L-
tyrosine t-butyl ester derivative 66 in a 20 % yield over the two reaction steps.  
1H NMR and 13C NMR spectroscopy could easily distinguish between the 
tyrosine analogues. The 1H NMR spectrum indicated the presence of the 
second quinone moiety of analogue 68 exhibiting two multiplet resonances at 
7.66 – 7.71 ppm and 8.04 – 8.07 ppm for the quinone cores now integrating 
for four protons each with respect to the aromatic signals of the tyrosine 
which integrates for a total of four protons (Figure 24). In addition, a second 
set of resonances for the alkyl chain were present and an additional singlet at 
2.22 ppm, that integrated for three protons was consistent with the second 
methyl substituent of the second quinone moiety.  
 
Figure 24: 1H NMR spectrum of analogue 68 consistent with the formation of the 
ester linkage to the second quinone moiety.  
Hydrolysis of the t-butyl ester analogues 61 – 66 revealed the carboxylic acid 
(Table 6). In addition to this, esters 61 – 66 were subjected to biological 
evaluation.  
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Table 6: Deprotection of t-butyl ester analogues 61 – 66 to produce analogues 70 - 
75. 
 
Entry t-Butyl Ester  Structure  Yield (%) 
1 61 
 
79 
2 62 
 
65 
3 63 
 
36 
4 64 
 
54 
5 65 
 
61 
6 66 
 
76 
 
Successful removal of the t-butyl protecting groups was consistent with the 
1H NMR and 13C NMR spectroscopic data. The absence of the t-butyl ester 
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was supported by the absence of the characteristic singlet at ~1.40 ppm 
integrating for nine protons in the 1H NMR spectra. Similarly, the 13C NMR 
spectra showed the absence of two signals, at ~82.0 and 28.0 ppm for the 
quaternary and methyl carbons respectively, which supports the loss of the t-
butyl group. The 1H NMR resonances for the quinone, propyl linker and 
amino acid portion remained within similar chemical shift ranges to their 
parent esters. However, there is one characteristic change that is seen in 
analogues containing a α-benzyl substituent in the amino acid fragment (L-
phenylalanine derivatives 61 and 70 and the L-tyrosine derivatives 66 and 
75). The two diastereotopic protons adjacent to the aromatic ring are part of 
an ABX type spin system and in the presence of the t-butyl group the proton 
signal presents as a apparent doublet of doublets. However, in the absence 
of the t-butyl group the splitting is more distinct with a downfield shift, giving 
two distinctive doublets of doublets (Figure 25). 
 
 
Figure 25: 1H NMR of L-phenylalanine derivatives 61 and 70 illustrating the splitting 
of the diastereotopic protons. 
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With a new set of compounds in hand, Ms Monila Nadikudi at the University 
of Tasmania performed biological evaluation of both ester and acid 
analogues (Note: all biological evaluation of all analogues from this point 
forward were performed by Monila Nadikudi). Analogues were primarily 
analysed for both their ability to provide cytoprotection and rescue ATP levels 
(Figure 26).  
 
 
Figure 26: Biological evaluation of amino t-butyl esters (light grey) and amino acids 
(dark grey) in two assays (a) Cytoprotection against rotenone induced complex I 
dysfunction by quinones at 10µM given as a relative percentage of cell survival 
compared to untreated HepG2 cells (b) ATP rescue by quinones at 10µM in the 
presence of rotenone-induced complex I dysfunction as percentage of untreated 
HepG2 cells. Data represents the mean of n=3 independent experiments with 6 
replicates each. 
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A sufficient number of analogues provided high levels of protection. The 
threshold for a compound to have a high level of activity is when the 
analogue restores ATP or viability to >80 % in the respective assay. Thus, 
indicating that L-phenylalanine methyl ester 40 represented a promising lead 
compound. Analogues containing amino esters excelled in their ability to 
restore ATP levels, with a number of analogues surpassing idebenone (11), 
however their cytoprotection levels were within range of idebenone (11) 
(Figure 26). Interestingly, the amino acids derivatives demonstrated the 
opposite trend, with some analogues greatly exceeding idebenone’s (11) 
ability to provide cytoprotection. However, their capacity to provide ATP 
rescue was suboptimal with ATP rescue levels less than idebenone (11). 
ATP rescue and cytoprotection data of each analogue was plotted investigate 
correlations (Figure 27).  
 
Figure 27: Protection of viability versus acute rescue of ATP levels against rotenone 
induced complex I dysfunction by naphthoquinones. Both cytoprotection and ATP 
rescue in HepG2 cells by naphthoquinones (10mM) are displayed as percentage of 
untreated control (no rotenone) with error bars omitted for clarity. Data represents 
the mean of n=3 independent experiments with 6 replicates each. 
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Interestingly, neither group of analogues (amino t-butyl esters or amino acid 
derivatives) showed activity within the zone of ideal activity. Although the 
amino ester analogues provided exceptional rescue of ATP levels, they did 
not provide high levels of cytoprotection. When converting the amino esters 
to amino acids, this trend was reversed. Specifically, their ability to provide 
cytoprotection greatly exceeds all other analogues, but their capacity to 
restore ATP levels is diminished once the ester functionality is removed. One 
analogue of interest was L-tyrosine t-butyl ester derivative 66 (Figure 28) 
which has obtained extremely high levels of ATP rescue, but still had the 
ability to increase cytoprotection levels that exceed idebenone (11) (Figure 
27) and was the first analogue to fall within what is termed the zone of ideal 
activity. 
 
Figure 28: Stucture of L-tyrosine t-butyl ester derivative 66. 
The polarity of L-tyrosine t-butyl ester derivative 66 is between the two 
groups of analogues, with the phenolic residue providing greater polarity 
when compared to the other ester analogues. However, this analogue is less 
polar than the amino acid derivatives. This result indicated that amino acids 
may be too polar to provide activity that correlates to both ability to restore 
ATP levels and provide cytoprotection. For this reason, the next suite of 
analogues that were prepared contained amino alcohol residues or 
equivalent amine residues as this would provide compounds of intermediate 
polarity. Formation of the mid-polarity analogues followed the same amide 
coupling procedure utilised for synthesis of the amino ester derivatives (Table 
7). 
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Table 7: Synthesis of analogues 76 – 87 containing mid-polarity (amino alcohols). 
 
Entry Amino Alcohol/Amine  Structure Yield (%) 
1 L-phenylalaninol 
 
49 
2 L-prolinol 
 
36 
3 L-phenyl glycinol 
 
69 
4 tyramine 
 
33 
5 
3,4-dimethoxy-
phenethylamine 
 
38 
6 phenethylamine 
 
50 
7 tryptamine 
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8 trans-4-hydroxy-L-proline 
 
59 
9 L-serine methyl ester 
 
53 
10 L-threonine methyl ester 
 
39 
11 butylamine 
 
40 
12 
(R)-2-hydroxy-4-amino 
butyric acid methyl ester 
 
16 
 
Formation of all analogues was consistent with spectrscopic data, particularly 
with the 1H NMR and 13C NMR data. Coupling of the amide portion is again 
supported by the 1H NMR spectrum with a doublet or triplet present in all 
analogues around ~6.20 ppm integrating for one proton which was identified 
as the proton attached to the nitrogen. An additional multiplet resonating at 
~4.15 – 4.30 ppm integrating for one proton was consistent with the proton 
alpha to the nitrogen in case of the amino alcohol derivatives 76 – 78 and 83 
– 85 or at ~3.44 – 3.55 ppm in the cases of the amide derivatives 79 – 82, 86 
and 87. In the 13C NMR spectra associated with analogues (76 – 87) the 
carbonyl of the carboxylic acid of carboxylic acid 32 experiences a shift from 
179.3 to ~173.0 ppm after formation of the amide bond. All remaining signals 
were consistent with the incorporation of the amine fragment into the product. 
Biological evaluation of the current suite of amino alcohol derivatives was 
O
O
N
O
OH
O
O
83
O
O
H
N
O
O
O
OH
84
O
O
H
N
O
O
O
OH
85
O
O
H
N
O
86
O
O
H
N
O
O
O
OH
87
Chapter	2:	Discussion	
	
	 49	
carried out, with primary analysis again studying the analogues ability to 
provide both cytoprotection and rescue ATP levels (Figure 29).  
 
 
Figure 29: Biological evaluation of amino alcohol and amide derivatives in two 
assays (a) Cytoprotection against rotenone induced complex I dysfunction by 
quinones at 10µM given as a relative percentage of cell survival compared to 
untreated HepG2 cells (b) ATP rescue by quinones at 10µM in the presence of 
rotenone-induced complex I dysfunction as percentage of untreated HepG2 cells. 
Data represents the mean of n=3 independent experiments with 6 replicates each. 
Pleasingly, a number of analogues provided the anticipated results. L-
Phenylalaninol derivative 76, L-prolinol derivative 77, tyramine derivative 79 
and 3,4-dimethoxyphenethylamine derivative 80 provided cytoprotection back 
to levels of the control. Where as tyramine derivative 79, 
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dimethyoxyphenethylamine 80 and tryptamine derivative 82 restored ATP 
levels back to those of the control. These analogues are able to provide 
cytoprotection as well as restore ATP levels as correlated in Figure 30, with 
this being highly important in moving forward in research into LHON. Studies 
in the literature indicated that as long as a compound can restore ATP levels, 
it should also provide cytoprotection as proposed with idebenone (11). The 
current hypothesis is that idebenone (11) simply acts as a complex I by 
pass4. However, this research has shown this does not appear to be the 
case.  
 
Figure 30: Protection of viability versus acute rescue of ATP levels against rotenone 
induced complex I dysfunction by naphthoquinones. Both cytoprotection and ATP 
rescue in HepG2 cells by naphthoquinones (10mM) are displayed as percentage of 
untreated control (no rotenone) with error bars omitted for clarity. Data represents 
the mean of n=3 independent experiments with 6 replicates each. 
Structurally, the analogues that provided the highest level of protection 
through both ATP rescue and cytoprotection were analogues that contained 
some form of aromatic ring and a heteroatom (i.e. oxygen or nitrogen). 
Analogues 61, 70 and 76 are all phenylalanine derivatives and all express 
high levels of activity, interesting analogue 76 is the amino alcohol derivative 
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and exhibits high levels of both ATP rescue and cytoprotection (Figure 31). In 
comparison, 61 which is the t-butyl ester of phenylalanine exhibited the 
highest level of ATP rescue but could not provide cytoprotection and 
analogue 70 as the phenylalanine acid exhibited the opposite trend.  
 
Figure 31: Biological evaluation of L-phenylalanine derivatives in two assays (a) 
Cytoprotection against rotenone induced complex I dysfunction by quinones at 
10µM given as a relative percentage of cell survival compared to untreated HepG2 
cells (b) ATP rescue by quinones at 10µM in the presence of rotenone-induced 
complex I dysfunction as percentage of untreated HepG2 cells. Data represents the 
mean of n=3 independent experiments with 6 replicates each. 
In comparison, the other highly active amino alcohol/simple amide analogues 
all contain the phenethylamine core. The reasons for the high levels of 
activity are currently unknown, with both ATP rescue and cytoprotection 
levels in the prescence of the new naphthoquinone analogues adequately 
restored back to within error of the control. The top five analogues were 
selected to undergo further investigation into structure activity relationships 
(SAR) in relation to linker length and optimisation of the core. These 
analogues were selected for their ability to provide protection and due to 
synthetic processes. This process has included L-phenylalanine derivative 70 
which was the analogue with the highest level of cytoprotection and L-
phenylalanine t-butyl ester derivative 61 due to synthetic processes as well 
as its ability to restore ATP alone (Figure 32). Lastly, three of the top 
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analogues that were best able to restore both cytoprotection and rescue ATP 
levels (L-phenylalaninol derivative 76, tyramine derivative 79 and 3,4-
dimethoxyphenethylamine  derivative 80) were selected (Figure 32). 
 
Figure 32: Structures of the top five analogues 61, 70, 76, 79 and 80 which were 
selected to allow further structure activity relationship (SAR) studies. 
Using these amino fragments, further investigation into other structural 
requirements were investigated. From the initial toxicity data it was proposed 
that the naphthoquinone core was ideal, providing significant less toxicity 
than the benzoquinone core. However, between the core and the amino 
fragment was a four-carbon linker. The impact the length of the linker had on 
the ability of the analogue to provide protection was unknown. For this 
reason analogues containing a three-, five- and six-carbon linkers were 
required to synthesise derivatives of the amino fragments that gave the best 
activity. Therefore, analogues of carboxylic acid 32 with differing linker 
lengths needed to be prepared on a multi-gram scale. These compounds 
were synthesised via the optimised conditions for the silver-mediated radical 
decarboxylation process (Table 8). Noteably, the synthesis of analogue 31 
was low yielding when compared analogues 88 and 89, this is a result of this 
reaction taking place with the bottle of ammion persulfate that was later 
identified to have decomposed. 
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Table 8: Synthesis of acid analogues 31, 88 and 89 containing differing lengths of 
the acid side-chain. 
 
Entry Carboxylic Acid Structure Yield (%) 
1 succinic acid 
 
20 
2 adipic acid 
 
78 
3 pimelic acid 
 
57 
 
Formation of the analogues proceeded as expected although the yield of the 
reaction employing succinic acid was low. 1H NMR and 13C NMR 
spectroscopy supported their formation with the absence again of a singlet 
peak at 6.84 ppm consistent with the loss of the proton attached to the C3 
position of the 2-methylnaphthoquinone (menadione, 12) in the 1H NMR 
spectrum. While the 13C NMR spectrum showed characteristic resonances 
below 35.0 ppm correlating to the resonances of the aliphatic linker, whilst an 
additional diagnostic signal at 179.6 ppm was present corresponding the 
carboxylic acid group. These analogues were then coupled to the top five 
amino fragments previously identified as providing the most activity for 
comparison (Table 9) with the exception of the three-carbon linker. Due to 
the low yield obtained for the formation of the three-carbon carboxylic acid 
derivative 31, L-phenylalanine t-butyl ester derivative 90 and L-phenylalanine 
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acid derivative 91 were synthesised. Two analogues and the carboxylic acid 
derivative 31 were deemed sufficient to determine if there was a difference in 
activity as a result of linker length. If there were any significant change in 
activity then the remaining analogues would be synthesised. 
Table 9: Synthesis of analogues 90 – 101 containing the top five amino groups.  
 
Entry n= Amino fragment  Structure  Yield (%) 
1 2 
L-phenylalanine    
t-butyl ester 
 
22 
2# 2 L-phenylalanine 
 
80 
3 4 
L-phenylalanine    
t-butyl ester 
 
69 
4# 4 L-phenylalanine 
 
33 
O
O
H2N R2
R1
DMAP, NEt3, EDCI
O
O
H
N
O R1
R2
O
OHn nn= 2   31
n= 4   88
n= 5   89
n= 2   90 – 91
n= 4   92 – 96
n= 5   97 – 101
O
O
N
H
O
O
O
90
O
O
N
H
O
OH
O
91
O
O
N
H
O
O
O
92
O
O
N
H
O
OH
O
93
Chapter	2:	Discussion	
	
	 55	
5 4 L-phenylalaninol 
 
59 
6 4 tyramine 
 
20 
7 4 
3,4-dimethoxy-
phenethylamine 
 
35 
8 5 
L-phenylalanine    
t-butyl ester 
 
59 
9# 5 L-phenylalanine 
 
84 
10 5 L-phenylalaninol 
 
34 
11 5 tyramine 
 
39 
12 5 
3,4-dimethoxy-
phenethylamine 
 
60 
# analogue formed via deprotection of the t-butyl ester of the corresponding analogue. 
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Formation of all analogues was supported by NMR spectroscopy and Infared 
(IR) analysis. In the 1H NMR and 13C NMR spectra, the characteristic peaks 
observed previously with the four carbon chain linker were present in the 
case of the three-, five- and six-carbon linkers indicating attachment of the 
amine. Analogues were then subjected to the same biological evaluation as 
all other analogues and a comparison between the three-, four-, five- and six-
carbon linkers made in relation to their ability to rescue ATP levels and 
provide cytoprotection (Figure 33).  
 
 
Figure 33: A comparison of linker length of top five analogues in assays (a) 
Cytoprotection against rotenone induced complex I dysfunction by quinones at 
10µM given as a relative percentage of cell survival compared to untreated HepG2 
cells (b) ATP rescue by quinones at 10µM in the presence of rotenone-induced 
complex I dysfunction as percentage of untreated HepG2 cells. Data represents the 
mean of n=3 independent experiments with 6 replicates each. 
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As seen in Figure 33, there was no significant difference between the three-, 
five- and six-carbon linkers with respect to the four-carbon linker. In general 
the four-carbon linker did provide the highest level of activity (Figure 33) with 
exception of the free carboxylic acid derivatives. Surprisingly, the free 
carboxylic acids showed a significant difference in activities. The five- and 
six-carbon carboxylic acid derivatives 88 and 89 had much improved activity 
in both ATP rescue and cytoprotection when compared to the three- and 
four- carbon carboxylic acid derivatives 31 and 32. In fact, addition of the 
amine derivative to the side chain barely had any effect on activity in these 
cases. However, these straight chained carboxylic acid derivatives would be 
suseptible to the same degradation issues faced by idebenone (11) and are 
still not quite to the standard of the L-phenylalanine methyl ester derivative 
40.4,63 This result combined with the fact that all initial analogues were 
sythesised from the four-carbon linker, suggested that there was no benefit to 
changing the linker length to explore any further structure activity 
relationships (SARs). Consequently, all subsequent work utilised the four-
carbon linker. 
It was proposed that if these analogues were not simply acting as a complex 
I bypass and their activity was in fact due to a particular interaction with an 
enzyme. Employing an amino fragment of the opposite enantiomeric series 
may provide some insight into molecular interactions. If polarity alone was 
responsible for activity, then no difference in activity would be expected. With 
this in mind, a series of analogues containing D-stereoisomers were 
synthesised. Of particular interest, were the two top five analogues, 70 and 
76.  
The cost and availability of D-phenylalanine t-butyl ester dictated that an 
alternative synthetic pathway was required to produce the enantiomer of 71. 
N-N’-Carbonyldiimidazole (102) is a common reagent for coupling carboxylic 
acids with amines to form amide bonds.85 This method for amide bond 
formation can be utilized without the need for protecting groups. Generation 
and isolation of the active acyl imidazole intermediate (103) prior to coupling 
allows for selective coupling of an unprotected amino acid (Scheme 7). As 
the imidazole group provides an excellent leaving group that enables 
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nucelophilic attack by the amine to form the amide bond to generate 
analogue 105. N-N’-Carbonyldiimidazole (102) is commonly used in place of 
aryl halides due to their ease of handling and greater stability.86  
 
Scheme 7: Formation of D-phenylalanine derivative 105 through the use of an acyl 
imidazole intermidiate. 
Formation of D-phenylalanine derivative 105 was supported by both 1H NMR 
and 13C NMR spectroscopy, with spectroscopic data identical to L-isomer 70. 
Although this method was employed for the formation of analogue 105, this 
reaction was low yielding with only a 14 % yield obtained over the two steps. 
Isolation and characterisation of the acyl imidazole intermediate indicated the 
initial step had proceeded in a 93 % yield. Formation of 103 was supported 
by 1H NMR spectroscopy with three singlet resonances present at 6.99, 7.40 
and 8.10 ppm all integrating for one proton each indicating the imidazole ring. 
Analysis by 13C NMR spectroscopy showed a characteristic shift of the 
carbonyl of the carboxylic acid of derivative 32 from 179.3 ppm to 168.9 ppm 
consistent with the formation of the amide bond. Formation of intermediate 
103 was also supported with a characteristic IR stretch at 1738 cm-1 for the 
carbonyl attached to the imidazole ring. The introduction of the amino acid 
resulted in the dramatic loss in yield. This is a clear indication that the 
reaction conditions for the second step, if used to prepare other analogues, 
would need significant optimisation. However, the quantity obtained was 
adequate for biological evaluation of 105.  
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The synthesis of the remaining D-enantiomers employed standard amide 
coupling techniques using the methyl ester derivatives. Due to previous 
issues associated with hydrolysing esters in the presence of the quinone 
moiety, re-investigation of hydrolysis conditions was required to obtain the D-
amino acid derivative to determine whether the stereochemistry would alter 
activity. The next suite of compounds prepared included both enantiomers of 
amino alcohols and unnatural amino ester residues such as D-
phenylalaninol, D-phenyl glycinol and L- and D- phenyl glycine methyl ester 
(Table 10).  
Table 10: Synthesis of D-analogues and unnatural amino derivatives. 
 
Entry Amino derivative  Structure Yield (%) 
1 D-phenylalaninol 
 
36 
2 D-phenyl glycinol 
 
62 
3 
L-phenyl glycine     
methyl ester 
 
72 
4 
D-phenyl glycine      
methyl ester 
 
69 
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Standard NMR and IR spectroscopic analysis supported the successful 
synthesis of analogues 106 – 109. The spectroscopic data for analogues 106 
to 109 was identical to that obtained for the opposite enantiomer. To obtain 
the amino acid derivatives of both L- and D-phenyl glycine methyl ester, 
suitable hydrolysis conditions were re-investigated. In a relevant prior study 
by Woolley and co-workers,75 base hydrolysis under standard conditions 
resulted in complete decomposition which was proposed to be due to the 
presence of the quinone moiety. Therefore both analogues were subjected to 
various acidic and basic hydrolysis conditions. Base hydrolysis was 
investigated with both lithium and potassium hydroxide. However, both 
reaction conditions resulted in rapid decomposition (Scheme 8). 
 
Scheme 8: Attempted base hydrolysis of methyl esters 108 and 109. 
Lithuim hydroxide is often used for deprotection of amino esters and as a 
result this base was utilised to optimise and screen the reaction conditions, 
including both solvent and temperature. Irrespective of the reaction 
temperature or time (Table 11), decomposition occurred. After the addition of 
base, the reaction mixture changed to black and when analysed by 1H NMR 
spectroscopy, a complex mixture of products were observed.  
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Table 11: Attempted conditions for base hydrolysis with lithium hydroxide 
Entry Dioxane/H2O Temperature °C Reaction Time (h) Product 
1 1:1 50 3 Decomposition 
2 1:1 r.t. 1 Decompositon 
3 2:1 50 3 Decomposition 
4 3:1 50 5 Decompositon 
  
Acid hydrolysis was then investigated. Reaction with 6 M hydrochloric acid 
with catalytic acetic acid was ultimately successful (Scheme 9). Purification of 
the respective acids was achieved by trituration with dichloromethane to yield 
L- and D- phenyl glycine analogues in 46 % and 14 % yields repectively. 
 
Scheme 9: Acid mediated hydrolysis of methyl esters 108 and 109 to form 110 and 
111. 
The successful formation of analogues 110 and 111 was consistent with 
spectroscopic data, particularly the 1H NMR and 13C NMR spectrum. The 1H 
NMR spectra associated with 110/111 showed a clear absence of a singlet at 
3.71 ppm for the methyl ester. With all D-analogues synthesised, primary 
biological evaluation of the enantiomers was performed in order to assess 
their ability to rescue ATP levels and provide cytoprotection (Figure 34).  
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Figure 34: A comparison between L- and D-enantiomers of amino fragments in 
assays (a) Cytoprotection against rotenone induced complex I dysfunction by 
quinones at 10µM given as a relative percentage of cell survival compared to 
untreated HepG2 cells (b) ATP rescue by quinones at 10µM in the presence of 
rotenone-induced complex I dysfunction as percentage of untreated HepG2 cells. 
Data represents the mean of n=3 independent experiments with 6 replicates each. 
Surprisingly, all analogues showed no difference in their ability to provide 
cytoprotection with the exception of the phenylalanine analogues (70/105) 
(Figure 34a). L- and D- enantiomers of phenylalanine provided remarkably 
different cytoprotective ability. Specifically, cytoprotection dropped almost 30 
% by swapping to the D-isomer. However, the ability to restore ATP levels by 
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all analogues was independent of stereochemistry (Figure 34b). With these 
results in mind, in general it appears that the stereochemistry of the 
analogues is not significant and the differences between phenylalanine 
analogues (70/105) may be a result of rates of metabolism. 
2.2.3 Synthesis of miscellaneous analogues via various methods 
All structure activity relationships have demonstrated the need for a 
naphthoquinone core (4), a four-carbon linker, and an amino alcohol portion 
or amide group in the side chain to provide high levels of cytoprotection and 
ATP rescue. Investigation into whether replacing the carbon atom alpha to 
the quinone core in the four-carbon linker with a hetero atom was required. 
This represented only a small preliminary investigation, in which the carbon 
atom was substitueted for a nitrogen or sulfur atom.  
Following the method of C. Chen  and co workers,87 the introduction of a 
sulfur chain was performed in a single step reaction from menadione (12) 
using mercapto-propanoic acid (112) to produce the sulfur-containing 
carboxylic acid derivative  113 (Scheme 10).  
 
Scheme 10: Formation of analogue 113. 
Analogue 113 was synthesised via a 1,4-addition of mercapto-propanoic acid 
(112) to the menadione (12) core followed by air oxidation to form the desired 
analogue in 48 % yield.88,89 1H NMR spectroscopic analysis of 113 was 
consistent with equivalient data reported in the literature, with the absence of 
a singlet peak at 6.84 ppm indicating the loss of the proton attached to the 
C3 position of menadione (12) in addition to new peaks visible in the aliphatic 
region.  
After the formation of 113, attempted coupling to L-phenylalanine t-butyl ester 
was performed (Scheme 11). A complex mixture of products was obtained 
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and isolation of the desired product 114 was not possible. It was postulated 
that the sulfur may act as a leaving group and this led to decomposition, 
however, this was not investigated further. 
 
Scheme 11: Failed synthesis of analogue 114. 
Obtaining the top five amino fragments with the sulfur derivative was put on 
hold until biological evaluation of the sulfur naphthoquinone acid (113) could 
be obtained. As hetero-atoms within the linker were desired, focus moved on 
to obtaining a nitrogen analogue. Using a literature method by Bittner and 
coworkers,90 formation of analogues on both the naphthoquinone (4) and 
menadione (12) was attempted (Scheme 12).  
 
Scheme 12: Formation of nitrogen containing analogues 115 and 116. 
Similar to the sulfur analogue (113), this reaction proceeded with a 1,4-
addition.90 However, despite both cores 4 and 12 being used as substrates, 
only the formation of the naphthoquinone analogue (115) occurred. It is 
reported within the literature that a facile reaction occurs with the 
naphthoquionone (4). However, minimal reaction takes place on the 
menadione (12) core with the reaction being descibed in the literature as 
“sluggish”.90 It is proposed that both steric hinderance and electronic effects 
could be responsible for disfavouring the addition to menadione (12).90 With 
this in mind, naphthoquinone analogue 115 was formed in a 20 % yield with 
all spectroscopic analysis consistent with the literature.90 However, this is not 
ideal as the analogue does not contain a methyl substituent at the C3-
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position to enable direct comparison to the top five analogues. The yield 
obtained was also significantly less than that reported in the literature, 
however, adequate quantites of analogue 115 were obtained for the 
purposes required. Analogue 115 was then subjected to coupling to L-
phenylalanine methyl ester to give the product in a poor 18 % yield (Scheme 
13). 
  
Scheme 13: Synthesis of analogue 117 via normal amide coupling methods. 
Formation of analogue 117 was consistent with both 1H and 13C NMR 
spectroscopic analysis, with two exchangable proton signals present at 5.96 
and 6.51 ppm indicating the prescence of two N-H’s within the molecule. 
Again the characteristic doublet of doublet signals for the two diastereotopic 
protons alpha to the benzyl substituent were present at 3.06 and 3.09 ppm. 
Both sulfur and nitrogen-containing analogues were then subjected to 
biological evaluation (Figure 35).  
 
Figure 35: A comparison between analogues containing hetero-atoms within the 
linker (a) Cytoprotection against rotenone induced complex I dysfunction by 
quinones at 10µM given as a relative percentage of cell survival compared to 
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untreated HepG2 (b) ATP rescue by quinones at 10µM in the presence of rotenone-
induced complex I dysfunction as percentage of untreated HepG2 cells. Data 
represents the mean of n=3 independent experiments with 6 replicates each. 
As seen in Figure 35, the addition of the nitrogen atom in both 115 and 117 
showed minimal ability to restore ATP levels or provide cytoprotection. The 
introduction of the sulfur atom had a positive influence on both ATP rescue 
and cytoprotection when compared to the straight carbon chain of carboxylic 
acid derivative 32. However, as there is no viable method for introducing 
various amino groups into the side chain at this stage, this is not considered 
a viable route for further SAR investigation. Due to poor efficiency of these 
reactions, the preparation of other analogues containing heteroatoms was 
not pursued further at this time. 
Investigation into the benefits of multiple amino acid fragments on activity 
was performed on the basis of SS-31 (10), which is a mitochondrial targeting 
peptide and contains four amino acid residues. Therefore, utilising analogue 
70, an additional amino acid residue was coupled via the normal amide 
coupling process before undergoing biological evaluation. L-Proline t-butyl 
ester was coupled to analogue 70 before undergoing the normal t-butyl ester 
deprotection with 10% TFA to reveal the dipeptide derivative 120 in 49 % 
yield (Scheme 14).  
 
Scheme 14: Synthesis of analogue 120 containing two amino acid fragments. 
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The successful synthesis of compound 120 was supported primarily by high 
resolution electrospray ionisation mass spectroscopy (HR ESI MS). For 
C29H30N2NaO6, the predicted HRMS was 525.2002 and it was found to be 
525.1990. The presence of amide rotamers or rotational isomers due to 
restricted rotation around the amide bond, complicated the analysis of the 1H 
and 13C NMR spectra in CDCl3. Often these issues can be resolved for small 
peptides by variable-temperature (VT) NMR (which causes the proton NMR 
signals to coalesce), solvent switching or the introduction of a complexing 
agent.91 However, these methods were not investigated as the amide 
coupling method was predictable and MS characterisation was satisfactory.  
In addition to the peptide-containing analogue, a tetrapeptide that was 
available from a project on peptide opioid analogues was coupled. This 
peptide contained the dimethyltyrosine moiety that is present in the 
mitochondrial targeting  SS-31 (10) peptide. Coupling of the carboxylic acid 
derivative 32 proceeded under standard conditions with DMT-Tic-Gly-Bnz 
(121) to give the tetrapeptide 122 in  27 % yield (Scheme 15). Formation of 
analogue 122 was also supported primarily by MS ESI showing a (M+H)+ at 
755 and {(M+Na)+ peak} at 777. As for the dipeptides, the 1H NMR and 13C 
NMR spectra were even more complex due to the presence of amide  
rotamers. 
  
Scheme 15: Formation of the tetrapeptide analogue (122). 
Both 120 and 122 were subjected to biological evaluation. Specifically, their 
ability to rescue ATP as well as their ability to provide cytoprotection was 
investigated. As seen in Figure 36, neither analogue showed any 
improvement on the already identified top five compounds and therefore no 
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other analogues were synthesised as the increase in polarity is consistent 
with a decrease in activity. 
	  
Figure 36: Biological evaluation of quinones containing multiple amino residues (a) 
Cytoprotection against rotenone induced complex I dysfunction by quinones at 
10µM given as a relative percentage of cell survival compared to untreated HepG2 
cells (b) ATP rescue by quinones at 10µM in the presence of rotenone-induced 
complex I dysfunction as percentage of untreated HepG2 cells. Data represents the 
mean of n=3 independent experiments with 6 replicates each. 
Figure 36 indicates that the addition of the second amino acid residue results 
in a large reduction in their ability to provide cytoprotection. Although these 
analogues have not provided any significant activity, they have very little 
structural resemblance to SS-31 (10). Therefore, further investigation into 
tetrapeptides was conducted with the intention to provide a direct comparison 
to SS-31 (10). This resulted in the use of solid phase peptide synthesis 
(SPPS) to enable high-yielding and relatively simple construction of the 
peptide backbone with the advantage that the quinone portion can also be 
introduced into the standard protocol. 
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2.3 Solid Phase Peptide Synthesis (SPPS) 
Solid phase peptide synthesis is a systematic process involving the stepwise 
addition of protected amino acids onto a growing peptide chain, which is 
bound to a resin (solid support). This allows for controlled peptide growth with 
exceptional yields. For the requirements of the analogues we proposed to 
synthesise, 2-chlorotrityl chloride resin was utilised as the solid support and 
9-fluorenylmethyl carbonyl (Fmoc) protected amino acids were required for 
the coupling.92 Fmoc protecting groups can be cleaved through the addition 
of base, with piperidine still the most commonly used reagent since first 
reported in the late 1970’s.93 This allows for orthogonal acid-labile protecting 
groups such as N-tert-butyloxycarbonyl (Boc) groups to be installed on 
additional fragments that require protection to ensure that unwanted side 
reactions do not occur. This allows for deprotection of the Fmoc groups in the 
presence of the acid-labile protecting groups without unwanted deprotection 
occurring.94  
The SPPS process required the initial swelling of the resin in 
dichloromethane for 30 min before the first Fmoc-amino acid was coupled to 
the resin with diisopropylethylamine (DIPEA) and dimethylformamide (DMF). 
Deprotection of the Fmoc protecting group was then achieved with 10 % 
piperidine in DMF before a repetitive coupling/deprotection process occurred 
with amino acid fragments coupled to the growing peptide chain with PyBOP 
(57)/DIPEA. After the last amino acid had been deprotected, the peptide is 
normally cleaved from the resin using 10 % 1,1,1,3,3,3-hexaflouro-
isopropanol in CH2Cl2 to yield the protected peptide. However, the quinone 
portion could also be incorporated into the solid phase synthesis to yield the 
desired derivatives directly and avoid lower yielding solution phase coupling. 
Once cleaved off the resin, the additional acid labile protecting groups can be 
removed with trifluoroacetic acid (TFA) before purification by trituration. SS-
31 (10) features an alternating aromatic-cationic sequence of aromatic and 
basic residues, with investigation into this pattern being of initial interest 
(Figure 37). 
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Figure 37: Primary structure of SS-31 (10) 
The design of SS-31 (10) derivatives resulted in a rapid library of analogues 
required for synthesis. Design of a quinone-peptide conjugate was proposed 
to combine the SAR completed earlier and the published results of SS-31 
(10). To develop a structure activity relationship, a variety of questions 
needed to be answered:  
• Is the sequence of amino acids important? i.e. even though the 
literature indicates alternating aromatic cationic groups, can an 
analogue with aromatic-aromatic-cationic-cationic produce the same 
effect? 
• As it is proposed that the dimethyltyrosine moiety is important for its 
antioxidant activities, can tyrosine without the dimethyl substituents 
provide a similar effect? How do other amino acids effect the acitivty?  
• Which end of the peptide should the quinone be attached, the C-
terminus or the N-terminus? 
With these questions in mind, the first seven analogues were synthesised 
with the quinone peptides isolated in quantitative yields (Table 12). Upon 
addition of the quinone fragment, the resin went from clear to bright-yellow, 
indicating the successful attachment of the quinone moiety.  
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Table 12: Synthesis of the SPPS analogues 123 – 129. 
 
Entry Amino Acid Sequence (AA1-AA2-AA3-AA4)  
1 Quin-N-Arg-Tyr-Lys-Phe-OH 123 
2 Quin-N-Phe-Lys-Tyr-Arg-OH 124 
3 Quin-N-Lys-Phe-Lys-Phe-OH 125 
4 Quin-N-Lys-Phe-Phe-Lys-OH 126 
5 Quin-N-Lys-Lys-Phe-Phe-OH 127 
6 Quin-N-His-Phe-His-Phe-OH 128 
7 Quin-N-Lys-Trp-Lys-Trp-OH 129 
 
As seen in Table 12, various peptides were synthesised utilising a range of 
amino acid residues. The first analogue synthesised was a derivative of SS-
31 (10), where the dimethyltyrosine (DMT) was simply swapped for tyrosine, 
to allow the effect of the dimethyl substituents to be investigated (123 + 124). 
Focus then shifted to the sequence of the amino acids residues. Although it 
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has been reported that the alternating aromatic-cationic feature is important, 
for the purposes of this study we decided to change the order of residues. 
This resulted in derivatives that contained grouped aromatic or cationic 
fragments. With analogues 125 – 127 synthesised, upon biological 
evaluation, a clear indication should be able to be obtained from these 
analogues. Lastly, SS-31 (10) requires charged amino acids, therefore 
swapping arginine and lysine for histidine and tryptophan will allow us to 
identify which charged unit will give the greatest activity (128 and 129). 
Unfortunately, due to time constraints, no biological testing has been 
performed on these analogues to date and therefore no comment in relation 
to either the order of amino acids or the type of amino acids used can be 
made on the modifications of the first suite of quinone-peptide conjugates.    
2.4 SAR Conclusions 
From the analogues investigated for SAR, a variety of important factors were 
identified. Through modification of the linker and the amide functionality, 31 
analogues provided higher levels of cytoprotection than that of the current 
drug, idebenone (11) (Figure 38). Development of SAR has given a clear 
indication that although the quinone core is essential to be able to shuttle 
electrons through the electron transport chain, it does not influence the 
analogue’s ability to provide cytoprotection or restore ATP levels. This was 
also supported by Erb et al. when investigating idebenone derivatives.2  
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Figure 38: Protection of viability versus acute rescue of ATP levels against rotenone 
induced complex I dysfunction by naphthoquinones. Both cytoprotection and ATP 
rescue in HepG2 cells by naphthoquinones (10mM) are displayed as percentage of 
untreated control (no rotenone) with error bars omitted for clarity. Data represents 
the mean of n=3 independent experiments with 6 replicates each. 
It was demonstrated that a naphthoquinone core in place of a benzoquinone 
core is essential to minimise toxicity levels. Similarly, a 4-carbon linker seems 
ideal, however, five- and six-carbon linkers can be utilised as well (Figure 
39). The most significant outcome has been the effect that polar groups in 
the side-chain have on the ability for an analogue to provide both 
cytoprotection and restore ATP levels. Although previous literature indicates 
the importance of an analogue’s ability to restore ATP levels as the key 
factor, little emphasis was placed on cytoprotection as it was assumed that 
increased ATP would result in cytoprotection. However, this study which 
represents the most in depth study on structure activity relationships (SAR’s) 
suggests that this is not the case. While ATP rescue is a rapid two-hour 
assay, it is not a realistic measure if the cells do not survive over time with 
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cytoprotection being a five-day assay. This study has demonstrated the 
importance of the side-chain to tune/modify activity independently of the 
quinone core, with numerous examples demonstrating increased ATP but no 
increase in cytoprotection. However, this should not preclude further 
investigation of the quinone core, particularly novel quinone moieties. 
Further investigation into modification of the naphthoquinone core is also 
required. 
 
 
 
 
 
Figure 39: Identified fragments for Structure Activity Relationship (SAR). 
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Chapter 3: Quinone core optimisation 
With the importance of the structure of the side-chain established in the two 
biological assays, the remaining portion of the active molecule to be 
investigated was the quinone core. Optimisation of the side-chain resulted in 
identification of the four-carbon linker and the requirement for an amino 
alcohol or equivalent amine fragment to provide cytoprotection and restore 
ATP levels. However, little investigation into the quinone moiety had been 
undertaken. The most readily available modification to perform on the 
quinone core was regarding the methyl substituent at the C3-position of the 
naphthoquinone core (Figure 40). The simplest modification to perform was 
to replace the methyl substituent with a proton. Therefore, analogues of the 
simple naphthoquinone core (4) with a proton at the-C3 position were 
synthesised.  
 
Figure 40: Structure of optimised analogue identifying the C3 position.  
3.1 Synthesis of non-methyl naphthoquinone analogues 
The preparation of analogues containing no methyl substituent in the C3-
position required the initial synthesis of a carboxylic acid analogue containing 
the naphthoquinone core (4) with the four-carbon chain attached. Synthesis 
of this analogue proceeded via the optimised silver-mediated radical 
decarboxylation process described in Chapter 2.2, Scheme 2. In this way, 
analogue 130 (Scheme 16) was prepared in 42 % yield. However, di–
alkylated analogue 131 was also formed in 9 % yield. The formation of the 
di–alkylated product was not ideal, however, di–alkylated analogue 131 could 
be separated from the desired product via chromatography. In this way, 
synthetically useful quantities of the mono–alkylated product were obtained 
to produce the suite of analogues required for analysis. 
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Scheme 16: Formation of analogue 130 and 131.  
Both 1H NMR and 13C NMR spectroscopy supported the formation of the 
mono– (130) and di–alkylated (131) products. Formation of the mono–
alkylated (130) product was supported by 1H NMR spectroscopy with a 
diagnostic shift of a singlet integrating for two protons at 6.98 ppm upfield to 
6.85 ppm and now presenting as a triplet with integration of one (J = 1.1 Hz 
for allylic coupling). This was a key indication that there was an alkyl chain 
present at the C2-position, which was supported by three additional peaks 
within the aliphatic region integrating for two protons each. The presence of 
an additional carbonyl signal in the 13C NMR at 176.8 ppm was consistent 
with a carboxylic acid. 
In comparison, the 1H NMR spectrum of the more polar di–alkylated 
derivative (131) did not feature signals at 6.85 or 6.98 ppm indicating there 
were no longer protons attached at the C2- or C3-position of the 
naphthoquinone core. There are nine carbon environments present in the 13C 
NMR spectrum and five proton environments in the 1H NMR spectrum (No –
OH signal in CD3OD), which is indicative of di–alkylation due to symmetry 
within the molecule. Carboxylic acid 130 was then coupled with each of the 
five lead-amido fragments that were previously identified as part of the SAR 
studies (Table 13). 
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Table 13: Synthesis of derivatives 132 – 136 containing the naphthoquinone core 
(4). 
 
Entry Amino Derivative  Structure Yield % 
1 
L-phenylalanine          
t-butyl ester 
 
67 
2# L-phenylalanine 
 
62 
3 L-phenylalaninol 
 
53 
4 tyramine 
 
33 
5 
3,4-dimethoxy-
phenethylamine 
 
36 
# Analogue formed via deprotection of the t-butyl ester 132. 
The successful synthesis of analogues 132 – 136 was supported by both 1H 
and 13C NMR spectroscopy. In each case, the respective NMR data was 
consistent with equivalent data obtained from analogues containing a methyl 
substituent at the C3-position. Coupling of the amide portion was supported 
by 1H NMR spectroscopy with a triplet present around 5.63 and 5.89 ppm in 
analogues 135 and 136, respectively. A doublet was present in the 1H NMR 
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spectra associated with amino derivatives (132 – 134) at ~6.10 ppm 
integrating for one proton. This is consistent with the proton attached to the 
nitrogen.  
Analogues 132 – 136 were subjected to biological evaluation to investigate 
their ability to restore ATP and provide cytoprotection in comparison to the 
analogues containing a methyl in the C3-position. As shown in Figure 41a, 
there was a significant decrease in the ability of two of the five analogues to 
provide cytoprotection when the methyl substituent was removed. However, 
as seen in Figure 41b, all analogues demonstrated a significant decrease in 
their capacity to restore ATP levels. This provided a clear indication that the 
presence of the methyl substituent enhanced activity, possibly by protection 
from oxidation or stopping other reactions occurring at the C3-position. 
 
 
Figure 41: Biological evaluation of methyl and non-methyl naphthoquinones in two 
assays (a) Cytoprotection against rotenone induced complex I dysfunction by 
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quinones at 10µM given as a relative percentage of cell survival compared to 
untreated HepG2 cells (b) ATP rescue by quinones at 10µM in the presence of 
rotenone-induced complex I dysfunction as percentage of untreated HepG2 cells. 
Data represents the mean of n=3 independent experiments with 6 replicates each. 
This effect was proposed to be due to metabolism by oxidation or conjugation 
of glutathione (Scheme 17). It is reported that menadione (12) readily forms a 
glutathione-S-conjugate via nucleophilic addition resulting in severe 
cytotoxicity.95 The loss of viability of HepG2 cells upon exposure to 
menadione (12) was always preceded by a rapid depletion of intracellular 
glutathione.96 This drop in glutathione is a result of either oxidation of 
glutathione to form the disulfide dimer or conjugation96 with menadione (12) 
to form adducts which are then excreted directly into bile or undergo a series 
of biotransformations before excretion.95  
 
Scheme 17: Oxidation or conjugation of menadione with glutathione. 
Thus, it was proposed that this same conjugation or oxidation by metabolism 
may be occurring with these naphthoquinone derivatives, and as a result the 
ability to restore ATP and provide cytoprotection would be diminished. As a 
consequence, the compound is no longer able to transport electrons through 
the electron transport chain and therefore a proton gradient cannot be 
maintained. To investigate this hypothesis, the synthesis of analogues 
containing hydroxyl substituents at the C3-position was undertaken in order 
to produce the structures that are proposed to result from metabolism 
(oxidation).  
3.2 Synthesis of hydroxyl-naphthoquinone analogues 
It was postulated that an epoxidation/hydrolysis sequence of analogues 132 
– 136 could provide C3-hydroxy analogues as the synthesis of phthiocol 
(138) from menadione (12) has been reported in the literature (Scheme 18).97 
This sequence was successfully reproduced for menadione (12). 
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Scheme 18: Epoxidation and hydrolysis of menadione (12) to form phthiocol (138). 
The successful synthesis of analogue 138 was consistent with the 
literature.97 Analysis by 1H NMR spectroscopy supported the formation of 
epoxide 137,98 with a diagnostic singlet at 3.86 ppm shifted downfield due to 
the presence of the epoxide. Similarly, the absence of a singlet peak at 6.84 
ppm indicated the loss of the proton attached at the C3-position of 
menadione (12), supported the epoxidation. Hydrolysis of the epoxide 137 
with conc. H2SO4 furnished analogue 138 as expected in a 33 % yield over 
the two steps. The yield obtained was lower than expected from the 
literature,97 however, it was suitable as a proof-of-concept. Both 1H NMR and 
13C NMR spectroscopy supported the formation of analogue 138, with the 
diagnostic singlet from the epoxidation product 137 at 3.86 ppm absent and 
an exchangeable proton singlet present at 7.29 ppm consistent the hydroxyl 
group. This data was consistent with the literature.97 
With the proof-of-concept reactions producing the desired compound, 
synthesis was focused on the transformation of analogues 132 – 136. 
Although the initial epoxide formation was successful, hydrolysis of the 
epoxide for the amide analogues 132 – 136 did not proceed under the same 
conditions as demonstrated for the menadione (12) derivative (Scheme 19).  
 
Scheme 19: Attempted epoxidation and hydrolysis of analogues 132 – 136. 
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Surprisingly, concentrated sulfuric acid did not hydrolyse the epoxide even at 
elevated temperatures. Depending on the reaction conditions, either the 
epoxide was recovered or decomposition occurred. However, further 
optimisation of these conditions was not conducted as all material available 
for the various analogues was consumed in the initial attempts. Synthesis to 
regenerate sufficient amounts of these amide analogues would have been 
required. Therefore, an alternative synthetic route was investigated. 
Formation of a hydroxyl version of carboxylic acid analogue 130 prior to 
amide coupling would reduce the number of synthetic steps. However, when 
carboxylic acid 130 was reacted via the same two-step sequence, the 
rearrangement of the epoxide failed. Therefore, it was proposed to add the 
side chain to a hydroxynaphthoquinone.  
The synthesis of hydroxy analogue of carboxylic acid derivative 32 was 
attempted by subjecting lawsone (139) to the standard silver-mediated 
radical decarboxylation method. However, this reaction was unsuccessful 
and likely due to the presence of the hydroxyl substituent. Concequently, a 
literature method by Kongkathip et al. who successfully C-alkylated lawsone 
(139) by α-bromoacetate ethyl ester (140) in DMF to form compound 141 in a 
40 % yield (Scheme 20) was investigated.99 
 
Scheme 20: Successful C-alkylation by of lawsone (139) by Kongkathip et al. 99 
The successful reaction conditions by Kongkathip et al. 99 suggested that the 
introduction of the side-chain could be achieved via C-alkylation using ethyl 
4-bromobutyrate to form 142 followed a subsequent hydrolysis step to reveal 
the acid fragment. However, the reported reaction conditions resulted in the 
formation of analogue 143 by O-alkylation (Scheme 21). 
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Scheme 21: Failed C-alkylation of lawsone (147) with Li2CO3. 
Both 1H NMR and 13C NMR spectroscopy supported the formation of 
analogue 143 rather than 142. The most compelling evidence that the O-
alkylation had occurred in place of C-alkylation was the presence of a proton 
in the 1H NMR spectrum at 6.14 ppm indicating the proton attached to the 
C3-position of lawsone (quinone) core (139). In addition to the diagnostic 
singlet, a resonance at 4.06 ppm integrating for two protons presenting as a 
triplet was a key indication that there was a -CH2- fragment adjacent to 
oxygen as it was shifted downfield due to deshielding by the oxygen. As this 
synthetic method had resulted in an undesired O-alkylation, alternative 
reaction conditions were explored.  
Although the silver-mediated radical decarboxylation method was 
unsuccessful for lawsone (139), there was literature precedence for the 
introduction of the alkyl chain through radical generation via an alternative 
silver-free method.100 Generation of the radical via thermal cleavage of a 
peroxyacid intermediate was previously investigated for menadione (12) in 
the preliminary study by Woolley and co-workers.75,77 Notably, Yakubovskaya 
and co-workers employed this same method for the successful introduction of 
alkyl chains onto the lawsone core (139) in 60 – 80 % yields (Scheme 22). 
 
Scheme 22: Successful introduction of an alkyl chain by radical formation by 
Yakubovskaya et al.100 
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Although this method contains a number of drawbacks as discussed in 
Chapter 2.2, the scale of synthesis required to generate sufficient quantities 
of a hydroxy analogue of carboxylic acid derivative 32 for subsequent 
reactions meant this literature method was viable.  
The nucleophilic attack of hydrogen peroxide of the carbonyl of the anhydride 
(47b) resulted in the formation of the peroxyacid 145 (Scheme 23). The 
oxygen of the peroxyacid then underwent the same nucleophilic attack on a 
second molecule of the anhydride (47b), to form the peroxide 48b.77 For 
safety reasons, this analogue was not scrupulously dried and was 
immediately subjected to the next step. Formation of the putative alkyl radical 
intermediate was generated through the slow addition of the peroxide to a 
solution of lawsone (139) in refluxing t-butanol.  
 
Scheme 23: Synthesis of analogues 149 via a peroxyacid intermediate to generate 
the carbon-centred radical. 
The formation of acid 149 was supported by 1H NMR and 13C NMR 
spectroscopic analysis. However, acid 149 could not be separated from a by-
product by either flash column chromatography or recrystallisation. Although 
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a small amount was obtained in pure form for characterisation purposes, it 
was decided that analogue 158 would be used as a crude mixture and 
purified after the amide coupling step. The crude mixture was subjected to 
amide bond formation with the five key amine fragments (Table 14).     
Table 14: Synthesis of derivatives 150 – 154 containing hydroxyl substituents. 
 
Entry Amino Derivative  Structure Yield (%)  
1 
L-phenylalanine         t-
butyl ester 
 
9* 
2# L-phenylalanine 
 
74 
3 L-phenylalaninol 
 
0 
4 tyramine 
 
4* 
5 
3,4-dimethoxy-
phenethylamine 
 
5* 
# Analogue formed via deprotection of the t-butyl ester 150. 
* Yield was calculated as if acid 149 was a pure compound. 
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With the exception of phenylalaninol derivative 152, all of the compounds 
were successfully prepared and characterised by 1H and 13C NMR 
spectroscopy. The yields of these analogues (150, 153 and 154) were very 
low (<10 %) but sufficient material was formed for biological evaluation. The 
1H NMR spectra associated with analogues 150, 151, 153 and 154 were 
consistent with the equivalent 1H NMR spectroscopic data associated with 
the respective non-methylated analogues (132, 133, 135 and 136). A key 
diagnostic shift at ~155.0 ppm in the 13C NMR spectrum associated with all 
analogues was consistent with the presence of the hydroxyl substituent on 
the quinone core. In the other C3-derivatives (Me or H), this carbon signal 
was present at ~145.0 ppm. 
Unfortunately, the formation of phenylalaninol derivative 152 was not 
successful when PyBOP (59) was used as the coupling agent. Analysis of 
the crude mixture by 1H NMR spectroscopy could not determine whether the 
amide coupling was successful. It is not clear if the alcohol was interfering 
with the coupling. Attempts using different coupling agents all proved fruitless 
and no products were isolated. Due to time constraints, biological evaluation 
was performed without L-phenylalaninol derivative 152 and synthesis of 
analogue 152 was no longer pursued. All successfully synthesised analogues 
were subjected to biological evaluation and compared against the methyl and 
non-methyl analogues as indicated in Figure 42. 
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Figure 42: Biological evaluation of methyl, non-methyl and hydroxyl substituted 
naphthoquinones in two assays (a) Cytoprotection against rotenone induced 
complex I dysfunction by quinones at 10µM given as a relative percentage of cell 
survival compared to untreated HepG2 cells (b) ATP rescue by quinones at 10µM in 
the presence of rotenone-induced complex I dysfunction as percentage of untreated 
HepG2 cells. Data represents the mean of n=3 independent experiments with 6 
replicates each. 
As observed with the non-methyl derivatives (132 – 136), the analogues 
containing a hydroxyl substituent showed a decrease in their ability to provide 
cytoprotection and restore ATP levels compared to the methyl derivatives 
(61, 70, 76, 79 and 80). A decrease in cytoprotection indicates the hydroxyl 
quinone derivatives 150, 151, 153 and 154 are more cytotoxic. Not only does 
this evidence support the hypothesis that the methyl substituent blocks 
metabolism or prevents some form of conjugation, it also highlights the need 
for further investigation into modifications of the quinone core.  
These results indicated the need for a substituent at the C3-position of the 
naphthoquinone core. However, quinones containing hydroxyl substituents 
such as embelin (155) and plumbagin (156) (Figure 43) are both found to 
induce apoptosis in various human cancer cells and increase ROS 
production.101-105 As these are undesirable characteristics for analogues that 
provide protection against mitochondrial dysfunction, hydroxyl groups should 
not be considered for further core modifications. 
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Figure 43: Structure of Embelin (155) and Plumbagin (156). 
Prior to further core modifications occurring such as halogenation in the C3-
position, it was proposed more evidence was required to determine if the 
naphthoquinone core was in fact optimal. All prior hypotheses were based of 
toxicity data and the comparison of idebenone (11) and the idebenone-like 
naphthoquinone derivative (13). Therefore, further evidence was required for 
a direct comparison of benzoquinones before additional core modifications 
were to be conducted. Therefore, the synthesis of analogues containing the 
plastiquinone and benzoquinone cores was required for comparison. This 
was attempted using the silver-mediated addition of an alkyl group to the 
corresponding quinone. 
3.3 Synthesis of plastiquinone analogues 
Synthesis of analogues containing the plastiquinone core required the 
oxidation of trimethylhydroquinone (157). The oxidation of hydroquinone was 
effected using a mixture of iodine, sulfuric acid and aqueous hydrogen 
peroxide at room temperature to afford 2,3,5-trimethyl-p-benzoquinone 
(plastiquinone) (5) in an 80% yield as reported in the literature (Scheme 
24).18    
 
Scheme 24: Formation of the plastiquinone core (5) via oxidation. 
The successful synthesis of the plastiquinone core (5) was consistent with 
the literature.18 Two diagnostic carbonyl signals present in the 13C NMR 
spectrum at 187.3 and 187.7 ppm indicated that oxidation to the quinone had 
occurred. With the formation of sufficient quantities of the plastiquinone core 
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(5), it was then subjected to the silver-mediated radical decarboxylation 
reaction to introduce the four-carbon chain as seen in Scheme 25.  
 
Scheme 25: Formation of analogue 158.  
Alkylation of the plastoquinone core 5 gave the desired analogue 158 in a 
moderate 33 % yield. This was not ideal, however, in order to prevent the 
formation of a by-product similar to that observed when synthesising the 
naphthoquinone carboxylic acid derivative 32, the reaction time was limited to 
0.5 h with sufficient quantities obtained to prepare subsequent compounds. 
The unreacted plastiquinone core (5) was recovered via chromatography and 
reused in subsequent reactions. Formation of analogue 158 was supported 
by both 1H and 13C NMR spectroscopic analysis, with no spectral data 
available in the literature for comparison. The diagnostic absence of a singlet 
in the 1H NMR at 6.46 ppm indicated that the proton at the C3-position of the 
plastiquinone core (5) was no longer present. Additional resonances in the 
aliphatic region of the 1H NMR spectrum indicated the successful introduction 
of the four-carbon chain. An additional carbonyl resonance in the 13C NMR 
spectrum at 179.2 ppm supported the presence of the carboxylic acid 
fragment of the new alkyl chain. The plastiquinone derivative containing the 
four-carbon chain (158) was then subjected to amide coupling of the top five 
fragments as seen in Table 15. 
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Table 15: Synthesis of plastiquinone derivatives 159 – 163.   
 
Entry Amino Derivative  Structure Yield %  
1 
L-phenylalanine                     
t-butyl ester 
 
24 
2# L-phenylalanine 
 
>95 
3 L-phenylalaninol 
 
11 
4 tyramine 
 
51 
5 
3,4-dimethoxy-
phenethylamine 
 
42 
# Analogue formed via deprotection of the t-butyl ester 168. 
The successful synthesis of analogues 159 – 163 was supported by 1H NMR 
and 13C NMR spectroscopy. The NMR spectra associated with analogues 
159 – 163 were consistent with the equivalent NMR spectroscopic data 
associated with the respective naphthoquinone derivatives (61, 70, 76, 79 
and 80). However, the yield of 161 was exceptionally low, prompting 
investigation as to why amide coupling had not been high yielding for the 
phenylalaninol. A second compound (164) (Figure 44) was isolated from the 
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reaction mixture; however, no yield for 164 was obtained. The formation of 
analogue 164 was proposed to be a result of decomposition of the coupling 
agent BOP (59) due to age, which allowed for amide coupling to the 
dimethylamine fragments.  
 
Figure 44: Structure of the by-product (164) and BOP (59).  
Formation of the by-product (164) was identified by 1H NMR spectroscopy 
with two very distinctive singlets at 2.92 and 2.98 ppm integrating for three 
protons each. The formation of the by-product (164) resulted in a decrease of 
the amount of the plastiquinone derivative (158) and accounted for the 
reduced yield of phenylalaninol derivative 161. Although the yields for all 
analogues were low, sufficient quantities were synthesised for the purpose of 
biological evaluation. However, before all plastiquinone analogues were 
subjected to biological evaluation, synthesis of the benzoquinone derivatives 
were required for comparison. 
3.4 Synthesis of 2,3-dimethoxy-5-methyl-1,4-benzoquinone 
analogues 
Synthesis of analogues containing the 2,3-dimethoxy-5-methyl-1,4-
benzoquinone core (6) required the synthesis of the core itself, which was 
achieved through a four-step synthesis (Scheme 26). 
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Scheme 26: Retrosynthetic analysis of analogues containing the 2,3-dimethoxy-5-
methyl-para-benzoquinone core (6).  
Synthesis of the benzoquinone core (6) required commercially available 
2,3,4-trimethoxytoluene (167) as a precursor. However, due to difficulties 
sourcing this compound, the key starting material was synthesised in the first 
instance.  
Synthesis of 3,4,5-trimethoxytoluene (167) 
2,3,4-Trimethoxytoluene (167) was synthesised by the literature method106 
starting from p-cresol (168), through bromination followed by O-methylation 
to produce 3,5-dibromo-4-methoxytoluene (170) before subsequent 
methoxylation to produce 3,4,5-trimethoxytoluene (167) (Scheme 27).106  
 
Scheme 27: Synthesis of 3,4,5-trimethoxytoluene (167). 
Formation of 2,6-dibromo-p-cresol (169) was consistent with the literature 
and required no purification.107 1H NMR spectroscopy supported the 
formation of the product with a lone singlet present in the aromatic region at 
7.20 ppm integrating for two protons indicating successful dibromonation with 
no proton signal splitting due to symmetry. O-Methylation of 2,6-dibromo-p-
cresol (169) with methyl iodide produced 3,5-dibromo-4-methoxytoluene 
(170) as a pale yellow oil in 90 % yield (Figure 45). The copper-catalysed C–
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O coupling of dibromide 170 provided 3,4,5-trimethoxytoluene (167) and 3,4-
dimethoxytoluene (171) in a 3:2 ratio respectively.108  
 
Figure 45: 1H NMR of a 3:2 mixture of 3,4,5-trimethoxytolune (167) and 3,4-
dimethoxytoluene (171). 
The two analogues were clearly distinguished by 1H NMR spectroscopy with 
two singlets present at 3.81 and 3.84 ppm integrating for three and six 
protons respectively, which is consistent with 3,4,5-trimethoxytoluene (167). 
In comparison, two singlets present at 3.85 and 3.86 ppm integrating for 
three protons each is consistent with 3,4-dimethoxytoluene (171). These two 
analogues co-eluted via column chromatography and although separation 
would have been possible by distillation, the mixture was not purified but was 
used in the next step as a crude mixture. The formation of the 3,4-
dimethoxytoluene (171) through de-halogenation was proposed to be a result 
of the quality of copper (I) iodide used. However, due to sufficient quantities 
of 3,4,5-trimethoxytoluene (167) obtained, further reactions with fresh copper 
(I) iodide were not pursued.  
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Synthesis of the 2,3-dimethoxy-5-methyl-benzoquinone core (6) and 
analogues 
2,3-Dimethoxy-5-methyl-benzoquinone core (6) was prepared according to a 
literature procedure by Wang and co-workers,109 who screened and 
optimised conditions for the conversion of 3,4,5-trimethoxytoluene (167) to 
2,3-dimethoxy-5-methyl-1,4-benzoquinone (6). Formation of 6 occured in 
metal-free conditions utilising hydrogen peroxide as an oxygen atom donor. 
The choice of solvent, formic acid/acetic acid, is reported to play an important 
role in the transformation.109 Formation of the benzoquinone core (6) 
proceeded in a 55 % yield and was easily purified by chromatography from 
the 3,4-dimethoxytoluene (171) (Scheme 28). 
 
Scheme 28:  Synthesis of 2,3-dimethoxy-5-methyl-1,4-benzoquinone (6). 
Formation of the benzoquinone core (6) was consistent with the literature109 
and supported by both 1H NMR and 13C NMR spectroscopy. With the 
formation of the core complete, this analogue was subjected to the silver-
mediated radical decarboxylation process to install the four-carbon chain 
(Scheme 29). 
 
Scheme 29: Formation of analogue 166. 
Reaction of benzoquinone 6 under the standard conditions gave the desired 
benzoquinone carboxylic acid 166 in a low 25 % yield. Despite the yield, the 
unreacted benzoquinone core 6 was recovered after column chromatography 
and re-used in subsequent reactions. Both 1H NMR and 13C NMR 
spectroscopy supported formation of analogue 166, with the absence of the 
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diagnostic peak at 6.42 ppm, indicating the proton attached to the C3-
position of the core was no longer present. Similarly, the presence of a third 
carbonyl signal at 178.5 ppm and additional aliphatic carbon signals in the 
13C NMR spectrum indicated the successful installation of the alkyl chain. 
The benzoquinone derivative containing the four-carbon chain (166) was 
then subjected to amide coupling of the top five fragments (Table 16). 
Table 16: Synthesis of benzoquinone derivatives 172 – 176.  
 
Entry Amino Derivative  Structure Yield (%)  
1 L-phenylalanine t-butyl ester 
 
12 
2# L-phenylalanine 
 
84 
3 L-phenylalaninol 
 
17 
4 tyramine 
 
13 
5 3,4-dimethoxy-phenethylamine 
 
11 
# Analogue formed via deprotection of the t-butyl ester 172. 
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Synthesis of the analogues proceeded as expected, albeit in low yields. 
These yields and reactions occurred prior to the knowledge that the integrity 
of the BOP (59) coupling agent was compromised. Therefore, a large 
percentage of the mass contained the dimethyl amide. Co-elution of this 
impurity was also an issue and the isolation of the pure product required 
multiple chromatographic attempts, which contributed to the low yields. Both 
1H NMR and 13C NMR spectroscopy supported the formation of all 
analogues, with characteristic signals associated with both the plastiquinone 
and naphthoquinone analogues also observed for the benzoquinone 
analogues (172 – 176).  
With both the plastiquinone and benzoquinone analogues synthesised, 
biological evaluation was undertaken to compare the three quinone cores 
with identical side-chains (Figure 46). In all but one case, the activity of the 
benzoquinone and plastoquinones was significantly less than the 
naphthoquinone. Notably, L-phenylalanine, L-phenylalaninol, tyramine and 
3,4-dimethoxyphenethylamine analogues containing either the plastiquinone 
or benzoquinone core showed no ability to provide cytoprotection or restore 
ATP levels.  
 
Figure 46a: Biological evaluation of naphthoquinone, plastoquinone and 
benzoquinone. Cytoprotection against rotenone induced complex I dysfunction by 
quinones at 10µM given as a relative percentage of cell survival compared to 
untreated HepG2 cells Data represents the mean of n=3 independent experiments 
with 6 replicates each. 
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Figure 46b: Biological evaluation of naphthoquinone, plastoquinone and 
benzoquinone. ATP rescue by quinones at 10µM in the presence of rotenone-
induced complex I dysfunction as percentage of untreated HepG2 cells. Data 
represents the mean of n=3 independent experiments with 6 replicates each. 
The comparison of the four-carbon acid analogues of all three quinone cores 
showed no difference in their ability to provide cytoprotection or restore ATP 
levels with all showing little activity in ATP rescue or cytoprotection. Within 
the top five optimised analogues, the naphthoquinone core was superior to 
both the plastiquinone and benzoquinone derivatives indicating the 
combination of the naphthoquinone core and side-chain provide superior 
activity. Both plastiquinone and benzoquinone derivatives were unable to 
provide cytoprotection or restore ATP levels with the exception of the L-
phenylalanine t-butyl ester derivatives, which provided unexpected results as 
all three quinone cores produced similar levels of protection. Although the 
naphthoquinone L-phenylalanine t-butyl ester analogue 61 did not provide 
excellent cytoprotection, it was expected that both the plastiquinone and 
benzoquinone analogues would still show a significant difference. This result 
prompted the question as to whether the quinone moiety was actually 
required or was a simple aryl group sufficient for this substrate. Therefore an 
analogue containing phenyl butyric acid coupled to L-phenylalanine t-butyl 
ester was synthesised (Scheme 30) to determine if ATP rescue and 
cytoprotection could be restored in the absence of a quinone moiety. 
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Scheme 30: Synthesis of analogue 178. 
The successful synthesis of analogue 178 from phenylbutyric acid and L-
phenylalanine t-butyl ester occurred in an 81 % yield. Both 1H NMR and 13C 
NMR spectroscopy supported the formation of the analogue with the 
characteristic doublet at 6.13 ppm integrating for one proton which was 
identified as the proton attached to the nitrogen. Biological evaluation of 
phenyl derivative 178 indicated it had no ability to restore ATP or provide 
cytoprotection, which was vastly different from the quinone derivatives. 
Therefore this indicated the requirement of the quinone core for activity was 
essential. The likely explanation for the results seen for the L-phenylalanine t-
butyl analogues with all three cores is the effect of polarity of the residues. 
There is potential that the less polar t-butyl esters resemble the types of 
compounds investigated by Erb et al.2 Nevertheless, this result does not 
affect the outcome of this research, as the L-phenylalanine t-butyl ester 
analogues do not provide the highest level of cytoprotection or ATP rescue 
levels seen by the other four fragments and the L-phenylalanine, L-
phenylalaninol, tyramine and 3,4-dimethoxyphenethylamine derivatives 
remain the most active. 
Therefore, core optimisation studies indicated the importance of the 
naphthoquinone core and the requirement for a substituent in the C3-
position. This potentially prevents metabolism of the naphthoquinone core. 
The methyl group represented the optimal C3-substituent investigated. The 
comparison of the three quinone cores illustrated the ineffectiveness of all 
potential therapeutics currently being investigated for mitochondrial 
dysfunction. Notably, to date no analogues contain the naphthoquinone core. 
Initial investigations into the phosphonium cation analogues MitoQ (8) and 
SKQ1 (9) have shown potential as therapeutics for mitochondrial dysfunction 
but again both have neglected to investigate the core properties. Similarly 
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with idebenone (11), a simple modification to the naphthoquinone has shown 
dramatic results. Therefore this result indicates that studies investigating 
quinone analogues for mitochondrial dysfunction should also include 
derivatives featuring naphthoquinone core for comparison. 
3.5 Synthesis of Indoloquinone analogues 
The idea of investigating novel organic cores was attempted with the 
introduction of the indoloquinone core (179) as a substitute for the 
naphthoquinone (Figure 47). Various indoloquinones are naturally occurring 
and are known to contain antifungal, antitumour activity and cytotoxic 
activities.110 One well known indoloquinone is Mitomycin C (MMC, 180) 
(Figure 47), which is an antitumour antibiotic (chemotherapeutic agent) and 
has been widely used for the treatment of various cancers.111,112 Since the 
discovery of MMC (180) and its clinical applications, a large number of 
synthetic indoloquinones have been developed. A synthetic analogue of 
MMC (180), apaziquone (EO9, 181) is currently in advanced clinical trials as 
a treatment for bladder cancer (Figure 47).113 
 
Figure 47: Structure of the indoloquinone core (179), Mitomycin C (MMC, 180) and 
synthetic analogue apaziquone (EO9, 181). 
Although the bioactive characteristics of Mitomycin C (180) are not ideal for 
analogues to treat mitochondrial dysfunction, it is important to note that the 
majority of indoloquinones within the literature are highly functionalised, 
which is vastly different from the application under investigation. The 
compounds proposed would be simple substrates with an alkyl chain at one 
of the four positions (Figure 48).  
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Figure 48: Structure if the indoloquinone core 179 with the four sites of modification 
highlighted. 
Initially, a propyl chain attached to the C3-position of the indoloquinone core 
would be required, which could be prepared by the proposed sequence in 
Scheme 31. The 4,7-dimethoxyindole (182) was required, which upon 
oxidation yields the indoloquinone core. The key step in the synthesis of  
indole 182 was a Hemetsberger–Knittel reaction meaning that 2,5-
dimethoxybenzaldehyde was required. 
 
Scheme 31: Proposed multi-step reaction route to obtain analogue 192. 
Synthesis of 2,5-dimethoxybenzaldehyde (183) proceeded according to 
literature methods via bromination of hydroquinone (193) to give 194.114-116 
Subsequent O-methylation of the hydroxyl groups with methyl iodide 
provided 195, then a bromine–lithium exchange and reaction with DMF 
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produced 2,5-dimethoxybenaldehyde (183)117 in ~62 % yield over the three 
steps (Scheme 32). 
 
Scheme 32: Synthesis of 2,5-dimethoxybenaldehyde (183). 
The successful synthesis of 183 was consistent with the literature and 
supported by both 1H NMR and 13C NMR spectroscopy.118 2,5-
Dimethoxybenzaldehyde (183) underwent a modified aldol condensation 
reaction (Knoevenagel condensation119) with methyl-2-azidoacetate (184) 
(Scheme 33) to form analogue 185. Compound 185 was subjected to thermal 
ring closure to form the indole core (186) via a Hemetsberger–Knittel reaction 
which involves insertion of a nitrene.120 Hydrolysis of ester of 186 revealed 
the carboxylic acid fragment in 187 in a 60 % yield.  
 
Scheme 33: Formation indole core 187. 
The 1H NMR and 13C NMR spectra of 185, 186 and 187 were consistent with 
equivalent data reported previously.121 The 1H NMR spectrum of indole 186 
showed two distinct doublets at 6.33 and 6.59 ppm each integrating for one 
proton, which was consistent with the protons attached to the C5 and C6 
position. The proton attached at the C3 position of the indole was consistent 
with a doublet at 7.44 ppm (J = 2.3 Hz). Hydrolysis to form 187 was 
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consistent with literature121 and in comparison to the 1H NMR spectrum of 
186, did not feature a singlet at 3.90 ppm, which previously integrated for 
three protons, suggesting the loss of the methyl substituent. 
Decarboxylation of 187 was problematic with the literature method resulting 
in a poor yield and therefore reaction conditions were optimised (Table 17). 
Optimisation of the literature method (Table 17, Entry 1) featured an 
investigation into copper loading, temperature and reaction time. In addition 
to optimisation of the reaction conditions, the work-up procedure was also 
altered. The literature method121 featured the evaporation of quinoline under 
reduced pressure followed by chromatography, however, difficulties of 
removing the quinoline prior to chromatography proved problematic. Instead, 
an aqueous extraction was effective in removing the quinoline before indole 
182 was purified by chromatography. 
Table 17: Optimisation of reaction conditions for the decarboxylation of 187 to yield 
182. 
 
Entry 
Copper 
Bronze (eq.) 
Reaction 
Time (h) 
Temperature 
(°C) 
Work up Procedure Yield % 
1 0.7 3 160 filtration 6 
2 0.7 18 160 filtration 22 
3 5 2.5 200 aqueous extraction 44 
4 5 4.5 200 aqueous extraction 60 
5 5 6 200 aqueous extraction 22 
  Note: Yield % is the pure mass after purification. 
Spectroscopic analysis of the decarboxylation of 4,7-dimethoxy-1H-indole-2-
carboxylic acid (187) to yield 4,7-dimethoxyindole (182) was consistent with 
that reported in the literature.121 However, an inability to replicate the results 
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(table 17, Entry 4) was a significant issue as yields varied from 19 – 60 %. A 
subsequent Vilsmeier–Haack formylation provided aldehyde 188122-124 and a 
Wadsworth–Emmons olefination was then performed to install the alkyl side 
chain (Scheme 34).   
 
Scheme 34: Formation of analogue 188 and 189. 
Formylation of 4,7-dimethoxyindole 182 gave aldehyde 188 in good yield (70 
%) according to the literature procedure.124 A diagnostic resonance at 10.30 
ppm in the 1H NMR spectrum was consistent with the introduction of an 
aldehyde while a singlet at 7.89 ppm was consistent with the proton attached 
to the C2-position, therefore supporting formylation at C3. This was further 
supported by an additional carbonyl resonance at 186.3 ppm indicating the 
successful installation of the aldehyde functionality. However, when 
subjected to the Wadsworth–Emmons olefination to produce novel 
compound 189, the reaction proceeded in a low 27 % yield. Both 1H NMR 
and 13C NMR spectra supported the successful conversion to analogue 189. 
The 1H NMR spectrum showed key diagnostic features for the introduction of 
an ethyl ester functionality with a distinct triplet at 1.33 ppm integrating for 
three protons and a quartet at 4.26 ppm integrating for two protons which 
was shifted downfield due to deshielding by the ester. In addition, two 
doublets were present at 6.41 and 8.30 ppm with a coupling of 14.0 Hz. This 
indicated the presence of a trans-alkene as expected from a Wadsworth–
Emmons olefination.  
The low yields obtained for the key steps such as the formation of 182 by 
decarboxylation and the Wadsworth–Emmons olefination of 188 to form 189 
dictated that the structure of the target molecule should be revised. A more 
synthetically accessible molecule was identified in order to evaluate the 
biological activity of an indoloquinone moiety as a Complex I bypass prior to 
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committing to prepare a more complex target. Therefore a new synthetic 
route was devised to utilise indoloquinone 197 to introduce side-chains to 
make compounds such as 198 (Scheme 35). This would require far fewer 
synthetic steps and used indole ester 186 already in-hand. 
 
Scheme 35: Proposed formation of analogue 198. 
Initial oxidation attempts were performed using ceric ammonium nitrate 
(CAN) as it is the most frequently used oxidant for formation of quinones. 
Oxidation of the indole methyl ester 186 to the indoloquinone core of 196 was 
performed following a literature method with reported quantitative conversion 
of derivative 199 to 200 (Scheme 36).125  
 
Scheme 36: Literature example of oxidation of an indole core 199 to the 
corresponding indoloquinone 200.125 
However, oxidation of the indole methyl ester 186 to the indoloquinone core 
of 196 using the literature method proved difficult. An unidentified product 
was obtained in high yield. Initially this was proposed to be over oxidation of 
the C3-position of the indole ring or introduction of a nitro (NO2) substituent 
through radical formation as no signal for H3 could be observed in the 1H 
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NMR spectrum. Therefore supporting a structure consistent with 201a. 
Optimisation of the reaction conditions focused on shortening of the reaction 
time, avoiding light to prevent the formation of nitro radicals and decreasing 
the reaction temperature (Table 18). Unfortunately, in all cases the desired 
product was not formed. 
Table 18: Oxidation of 186 using CAN. 
 
Entry 
Temperature 
(°C) 
CAN 
(Eq.) 
Light/Dark 
Reaction 
Time (h) 
196 201a 
1 r.t. 3 Light 2 ✗ ✓ 
2 r.t. 3 Dark 1 ✗ ✓ 
3 0 3 Dark 1 ✗ ✓ 
 
Formation of the indoloquinone portion of the oxidation product 201a was 
supported by two doublets present in the 1H NMR spectrum at 6.57 and 6.70 
ppm integrating for one proton each with a coupling of 10.3 Hz indicating H5 
and H6 protons. In addition to this, two carbonyl signals at 179.1 and 184.2 
ppm for C4 and C5 indicated the successful oxidation to the indoloquinone 
core. The structural assignment of the molecule could be determined with the 
exception of the C3-substituent. Analysis of the sample by MS indicated that 
a dimer had formed and therefore the structure of the oxidation was 
bispyrrole 201 (Figure 49). The predicted HRESIMS for C20H12N2NaO8 was 
431.0486 and it was found to be 431.0487 for analogue 201.  
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Figure 49: Structure of by-product 201. 
This suggests that the desired product was formed but reacted further and 
therefore alternative oxidants were investigated. A literature method for 
oxidising indoles to indoloquinones via silver oxide and nitric acid was 
employed, however, decomposition occurred.126 Therefore alternative 
conditions were explored. Hypervalent iodine (III) oxidant, PIFA (phenyliodine 
(III) bis(trifluoroacetate)), was shown to oxidise indoles to indoloquinones in 
aqueous reaction conditions in good yields (Scheme 37).127  
 
Scheme 37: Literature example of oxidation of an indole (202) to the corresponding 
indoloquinone (203) using PIFA.127  
 Utilising PIFA under the reported conditions, the desired product (196) was 
obtained (Table 19, Entry 1), but the undesired bisindoloquinone 201 formed 
in the CAN reactions was observed as the major product in a 1:2 ratio of 
196:201. Therefore the reaction conditions for PIFA oxidation were optimised 
to increase conversion of the desired product (196) and minimise formation 
of the undersired bispyrrole 201 (Table 19).  
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Table 19: Oxidation of analogue 186 using PIFA.  
 
Entry PIFA (Eq.) Reaction Time (h) Temperature (°C) 186 : 196 : 201 
1 4 2 r.t. 0 : 1: 2 
2 4 0.75 r.t. 0 : 1 : 2 
3 1.5 1 0 3.5 : 5 : 4.5 
4 1.5 1 r.t. 1 : 1 : 0.2 
5 1.5 1 40 1 : 1 : 0.5 
 
Decreasing the reaction time from 2 h to 0.75 h did not alter the product ratio. 
However, decreasing the equivalents of PIFA from 4 to 1.5 resulted in a 
decrease in the formation of the undesired bispyrrole 201. A decrease in 
reaction temperature resulted in both 196 and 201 forming at similar rates. 
The reaction conditions (Table 19, Entry 4) were deemed to be the conditions 
for future oxidation as minimal by-product was formed. Notably there is 
starting material present, however chromatography enabled the separation 
and recovery of both materials. Thus, the recovered starting material could 
be reused.  
The structure of the desired indoloquinone 196 was supported by both 1H 
NMR and 13C NMR spectroscopy and was consistent with the spectral data 
reported in the literature.128 The successful oxidation to indoloquinone 196 
was supported by 13C NMR spectroscopy with the presence of two new 
carbonyl signals at 177.7 and 182.3 ppm. A doublet at 7.23 ppm with a 
coupling for 1.7 Hz and an integration of one was consistent with the 
presence of the C3 proton in the 1H NMR spectrum.  
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The formation of the bisindoloquinone 201 was proposed to result from an 
Scholl oxidation, which is the dimerization of an aryl, however, electron rich 
heteroarenes such as pyrroles and indoles have also been reported to 
undergo such reactions.129,130 Specifically, Kita and co-workers developed 
the use of PIFA and a Lewis acid additive in the oxidative coupling of pyrroles 
(204) to give bipyrroles (205) (Scheme 38).127,131  
 
Scheme 38: Oxidative coupling of pyrroles using PIFA to give bipyrroles.129,130 
Therefore, it is not surprising that an indoloquinone dimer was obtained in the 
presence of PIFA. In the literature examples of 200 and 203 with CAN and 
PIFA respectively, the bispyrrole is likely not formed due to an electron-
withdrawing group present on the nitrogen of the pyrrole. Notably, it appears 
that there are no reports in the literature of CAN effecting this type of 
reaction. With sufficient quantities of 196 now available, an attempted 
hydrolysis of the methyl ester to reveal the acid moiety was performed as 
indicated in Scheme 39. 
 
Scheme 39: Attempted hydrolysis of 196 to form 197, (a) 10 % NaOH (b) H2SO4, 
AcOH, H2O. 
However, both base and acid hydrolysis under standard conditions resulted 
in rapid decomposition. Therefore it was proposed that changing the reaction 
sequence to the hydrolysis of the methyl ester, oxidation to the indoloquinone 
and then subsequent amide coupling was one potential synthetic pathway or 
hydrolysis followed by amide coupling and then oxidation to the 
indoloquinone as the alternative pathway to investigate. Oxidation of the 4,7-
dimethoxy-1H-indole-2-carboxylic acid 187 to the resulting indoloquinone via 
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the optimised PIFA reaction conditions resulted in complete decomposition. 
Therefore, coupling of L-phenylalanine t-butyl ester to 4,7-dimethoxy-1H-
indole-2-carboxylic acid 187 prior to oxidation was investigated. Coupling of 
4,7-dimethoxy-1H-indole-2-carboxylic acid 187 with L-phenylalanine t-butyl 
ester resulted in the formation of analogue 206 in a 50 % yield (Scheme 40). 
 
Scheme 40: Formation of analogue 198. 
Formation of the coupled product 206 was supported by 1H NMR and 13C 
NMR spectroscopy. The 1H NMR spectrum featured a doublet present at 
6.77 ppm integrating for one proton with a coupling of 7.7 Hz, which is 
consistent with the proton attached to the nitrogen. The presence of the C3 
proton was supported by a doublet at 6.97 ppm with a coupling of 1.7 Hz. 
Analogue 207 was then oxidised to the indoloquinone following the optimised 
PIFA conditions, producing the indoloquinone analogue 207 in a 25 % yield. 
Notably, the undesired dimer of 207 was also present. Formation of 207 was 
supported by both 1H NMR and 13C NMR spectroscopy. The key diagnostic 
signals that suggested that the successful oxidation had occurred were the 
two carbonyl signals at 177.4 and 182.6 ppm in the 13C NMR spectrum. 
Additional support for this was the absence of the singlet at 3.89 ppm, which 
integrated for 6 protons and had previously been attributed to the methoxy 
substituents. Lastly, a singlet at 6.93 indicated the proton attached to the C3-
position had been retained throughout the oxidation process. 
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In the final step, deprotection of the t-butyl ester revealed acid 198. 
Successful removal of the protecting group was supported by both 1H NMR 
and 13C NMR spectroscopy. In the 1H NMR spectrum, the absence of a 
singlet at 1.44 ppm integrating for nine protons was consistent with this. 
Furthermore, the 13C NMR spectrum displayed the loss two signals at 83.2 
and 28.1 ppm for the quaternary and methyl carbons respectively, which 
supports the loss of the t-butyl group.  
The successful synthesis of indoloquinone 198 clearly was inefficient and 
required a large number of synthetic steps. Most importantly it indicated this 
was not a viable route to obtain a library of compounds containing the 
indoloquinone core moiety for SAR. Thus, due to the significant synthetic 
challenges encountered and the exceptionally low yields for a number of 
reaction steps, a new synthetic pathway was required. A possible alternative 
may employ a synthetic method developed by Eastabrook et al. which utilises 
a C–H borylation method (Scheme 41).128  
 
Scheme 41: Literature method by Eastabrook et. al. for rapid three step synthesis of 
indoloquinones.128 
However, due to time restraints no other indoloquinone analogues were 
synthesised until the results of biological testing on analogue 198 were 
obtained.  
3.6 Conclusions 
In summary, in this chapter a number of important factors were identified:-  
1. The methyl substituent at the C3-position of the naphthoquinone core 
was identified as highly important, as removal of this substituent 
resulted in a decrease in cytoprotection and the ability to restore ATP 
levels.  
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2. This effect was proposed to be due to oxidation or conjugation with 
glutathione that prevented the analogues to shuttle in and out of the 
mitochondria.  
3. The superiority of the naphthoquinone core over both plastiquinone 
and benzoquinone analogues was determined. It was demonstrated 
that both the plastiquinone and benoquinone derivatives were unable 
to rescue ATP levels and provide cytoprotection under identical 
conditions in a comparative analysis featuring five common side-
chains.  
4. Therefore, the identified analogues that are superior to idebenone 
require a naphthoquinone core with a methyl substituent in the C3-
position, a side chain containing a four-carbon linker and an amino 
alcohol or equivalent amine attached through an amide linkage (Figure 
50).  
With the SAR complete, the next stage will be to select compounds for in 
vivo analysis. 
 
 
 
 
 
 
 
Figure 50: Identified fragments for structure activity relationship (SAR). 
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Chapter 4: Redox active dye synthesis 
A molecular probe that provides a fluorescent reporter signal upon enzyme 
activation is highly sought after for many biological applications. This group of 
molecules are often referred to as optical contrast agents and are currently 
being explored by researchers for visualizing biological processes at the 
molecular level within living systems.132,133 In the literature, there are many 
examples of quinones coupled to profluorescent molecules that upon 
reduction with NQO1 release fluorophores resulting in fluorescence.134 One 
such example by Silvers and co-workers, employs compound 212 (Scheme 
42) as a rapid and selective tool for visualising and detecting human cancer 
cells that over express NQO1.134 In the context of this project, the monitoring 
of enzymes that can reduce quinones may be beneficial.  
For example, a profluorophore would be highly beneficial for identifying 
patients that have an inactivating NQO1 polymorphism, which are described 
in the general population, such as 609C>T polymorphism that results in 
decreased or even absent enzymatic activity of NQO1.14,64,65 If there is 
decreased or absent enzymatic activity, no fluorescence would be observed 
using such a probe. Identifying patients who have a NQO1 inactivation is of 
high importance as failure to reduce the quinone can lead to cytotoxicity.2 
Therefore, synthesis of a probe utilising the well-known naphthalimide dyes 
was investigated (Scheme 42).  
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Scheme 42: Representative reduction of a profluorophore 212 to release dye 215. 
This probe will be designed such that the fluorescence of the naphthalimide 
portion is quenched by being in close proximity to the quinone motif.133,134 
Upon reduction of the quinone to the hydroquinone, the molecule will 
undergo lactonisation and release of the fluorophore resulting in a 
fluorescence signal. Structural modifications to the profluorophore can be 
broken down into three sections, the quinone acid, the linker and lastly the 
dye itself (Figure 51). It has been demonstrated previously that the carbon-
chain between the quinone and the carbonyl need gem-dimethyl 
substituents.134 This exploits the Thorpe–Ingold effect and cyclisation is >103 
faster than analogues without the gem-dimethyl substituents.134  
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Figure 51: Identified portions of the profluorophore 212 for modification. 
While probe 212 has been reported for NQO1, a new probe was designed 
based on the SAR developed in the previous chapters. After establishing the 
superiority of the naphthoquinone core over benzoquinones in Chapter 3, the 
design of the new probe contained the naphthoquinone core attached to the 
gem-dimethyl propionic chain. However, to develop an accurate SAR, 
comparison to the plastiquinone and benzoquinone core was required. The 
design of the linker portion of 212 was not discussed134 and is not clear that 
all the elements are necessary. To allow a methodical approach to 
developing a SAR, the linker portion of the new probe will contain the minimal 
amount of functionality possible in the first suite of compounds. Additional 
functionality would be introduced into the linker in the next suite of 
compounds if required. To reduce the number of structural changes in the 
first suite of probes, the proof of concept was performed without modification 
to the dye portion. In the future, the butyl chain of the naphthalimide can be 
altered for solubility reasons or to introduce polarity.  
The first suite of compounds proposed contained the unaltered naphthalimide 
portion directly to the quinone acid. Therefore, the first suite of compounds 
will remove the extra amino ethanol linker. For comparative reasons, three 
probes will be synthesised with each containing a different core. 
4.1 Synthesis of the quinone acid moieties 
Synthesis of the plastiquinone propionic acid (216) was performed according 
to the literature as reported by Borchardt et al. (Scheme 43).135 2,3,5-
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Trimethylhydroquinone (157) readily underwent Friedel–Crafts alkylation/ 
lactonisation under acidic conditions to form lactone 214 in 38 % yield. The 
successful synthesis of 214 was supported by both 1H NMR and 13C NMR 
spectroscopy, which was consistent with that reported in the literature.136 
 
Scheme 43: Synthesis of plastiquinone gem-dimethyl propanioc acid derivative 216. 
Oxidation and hydrolysis to the quinone was performed using NBS in 
quantitative yield.135 The formation of quinone 216 was supported by 13C 
NMR spectroscopy with shift in the carbonyl signal of the lactone from 168.9 
to 178.8 ppm consistent with a carboxylic acid moiety, along with two 
additional carbonyl signals present at 187.4 and 190.8 ppm indicating 
oxidation to the quinone. With formation of the plastiquinone derivative 
complete, focus shifted to the naphthoquinone moiety. Reduction of 
menadione (12) to menadiol (217) by sodium dithionite provided the 
hydroquinone (217) in a quantitative yield (Scheme 44).137-139  
 
Scheme 44: Reduction of menadione (12) to menadiol (217) followed by failed 
Friedel–Crafts alkylation/ lactonisation to yield 218. 
Attempts to lactonise menadiol (217) using the previously successful 
conditions failed to provide compound 218, with complete decomposition 
being observed. Therefore focus moved to a literature method specifically 
reported for the naphthoquinone moiety.140 However, these conditions did not 
yield the desired compound (Table 20, Entry 1).140 Screening of reaction 
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conditions by altering the reaction temperature, reaction time and the acid 
percentage did not improve the reaction outcome (Table 20).  
Table 20: Attempted lactonization of menadiol (217) to form 218. 
 
Entry Reaction Mixture 
Temperature 
(°C) 
Reaction time 
(h) 
Outcome 
1 CH3SO2H 70 2 Decomposition 
2 CH3SO2H Reflux 2 Decomposition 
3 CH3SO2H 40 2 Decomposition 
4 CH3SO2H r.t. 2 Decomposition 
5 
10 % CH3SO2H/ 
CH2Cl2 
Reflux 1.5 Decomposition 
6 Toluene (Microwave) 
170         
(300 watts) 
1 
Starting material 
+ menadione 
(12) 
7 Neat (Microwave)  
100          
(100 watts) 
0.5 
Starting material 
+ menadione (12) 
 
The addition of methanesulfonic acid to menadiol (217) resulted in an 
immediate colour change to dark purple then black, suggesting possible acid-
promoted decomposition. However, attempts to form lactone 218 in acid-free 
conditions at high temperature under microwave irradiation resulted in the 
return of starting material and menadione (12). Therefore, it was proposed 
that forming the gem-dimethyl acid of naphthoquinone could be achieved via 
the silver-promoted decarboxylation process (Scheme 45). 2,2-
OH
OH217
O
OH218
O
OH
O
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Dimethylsuccinic anhydride (219) was converted to mono-ester 220 in order 
to enable the introduction to the quinone core selectively. Ethanol opened the 
anhydride by attack at the least hindered carbonyl group. 
 
Scheme 45: Attempted formation of 221 via the silver-catalysed decarboxylation 
method. 
Formation of mono-ester 220 was supported by both 1H NMR, 13C NMR  and 
HMBC spectroscopy. In the HMBC, the hydrogen of the -CH2- of the ethyl 
ester displayed a three-bond correlation to the ester carbonyl. Where as the 
hydrogens of the gem-dimethyl substituents showed a correlation to the 
carbonyl of the carboxylic acid. Because these two groups did not show 
correlations to the same carbonyl group, this supported the ethyl ester 
formation at the least hindered carbonyl group (Figure 52). 
	  
Figure 52: HMBC spectrum of 220. 
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With acid 220 in hand, the synthesis of compound 221 via the silver-
mediated decarboxylation process was attempted. However, only menadione 
(12) was recovered. With the failure to obtain the naphthoquinone lactone 
218 or to form ester 221, focus shifted to synthesising the benzoquinone 
derivative. As the synthesis of 2,3-dimethoxy-5-methylbenzoquinone core (6) 
features the oxidised quinone moiety, reduction to the hydroquinone was 
required. The 2,3-dimethoxy-5-methyl-benzoquinone core (6) was reduced to 
the hydroquinone 222 in a 54 % yield via a sodium borohydride reduction, 
utilising a biphasic solvent mixture (Scheme 46).140 
 
Scheme 46: Sodium borohydride reduction of 6 to form 222. 
Hydroquinone 222 was then subjected to the Friedel–Crafts alkylation/ 
lactonisation reaction under acidic conditions as seen with the plastiquinone 
derivative (Scheme 47). Lactone 223 was formed under these conditions, in 
low yield (20 %). The literature indicates use of methanesulfonic acid as both 
the solvent and the catalyst for the synthesis of the benzoquinone derivative 
as seen with the naphthoquinone.140 However, due to decomposition 
observed with the naphthoquinone derivative and sufficient material obtained 
by this approach, no further optimisation was required.  
 
Scheme 47: Synthesis of gem-dimethyl lactone derivative 223. 
Lactonisation to form 223 was consistent with both 1H NMR and 13C NMR 
spectroscopy. Two additional singlets in the 1H NMR spectrum at 1.44 ppm 
integrating for six protons indicating the two gem-dimethyl substituents and a 
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singlet at 2.56 ppm integrating two protons which is consistent with the 
protons adjacent to the carbonyl group is consistent with formation of 223. A 
diagnostic carbonyl signal was now present in the 13C NMR spectrum at 
167.8 ppm for the lactone carbonyl. The lactone was also supported by IR 
spectroscopy with a carbonyl stretch observed at 1767 cm-1. 
The subsequent oxidation and ring-opening of compound 223 led to 
significant decomposition. The same reaction conditions that produced 
plastiquinone 216 resulted in complete decomposition of the benzoquinone 
derivative 224. Visual observation of the reaction mixture upon dropwise 
addition of NBS indicated a rapid colour change from clear to bright yellow 
indicating the successful formation of the quinone moiety. However, after 10 
min the bright yellow-coloured solution turned black. Therefore, the reaction 
was repeated with immediate quenching after the addition of NBS to prevent 
further decomposition (Scheme 48). Under these conditions the desired 
quinone 224 was formed in 18 % yield and unreacted lactone could be 
recovered and re-subjected to the reaction conditions. 
 
Scheme 48: Ring opening and oxidation of 223 to yield 224. 
The successful formation of 224 was indicated by 1H NMR and 13C NMR 
spectroscopy.84 A diagnostic shift of the lactone carbonyl signal from 167.8 
ppm to 177.8 ppm was consistent with the presence of a carboxylic acid and 
the presence of two additional carbonyl signals at 184.5 and 186.4 ppm 
indicating successful oxidation to the quinone. The IR also showed 
absorptions at 1711 and 1684 cm-1 for the carboxylic acid and 1,4-quinone 
respectively. 
With two of the three quinone acid moieties synthesised, focus moved on to 
synthesising the simplified probes from the plastiquinone carboxylic acid  
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216. This would illustrate whether the fluorescence would be quenched due 
to the proximity of the quinone moiety. And therefore demonstrate proof-of-
concept before any further attempts to synthesise the naphthoquinone 
derivative.  
The first quinone-dye analogue proposed was the quinone moiety coupled 
directly to the amino-naphthalimide dye with no linker fragment (Figure 53). 
This would enable the importance of the linker fragment and what influence it 
has on the probes ability to act as a profluorophore to be determined. 
 
Figure 53: Structure of the first proposed profluorophore (225). 
4.2 Synthesis of the dye fragment 
Formation of the probe consisted of a multi-step synthesis following literature 
procedures (Scheme 49). Commercially available 4-bromo-1,8-naphthalic 
anhydride (226) was reacted with sodium azide at 100 °C to provide the 
azido compound 227 in 72 % yield (Scheme 49).141 Upon hydrogenation with 
Pd/C the 4-amino-1,8-naphthalic anhydride (228) was obtained in moderate 
yield.141 Formation of amine 228 was supported by 1H NMR spectroscopy 
with an exchangeable proton signal present at 7.08 ppm integrating for two 
protons, consistent with the presence of the amine. Introduction of the N-
butyl chain was achieved by heating the anhydride and N-butylamine in 
ethanol to deliver probe fragment 229. The 1H and 13C NMR spectroscopic 
data was consistent with equivalent data reported in the literature.134,142 
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Scheme 49: Formation of the dye fragment 229. 
The successful introduction of the butyl chain in 229 was consistent with both 
1H NMR and 13C NMR spectra. In the 1H NMR spectrum, four proton signals 
are present in the aliphatic region, with three of those signals located 
between 0.5 and 2.0 ppm and the fourth signal shifted upfield to 4.09 ppm as 
a triplet indicating its attachment to the nitrogen of the naphthalimide. These 
same trends were observed in the 13C NMR spectrum with four signals below 
45.0 ppm indicating the presence of four sp3-hybridised carbons. With the 
dye portion successfully prepared and synthetically useful amounts of the 
gem-dimethyl plastiquinone acid (216) readily available, coupling of the two 
portions via amide coupling as previously used for all naphthoquinone 
derivatives was attempted (Scheme 50). 
 
Scheme 50: Attempted amide coupling of 216 and 229 to yield 225. 
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With many successful amide couplings performed with the scope of this 
project, it was surprising to realise that this coupling was not successful. The 
inability to form the amide bond is attributed to the amine of the probe being 
a poor nucleophile due to its location on the naphthalene ring and the greater 
delocalisation of the nitrogen lone pair due to the presence of the imide. 
While no desired product was obtained, both starting materials were 
recovered from the reaction mixture. To support this hypothesis that probe 
229 is a poor nucleophile, L-phenyl glycinol and L-phenylalaninol were each 
successfully coupled to the gem-dimethyl plastiquinone acid (216) (Scheme 
51). The successful coupling of the two amine fragments indicate the 
coupling agent was active and the inability to couple the probe to the gem-
dimethyl plastiquinone acid (216) was a result of the poor nucleophilicity of 
compound 229.  
 
Scheme 51: Successful amide coupling of L-phenyl glycinol derivative (230) and L-
phenylalaninol derivative (231) to the gem-dimethyl plastiquinone acid (216). 
The successful synthesis of analogues 230 and 231 was supported by both 
1H and 13C NMR spectroscopy. An exchangeable proton signal was present 
in both analogues at 6.15 ppm and 5.63 ppm for analogue 230 and 231 
respectively, with both integrating for one proton, which was identified as the 
proton attached to the nitrogen. Similarly, in the 13C NMR, a shift of the 
carbonyl due to the formation of amide bond is seen from 178.8 ppm to 172.4 
ppm.  
With support for the hypothesis that the amine fragment is a poor 
nucleophile, an alternative method was sought. It was proposed that a 
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Staudinger-type reaction would allow successful coupling of an azide and 
carboxylic acid in anhydrous conditions.143 Because the Staudinger reaction 
employs azide substrates, formation of the probe fragment 232 was 
synthesised (Scheme 52). Therefore, azido-napthalimide 232 was obtained 
from 4-azido-1,8-naphthalic anhydride and n-butylamine in a low 22 % yield.  
 
Scheme 52: Synthesis of dye portion 232. 
Formation of the naphthalimide 232 was consistent 1H NMR, 13C NMR and 
infrared spectroscopy (IR).144 A strong IR band was present at 2127 cm-1 in 
the IR spectrum, which is indicative of an azide group. Similarly, both 1H 
NMR and 13C NMR spectroscopy supported the introduction of the butyl 
chain with analogous signals to those of the amine 229 present. With 
successful formation of the azide 232 the Staudinger reaction was attempted. 
Surprisingly, no amide was formed and, instead, the stable 
iminophosphorane (233) intermediate was isolated (Scheme 53). 
 
Scheme 53: Attempted Staudinger reaction to form 225. 
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1H NMR spectroscopy supported the formation of 233 with multiplets present 
between 7.50 ppm and 7.90 ppm integrating for a total of fifteen protons 
indicating the presence of the three phenyl groups, which was also consistent 
with data reported in the literature.145 Iminophosphorane (233) is a known 
compound and, surprisingly, synthesised via the same conditions that were 
utilised in the Staudinger reaction.145 After purification and isolation of 
intermediate 233, additional gem-dimethyl plastiquinone acid (216) was 
added and the mixture refluxed in toluene overnight. However, all attempts 
failed to cleave the nitrogen – phosphorous double bond. Therefore, it was 
decided that this was not a viable way to form the profluorophore. 
Recently it was reported that the amide bond of a naphthalimide could be 
formed by a palladium-mediated protocol from a primary amide and 4-bromo-
1,8-naphthalic anhydride (226) (Scheme 54). This would avoid the problems 
of nucleophilicity of the amine attached to the naphthalimide. Therefore the 
synthesis of the quinone primary amide 234 was required (Scheme 54). 
Initially, the optimistic approach was taken with using excess ammonium 
chloride as the ammonia source and subjecting this to the normal amide 
coupling reaction previously optimised (Scheme 54).   
 
Scheme 54: Attempted synthesis of 234. 
Unfortunately, no product was obtained with a complex mixture of undesired 
products observed when analysed by 1H NMR spectroscopy. Therefore, the 
synthesis of amide 234 was investigated via acid chloride 236 (Scheme 55).  
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Scheme 55: Formation of acid chloride intermediate 236 before failed attempts of 
obtaining 234. 
The synthesis of 234 was not successful when subjecting the acid chloride 
intermediate 236 to bubbling ammonia gas. A possible explanation for no 
formation of 234 was insufficient removal of excess thionyl chloride. 
Formation of intermediate 236 was expected, however, it was difficult to 
isolate and sufficiently characterise the intermediate. Therefore, an 
alternative active intermediate was sought. An N-acyl imidazole intermediate 
would allow for isolation and characterisation prior to reaction with ammonia 
(Scheme 56). 
 
Scheme 56: Formation of the carbonyl imidazole intermediate 237 before failed 
attempts of obtaining 234.  
1H NMR spectroscopy supported the successful synthesis of intermediate 
237. Three singlets present in the 1H NMR spectrum at 7.03, 7.39 and 8.11 
ppm each integrating for one proton were consistent with the incorporation of 
the imidazole in compound 237. With evidence supporting the formation of 
the intermediate, 237 was then subjected to either liquid ammonia in CH2Cl2 
at –78°C and then warmed to room temperature or ammonia gas bubbled 
through the reaction mixture at 0°C. Surprisingly, no product was obtained by 
employing either set of reaction conditions. In both cases, the lactone 214 
was recovered upon purification of the reaction mixtures, indicating that a 
reduction of the quinone had unexpectedly occurred. This result in itself is 
odd, as a reduction must occur for formation of the lactone and, currently, 
there is no logical explanation for this.  
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With various unsuccessful attempts at forming the amide portion, it was 
decided that coupling the dye directly to the quinone moiety was no longer a 
viable option. Instead, it was proposed that the linker portion might be 
essential to coupling the two fragments together. The initial carbamate 
linkage was not initially investigated as it adds a significant number of 
synthetic steps to the sequence. Therefore, a new quinone coupled probe 
was proposed that featured a simple linker fragment and the smallest number 
of carbon atoms (Figure 54). In this way, profluorophore 238 which features 
an ethylenediamine linker was identified. 
 
Figure 54: Structure of the newly proposed profluorophore 238. 
Due to the addition of the linker, formation of the dye fragment 239 was 
synthesised from 4-bromo-1,8-naphthalic anhydride 227. The installation of 
the N-butylamine chain occurred prior to the installation of the 
ethylenediamine fragment (Scheme 57).  
 
Scheme 57: Formation of the new dye portion 239 containing the ethylenediamine 
linker. 
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was then subjected to ethylenediamine in 2-methoxyethanol to produce the 
desired probe 239 in 52 % yield. Formation of 239 was consistent with data 
reported in the literature with both 1H NMR and 13C NMR spectroscopy 
supporting the addition of the ethylenediamine fragment.147 An additional 
triplet and quartet were present in the 1H NMR spectrum at 3.20 and 3.55 
ppm respectively both integrating for two protons with a coupling of 5.6 Hz 
indicated the addition of the ethylenediamine fragment. This successful 
addition was supported by 13C NMR spectroscopy with six carbon signals 
below 45.0 ppm indicating the presence of six sp3-hybridised carbons. With 
the successful formation of the probe (239), amide coupling was attempted 
with the gem-dimethyl plastiquinone acid 216 (Scheme 58). 
 
Scheme 58: The successful coupling the probe  (239) to the gem-dimethyl quinone 
acid (216) to form 238. 
The successful coupling of the two fragments to produce 238 proceeded in 
an excellent 86 % yield. Formation of 238 was supported by full analysis, 
including 1H NMR, 13C NMR, IR and high resolution mass spectroscopy 
(HRMS). HRESIMS for C32H37N3O5Na gave a predicted value of 566.2631 
and analogue 238 was found to have a mass of 566.2646. Significant support 
for 238 was obtained from the 1H NMR with two exchangeable proton signals 
present at 6.22 ppm presenting as a triplet and a broad singlet at 7.03 ppm 
both integrating for one proton each indicating the two N–H bonds (Figure 
55). Similarly, five singlets are present between 1.35 and 3.00 ppm indicating 
the presence of the five methyl groups and the -CH2- of the gem-dimethyl 
plastiquinone core fragment. This is also supported in the 13C NMR spectrum 
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with three carbonyl resonances of the quinone core and amide bond present 
at 175.5, 187.2 and 191.1 ppm as well as the two carbonyls of the 
naphthalimide present at 164.4 and 164.7 ppm.  
 
Figure 55: 1H NMR spectrum of the probe 238. 
With the successful formation of the probe 238, investigation into the probe’s 
ability to act as a profluorophore was performed. Probe 238 was designed 
with the intention that the proximity of the quinone moiety would quench the 
fluorescence of the naphthalimide portion. Upon reduction of the quinone 
moiety to the hydroquinone, elimination of the naphthalimide dye 239 would 
then lead to a rapid increase in fluorescence due to the liberation of 
naphthalimide portion. Comparison of the fluorescence of the probe 238 
compared to the dye 239 can been observed in Figure 56.  
 
Figure 56: Fluorescence of 1.0 x 10-4 M solutions of a) probe (238) and b) dye (239) 
in ethanol at λex = 365 nm. 
a	 b	
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The fluorescence is significantly brighter when the naphthalimide is not 
attached to the quinone (i.e. 239 vs. 238) (Figure 56). There is highly 
effective proximity-induced quenching of the naphthalimide 239 when 
coupled to the plastiquinone acid 216. Therefore, supporting the hypothesis 
that conjugation quenches fluorescence, although not completely. As a result 
the fluorescence and emission spectra were obtained (Figure 57).  
 
 
Figure 57: Absorption and emission spectra of 2.0 x 10-6 M probe (238) and dye 
(239) in ethanol. Absorption (A and C); fluorescence emission spectra (B and D) at 
λex = 445 nm. 
Figure 57a,c illustrates that probe 238 absorbs over the range of 360–500 
nm with a λmax at 438 nm. In comparison, dye 239 absorbs over 360–510 nm 
with a λmax at 435 nm. The emission energy maxima are 514 and 524 nm for 
probe 238 and dye 239 respectively. This large Stokes shift observed when 
comparing absorption and emission maxima is reported by Prasai and co-
workers133 and is characteristic of the naphthalimide dyes. The increase in 
fluorescence of Figure 57.b when compared to Figure 57.d supported the 
fluorescence quenching ability of the quinone moiety. The literature indicates 
that the quenching by the quinone moiety of probe 238 will be drastically 
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increased due to the decreased length of the linker portion.133 Unfortunately, 
as seen in Figure 56, complete quenching of the coupled probe at high 
concentrations is not observed. However, upon application to cells or 
chemically induced reduction, a high degree of contrast should be observed. 
With this data, the ability of probe 238 to release the free dye 239 through 
chemically induced reduction of the quinone core to the hydroquinone was 
investigated. Probe 238 was subjected to reduction by sodium dithionite with 
the fluorescence measured every ten seconds over an 8 min period to 
monitor the formation of the dye 239 (Figure 58).  
 
Figure 58: Comparing the sodium dithionite initiated formation of Dye 239 from 
Probe 238. The fluorescence (λex = 445, λem = 525) from 3 mL solution of 2.0 x 10-6 
M of probe 238 in pH 7.5, 0.1 M PBS buffer was monitored after reduction of probe 
238 by the addition of 0.5 mg of sodium dithionte (denoted by arrow). Probe 238 and 
Dye 239 as controls in analogous conditions in the absence of sodium dithionite.  
As indicated in Figure 58, rapid fluorescence was observed over a 1.5 min 
period after the addition of sodium dithionite, with maximum fluorescence 
achieved with in 3 min. This result provides proof-of-concept and gives a 
clear indication that fluorescence is quenched due to the proximity of the 
quinone core to the naphthalimide. With evidence that the reduction triggered 
cyclisation is occurring, it is expected that this probe could proceed in a 
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similar manner in the presence of enzymes such as NQO1 as initially 
hypothesised. 
The potential of probe 238 to be reduced by NQO1 was investigated in a cell 
free assay. A solution of the probe 238 with NADPH and NQO1 and dye 239 
with NADPH and NQO1 were compared against probe 238 with NADPH over 
a 30 min period (Figure 59).  
 
Figure 59: The fluorescence (λex = 460 nm, λem = 538 nm) from total volume of 100 
µL solution of 1.0 x 10-5 M of probe 238 or dye 239, 10mM NADPH (10 µL) + 0.5 
mg/mL NQO1 (10 µL), probe 238 in pH 7.4, 0.1 M PBS was monitored after the 
addition of NQO1. 
As seen in Figure 59, in the presence of NAPH, probe 238 only showed base 
line fluorescence indicating no reduction of the quinone. However, upon the 
addition of NQO1, fluorescence rapidly increased over the first 10 min before 
plateauing. Although this did not reach the full level of fluorescence of the 
uncoupled probe, this can be attributed to all the NADPH being consumed 
and therefore unable to provide the energy NQO1 required to reduce the 
quinone moiety further. However, in a biological setting such as a cellular 
assay, this would not be an issue and would give an on/off response. This 
would provide a yes or no answer to NQO1 activity in the cells accordingly. 
With proof of concept illustrated by both chemical and enzyme reduction 
resulting in a dramatic increase in fluorescence, further investigation into 
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SAR is required to develop a probe that has no background fluorescence. 
Although the proposed benzoquinone moiety 224 was synthesised, due to 
time constraints coupling of the probe did not occur. However, the proposed 
naphthoquinone moiety is required, such that the potential reducing power of 
the cells can be investigated. In addition to this, further investigation into the 
linker fragment may be required, as particular functional groups attached to 
the naphthalimide can shift the region of absorption and emission to prevent 
back ground fluorescence being a problem.133 Potential optimisation of probe 
238 are summarised in Figure 60. Due to time constraints, these 
optimisations and investigations are work for the future.  
 
 
 
 
 
Figure 60: Identified modifications to the three fragments of coupled probe 238. 
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Chapter 5: In vivo Studies 
After extensively analysing the in vitro activity of the top five analogues (L-
phenylalanine t-butyl ester derivative 61, L-phenylalanine derivative 70, L-
phenylalaninol derivative 76, tyramine derivative 79 and 3,4-
dimethoxyphenethylamine derivative 80) two analogues were identified to 
progress to the in vivo studies (Figure 61).   
 
Figure 61: Biological evaluation of the top five analogues (61, 70, 76, 79, 80). (a) 
Cytoprotection against rotenone induced complex I dysfunction by quinones at 
10µM given as a relative percentage of cell survival compared to untreated HepG2 
cells (b) ATP rescue by quinones at 10µM in the presence of rotenone-induced 
complex I dysfunction as percentage of untreated HepG2 cells. 
From the data shown in Figure 61, L-phenyl derivative 70 was selected due 
to its dramatic ability to provide cytoprotection and increased solubility due to 
the acid fragment. The decrease in ATP activity of analogue 70 was 
proposed not to be an issue as over time cytoprotection is extensive. In 
addition, 3,4-dimethoxyphenethylamine derivative 80 was selected due to its 
ability to restore both ATP levels and provide cytoprotection. With these two 
selected derivatives, in vivo studies were conducted in two different disease 
models. 
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5.1 In vivo studies in a mouse model LHON 
Collaborators in the School of Medicine – Pharmacy at the University of 
Tasmania (PhD candidate Ms. Monila Nadikudi) tested both L-phenylalanine 
derivative 70 and 3,4-dimethoxyphenethylamine derivative 80 in a mouse 
model of LHON. Mice were treated according to a previously described 
method by Heitz et al..3 The mice were pre-treated with the selected 
compounds at 200 mg/kg via their diet for one week prior to commencement 
and subsequently for the entire time period of the study as previously 
described.3 The animals received an injection of the synthetic complex I 
inhibitor rotenone (1 µl of a 5 mM solution) directly into the left eye over a two 
minute period.  Over the next seventy days, visual acuity was evaluated by 
placing the mice on a stationary platform, surrounded by an optomotor drum 
with black and white stripes (1cm thick). The number of stimulus-induced 
reflex-head-turns by the mice were counted, while the optomotor drum was 
rotated at 2 rpm for 2 min each in both clockwise and anticlockwise direction 
(Figure 62). Head-turns were also monitored 1 to 3 times before injection of 
rotenone to establish a baseline for visual acuity of each animal. Head-turns 
in a clockwise direction indicate the visual acuity of the left (injected) eye, 
whereas head-turns in the counter-clockwise direction represent the visual 
acuity of the right (control) eye.  
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Figure 62: Novel short-chain quinones restore visual acuity under conditions 
of  mitochondrial dysfunction-induced blindness. Visual acuity was evaluated by 
placing the mice on a stationary platform, surrounded by an optomotor drum with 
black and white stripes (1 cm thick). The number of head-turns made by the mice 
was counted while the optomotor drum was rotated at 2  rpm for 2min each in both 
clockwise and anticlockwise direction. All mice were treated with the respective 
compounds at a dosage equivalent to 200mg/kg body weight of idebenone. a) 
Quantification of clockwise head-turns, b) Quantification of counter-clockwise head-
turns. . 
As shown in Figure 62, animals showed a time-dependent recovery of sight 
when subjected to both 70 and 80, up to ~50 % of baseline level. Noticeable 
restoration of vision occurred at 10 days post treatment. In contrast, 
idebenone (11) treated animals showed no recovery of vision in this study. 
Interestingly, when Heitz et al.3 described recovery of vision in this animal 
model using idebenone (11) alone; idebenone was administered at ten times 
the concentration used in the current study and required ~70 days of 
treatment to show a noticeable recovery. Therefore, analogues 70 and 80 
restored sight at significantly lower concentrations that the lead compound, 
which represented a significant increase in drug potency and could facilitate 
their therapeutic use. 
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5.2 In vivo studies into diabetic retinopathy 
In further testing at the School of Medicine – Pharmacy at the University of 
Tasmania both L-phenyl derivative 70 and 3,4-dimethoxyphenethylamine 
derivative 80 were also tested in a rat model of diabetic retinopathy. Diabetic 
retinopathy is a leading cause of progressive vision loss.40 There is growing 
recognition that retinal dysfunction and impaired visual behaviour is present 
prior to permanent damage occurring.40 Diabetic complications in the first 
phase of diabetic retinopathy are associated with many metabolic processes 
that are upregulated. These metabolic processes are linked by mitochondrial 
production of reactive oxygen species (ROS) and evidence within the 
literature suggests that normalising mitochondrial dysfunction can mitigate 
the damage.148,149 Therefore, it was suggested that early intervention and 
normalising of mitochondrial dysfunction prior to permanent damage 
occurring in diabetes patients may provide an effective treatment.  
In a study by Alam et al., the effect of SS-31 (10) on diabetic retinopathy was 
evaluated. In this mouse model, SS-31 (10) reversed visual decline without 
effecting the diabetes.40 With this promising result, L-phenylalanine derivative 
70 and 3,4-dimethoxyphenethylamine derivative 80 were subjected to a rat 
model to determine if these analogues could have a similar effect on diabetic 
retinopathy compared to SS-31 (10). This work was performed by UTAS PhD 
candidate Mr. Abraham Daniels. Prior to inducing diabetes, each rat had its 
sight and blood sugar levels monitored for four weeks to establish robust 
basal levels. At week four, an osmotic pump was implanted on the rats’ 
backs that administered streptozotocin (STZ) at a level of 125 mg/kg over a 
two week period. STZ kills the pancreatic beta cells (insulin producing cells), 
which is a common technique for studies into hyperglycaemia and it typically 
provides in a model for type I diabetes. In addition, the animals were also fed 
a high fat diet for the period of the study, which results in a mixed model of 
type I and II diabetes. As seen in Figure 63, the visual response of all 
animals (measured by the same rotating drum as in the previous LHON 
model) dropped dramatically over the next weeks. After ten weeks of being 
severely diabetic, the rats received the test compounds formulated as eye 
drops to their right eye. Due to vision loss in both eyes and being able to 
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locally treat the right eye only, the left eye was used as an internal control. As 
seen in Figure 63, both analogues as well as idebenone (11) restored vision 
over only a very short treatment period as indicated by a rapid increase in 
head turns towards the treated eye. 
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Figure 63:	 Visual response following daily eye drop treatment with test-
compounds in diabetic Long Evans (LE) Rats. Using 0.1 cycle per degree 
optokinetic drum, visual acuity testing was performed for both the left and right eyes of LE 
rats at a speed of 2.61 rpm for 2 minutes over a period of 19 weeks. Upon administration of 
STZ (week 4), a significant drop in reflex head movement was evident by week 9, with 
further reduction by week 14. a) Daily idebenone (11) (10 mg/ml) treatment of the right eyes 
(shaded area), significantly improved head tracking score within 3 weeks of treatment. n = 6, 
b) Daily L-phenylalanine analogue 70 (>2 mg/ml) treatment on right eyes alone which is 
indicated by shading, resulted in significant improvement of head tracking score within two 
weeks of treatment on the right eyes. n = 4, c) Daily 3,4-dimethoxyphenethylamine 80 (>2 
mg/ml) treatment on right eyes alone which is indicated by shading, resulted in significant 
improvement of head tracking score within one week of treatment on the right eyes. n = 4, 
Error bars = SEM, P < 0.05 (using one-way ANOVA, Dunnett’s multiple comparison test). 
Left eye vision (Blue = No treatment), Right eye vision (Red = treatment). 
Both L-phenylalanine derivative 70 and 3,4-dimethoxyphenethylamine 
derivative 80 as well as idebenone (11) showed promising ability to restore 
sight in the diabetic animals. Figure 63 indicates L-phenylalanine derivative 
70 and 3,4-dimethoxy phenethylamine derivative 80 provide the same effect 
as idebenone (11) even though they were administered at five times less 
concentration due to solubility issues associated with novel derivatives in the 
eye drop formulation. It is worth mentioning that the slight increase in the 
control (left eye) is due to the increase of sight in the right eye. A recent study 
showed that in contrast to mice, the optokinetic reflex (OKR) in rats is not 
fully separated for the left vs right eye and that there is some cross over in 
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sight from the opposite eye.150 This effect is likely responsible for the partial 
response of the untreated eye observed in this study. Over the course of this 
study, blood glucose levels were analysed and, notably, irrespective of the 
treatment-induced recovery of visual response, all animals remained 
extremely diabetic over the entire course of the study (Figure 64).  
 
Figure 64: STZ at 125 mg/kg induces severe hyperglycemia in all 3 groups of Long 
Evans rats 2 weeks after administration and this high blood glucose level was 
sustained throughout out the experiment. 
This evidence (Figure 64) indicates that local treatment of vision loss does 
not affect the diabetic state of the animals. These results are also consistent 
with a previous study that also described improvements in visual acuity using 
SS-31 (10) with no improvement in the diabetic state of the animals.40 
Therefore, this positive outcome leads to further investigation into in vivo 
diabetic retinopathy studies, with future work moving to oral treatment with 
the lead compounds in order to ascertain their capacity to positively affect the 
diabetic state of the animals. Notably, oral treatment will remove any 
uncertainty associated with the solubility issue of the novel naphthoquinone 
derivatives when formulating the eye drops. 
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5.3 Conclusions of in vivo studies 
Both in vivo studies into LHON and diabetic retinopathy showed promising 
preliminary results. The extensive structure activity relationship (SAR) 
developed in Chapter 2 demonstrated an adequate representation of 
responses in vivo. Both analogues provided exceptional levels of activity. The 
most significant outcome from the LHON study was the superiority of the 
naphthoquinone derivatives over idebenone (11). At the concentration used 
(200 mg/kg), idebenone (11) was unable to restore visual acuity, with the 
novel compounds having an effect after 10 days. Similarly, in the diabetic 
retinopathy study, the novel derivatives provided a similar response to 
idebenone when administered at one fifth of the concentration. Therefore 
further investigations into these analogues ability to act as a therapeutic in 
other disease models associated with mitochondrial dysfunction needs to be 
undertaken. 
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Chapter 6: Experimental Details 
6.1 General Experimental Details 
Nuclear Magnetic Resonance Spectroscopy 
Proton (1H) and carbon (13C) nuclear magnetic resonance spectra were 
recorded in deuterated chloroform (CDCl3), methanol (CD3OD), 
dimethylsulfoxide (DMSO-D6) or acetone-D6 on a Bruker Avance III 
operating at 400 MHz for 1H and 100 MHz for 13C. Chemical shifts were 
recorded as δ values in parts per million (ppm) and referenced to the solvent 
used. In the case of CDCl3 solvent references were at 7.26 ppm and 77.16 
ppm for 1H and 13C respectively, For CD3OD solvent references were 3.31 
ppm and 49.3 ppm for 1H and 13C respectively, DMSO-D6 solvent references 
were at 2.50 ppm and 39.52 ppm for 1H and 13C respectively, similarly for 
acetone-D6 solvent references were at 2.05 ppm for 1H and 29.84 and 
206.26 for 13C151. The following abbreviations were used to describe 1H 
spectra peak splitting patterns; s = singlet, bs = broad singlet, d = doublet, bd 
= broad doublet, dd = doublet of doublets, t = triplet, ddt = doublet of doublets 
of triplets, qd = quartet of doublets, q = quartet, quin = quintet, sex = sextet, 
m = multiplet. 
 
Cyclic Voltammetry 
Cyclic voltammetry (CV) studies were carried out using a Metrohm 797 VA 
potentiostat fitted with a glassy carbon working electrode, a platinum auxiliary 
electrode and a saturated calomel reference electrode (SCE). Measurements 
were performed at room temperature in 20 mL of a 0.1 M 
tetrabutylammonium perchlorate solution in acetonitrile containing the 
naphthoquinones at a concentration of 1 mM. The electrochemical cell was 
deoxygenated by purging with N2 for 2 min before scanning between –0.850 
and 0.500 V (vs SCE) at a scan rate of 100 mV/s. The electrodes and 
measurement cell were rinsed with acetonitrile between each experiment. 
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Infrared Spectroscopy 
Infrared spectroscopy was performed on a Shimadzu FTIR 8400s 
spectrometer, using NaCl plates. Liquids and solids were recorded as thin 
films from CH2Cl2 in cm-1. 
Mass Spectrometry 
Mass spectrometry was performed on Kratos Concept ISQ using electron 
ionisation with 70eV electrons with an accelerating voltage of 5.3 kV or a 
Water Xero Triple Quadrupole using 2.5 kV needle voltage with direct 
infusion electrospray ionisation measuring positive ions. Accurate mass was 
also measured by ‘peak matching’ at 10,000 resolution against 
perfluorokerosene.  
Analytical analyses were performed by the Central Science Laboratory at the 
University of Tasmania. The molecular ions and fragments are quoted with 
the relative intensities of the peaks referenced to the most intense taken as 
100 %. 
Column Chromatography 
Merck flash grade silica (32-63 µm) was used for column and flash 
chromatography and were performed according to the general method of Still 
et al.152  
Thin Layer Chromatography (TLC) 
Merck Silica gel 60 F254 aluminium backed sheets were used for analytical 
thin layer chromatography. TLC plates were visualised under a 254 nm UV 
lamp and/or by treatment with a phosphomolybdic acid (37.5 g), ceric acid 
(7.5 g), sulfuric acid (37.5 mL), water (720 mL) dip or a potassium 
permanganate dip (3 g, KMnO4, 20 g K2CO3, 5 mL 5 % aqueous NaOH, 300 
mL), followed by heating. 
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Solvents and Reagents 
All standards and reagents were purified by standard laboratory 
procedures.153 Anhydrous magnesium sulfate was used as the drying agent 
for organic extracts unless otherwise stated and solvents removed under 
reduced pressure on a rotary evaporator.  
Melting Points 
Melting points were obtained with a Stuart Scientific melting point SMP1 
apparatus and are uncorrected. 
Optical Rotation 
Optical rotations were obtained using a Rudolph research analytical Autopol 
III automatic polarimeter. 
Spectroscopic Methods 
UV-Vis absorption spectra were recorded in a 1.0 cm path length cuvette on 
a UV-1800 Shimadzu UV spectrophotometer. All fluorescence experiments 
were performed with a PerkinElmer LS55 spectrofluormeter in a 1.0 cm x 0.2 
cm quartz cuvette. 
6.2 Chapter 2 Experimental Details 
6.2.1 General Procedures 
General Procedure A: Silver-mediated radical decarboxylation general 
method: 
 
Carboxylic acid (2 equiv.) was added to a solution of menadione (1 equiv.) in 
CH3CN/H2O (3:1) and the mixture was heated to 75 °C. To this solution, 
AgNO3 (0.1 equiv.) was added followed by the slow addition of (NH4)2S2O8 
(2.5 equiv.) in H2O (5 mL) over 10 min. The resulting mixture was stirred for a 
further 1 h. The mixture was cooled to room temperature, extracted with 
O
O
O
O
R
R OH
O
(NH4)4S2O8, AgNO3
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CH2Cl2 and the organic extract washed with sat. NaHCO3 and H2O. The 
organic layer was dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the crude product, which was purified by flash 
chromatography (silica gel). 
General Procedure B: Quinone amide coupling general method: 
 
Quinone acid (1 equiv.) was added to anhydrous dichloromethane (5–10ml) 
under an atmosphere of N2 and cooled to 0 °C. Amino acid (1 equiv.), 
dimethylaminopyridine (DMAP, 0.1 equiv.), triethylamine (Et3N, 2.5 equiv.) 
and either EDCI, BOP or PyBOP (1.4 equiv.) were added successively and 
the reaction mixture warmed slowly to room temperature before leaving 
overnight. The reaction was quenched with H2O (20mL) and the organic layer 
washed with sat. KHSO4 solution, sat. NaHCO3 solution and H2O. The 
organic layer was dried with MgSO4, filtered and the solvent removed under 
reduced pressure to give a crude product, which was purified by flash 
chromatography (silica gel) to give the amide. 
General Procedure C: t-butyl ester deprotection method: 
 
The t-butyl esters were added to 10% TFA in dichloromethane (5.0 mL) and 
the reaction mixture stirred at room temperature overnight and the solvent 
removed under reduced pressure. The crude product was obtained and 
purified by flash chromatography (silica gel) to give the pure carboxylic acid. 
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6.2.2 Synthesis of Compounds for SAR 
4-(3-methyl-naphthoquione-2-yl)butanoic acid and 3,3'-(propane-1,3-
diyl)bis(2-methyl-1,4-naphthoquinone) (32 and 52) 
               
32 was prepared according to general procedure A from menadione (12) 
(5.998 g, 34.83 mmol) and glutaric acid (49) (4.611 g, 34.89 mmol) and the 
product purified by flash chromatography (100 % dichloromethane followed 
by 100% ethyl acetate) to give 32 as a bright yellow crystalline solid in 62 % 
yield (5.579 g, 21.67 mmol). 
Modified General Procedure A: Glutaric acid (49) (4.368 g, 0.0331 mol) 
was added to a solution of menadione (2.984g, 0.0173 mol) in CH3CN/H2O 
(3:1, 50 mL) and the mixture was heated to 75 °C. To this solution, AgNO3 
(321 mg, 1.891 mmol) was added followed by the slow addition of 
(NH4)2S2O8 (9.897 g, 0.0434 mol) in H2O (20 mL) over 1.5 h. The resulting 
mixture was stirred for a further 2 h, before being left o/n at room 
temperature. The mixture was extracted with CH2Cl2 (3 x 50 mL) and the 
organic extract washed with H2O (4 x 50 mL). The organic layer was dried 
over MgSO4, filtered and the solvent removed under reduced pressure to 
give the crude product, which was purified by a Reveleris ® X2 automated 
flash chromatography system (Eluent: gradient 100 % Hexanes - 100 % ethyl 
acetate, Column: Reveleris ® Silica 40 g, Flow rate: 30 mL/min) to two 
products, identified as 52 as a yellow needle crystals in <1 % yield (10 mg, 
0.0.0260 mmol) and 32 in as a yellow solid in 18 % yield (791 mg, 0.3063 
mmol). 
4-(3-methyl-naphthoquione-2-yl)butanoic acid (32) 
Melting point:  75-77 °C 
1H NMR δ (CDCl3, 400 MHz):  1.82 (quin, J =7.4 Hz, 2H), 2.20 (s, 3H), 
2.46 (t, J =7.4 Hz, 2H), 2.69 (t, J = 7.4 Hz, 
O
O
OH
O
O
O
O
O
+
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2H), 7.66 – 7.69 (m, 2H), 8.04 - 8.06 (m, 
2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 23.5, 26.4, 33.8, 126.4, 126.5, 132.2, 
132.28, 133.61, 133.62, 144.1, 146.2, 
179.3, 184.7, 185.3 
IR Vmax:  3064, 2938, 1706 (C=O), 1695 (C=O), 
1658, 1616, 1595, 1412, 1379, 1295, 1260, 
717, 660 cm-1  
3,3'-(propane-1,3-diyl)bis(2-methyl-1,4-naphthoquinone) (52) 
1H NMR δ (CDCl3, 400 MHz):  1.66 – 1.74 (m, 2H), 2.20 (s, 6H), 2.76 (t, J 
= 8.0 Hz, 4H), 7.66 – 7.70 (m, 2H), 8.02 – 
8.07 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 27.3, 27.4, 126.3, 126.4, 132.22, 
132.26, 133.53, 133.54, 143.7, 146.6, 
184.7, 185.2  
IR Vmax:  1658 (C=O), 1618, 1595, 1377, 1325, 
1296, 711 cm-1 
2-Methyl-3-(3,3,3-trifluoropropyl)-1,4-naphthoquinone (41) 
 
41 was prepared according to general procedure A from menadione (12) 
(910 mg, 5.284 mmol) and trifluorobutyric acid (268 mg, 1.883 mmol) and the 
product purified by flash chromatography (70 % CH2Cl2/hexanes) to give 41 
as a bright yellow crystalline solid in 59 % yield (299 mg, 1.115 mmol) with a 
melting point of 61–62 °C. 
1H NMR δ (CDCl3, 400 MHz):  2.13 (s, 3H) 2.21 – 2.33 (m, 2H), 2.81 (t, J 
= 7.8Hz, 2H), 7.60 – 7.62 (m, 2H), 7.93 – 
7.95 (m, 2H) 
O
O
F
F
F
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13C NMR δ (CDCl3, 100 MHz):  12.4, 20.1 (q, J C-F = 3.5 Hz), 32.2 (q, J C-F 
= 29.1 Hz), 126.2, 126.3, 126.6 (q, J C-F = 
277.6 Hz), 131.8, 131.9, 133.56, 133.59, 
143.6, 144.6, 184.0, 184.6 
IR Vmax:  1660 (C=O), 1622, 1595, 1456, 1381, 
1294, 1251, 1238, 1138, 991, 717 cm-1 
2-Methyl-3-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-1,4-
naphthoquinone (42) 
 
42 was prepared according to general procedure A from menadione (12) 
(7478 mg, 4.342 mmol) and 3-(trifluoro)-3-hydroxybutyric acid (245 mg, 1.425 
mmol) and the product purified by flash chromatography (90 % 
CH2Cl2/hexanes) to give 42 as a crystalline yellow solid in 14 % yield (60 mg, 
0.201 mmol) with a melting point of 42–44 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.32 (s, 3H), 2.25 (s, 3H), 2.94 (d, J = 14.0 
Hz, 1H), 3.23 (d, J = 14.0 Hz, 1H), 4.12 
(bs, 1H), 7.72 – 7.74 (m, 2H), 8.07 – 8.10 
(m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  14.2, 20.8, 3.28, 74.1 (q, J C-F = 28.2 Hz), 
126.2 (q, J C-F = 285.0 Hz), 126.7, 126.9, 
131.7, 132.0, 133.9, 134.3, 140.8, 148.0, 
184.6, 187.6    
IR Vmax:  3462 (-OH), 1662 (C=O), 1618, 1539, 
1462, 1381, 1332, 1286, 1153, 1097, 779 
cm-1 
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2-Isopentylnaphthoquinone and 2,3-Diisopentyl-1,4-naphthoquinone (43 
and 44) 
 
43 was prepared according to general procedure A from naphthoquinone 
(0.530 g, 3.351 mmol) and 4-methyl valeric acid (1.476 g, 12.71 mmol). 
Purification by flash column chromatography (50 % CH2Cl2/hexanes) resulted 
in two products being identified, 44 as a yellow viscous in a 10% yield (10 
mg, 0.0322 mmol) and 43 as a yellow crystalline solid in 35 % yield (271 mg, 
1.188 mmol). 
2-Isopentylnaphthoquinone (43) 
MP:     35 – 38 °C 
1H NMR δ (CDCl3, 400 MHz):  0.95 (d, J = 6.7 Hz, 6H), 1.42 – 1.48 (m, 
2H), 1.65 (septet, J = 6.7 Hz, 1H), 2.57 (td, 
J = 8.1, 1.4 Hz, 2H), 6.78 (t, J = 1.4 Hz, 
1H), 7.70 – 7.73 (m, 2H), 8.04 – 8.06 (m, 
1H), 8.08 – 8.10 (m, 1H) 
13C NMR δ (CDCl3, 100 MHz):  22.5, 27.6, 28.1, 37.2, 126.1, 126.7, 132.2, 
132.5, 133.72, 133.75, 134.7, 152.4, 185.3, 
185.7 
IR Vmax:  2956, 2928, 2870, 1662 (C=O), 1620, 
1595, 1467, 1367, 1329, 1301, 1265, 779 
cm-1 
2,3-Diisopentyl-1,4-naphthoquinone (44) 
1H NMR δ (CDCl3, 400 MHz):  1.00 (d, J = 6.7 Hz, 12H), 1.36 – 1.41 (m, 
4H), 1.72 (ap. Octet, J = 6.6 Hz, 2H), 2.59 
– 2.64 (m, 4H), 7.69 – 7.71 (m, 2H), 8.07 – 
8.09 (m, 2H) 
O
O
O
O
+
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13C NMR δ (CDCl3, 100 MHz):  22.5, 25.1, 28.9, 38.7, 126.2, 132.4, 133.3, 
147.5, 185.2  
IR Vmax:  2956, 2924, 2852, 1660 (C=O), 1597, 
1465, 1367, 1317, 1284, 1259, 1103, 719 
cm-1 
(S)-tert-Butyl-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-3-
phenylpropanoate (61) 
 
61 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (504 mg, 1.952 mmol) and L-
phenylalanine t-butyl ester.HCl (489 mg, 1.902 mmol) and the product 
purified by flash chromatography (40 % ethyl acetate/hexanes) to give 61 as 
yellow oil in 36 % yield (317 mg, 0.687 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.40 (s, 9H), 1.78 (quin, J = 7.6 Hz, 2H), 
2.17 (s, 3H), 2.27 (t, J = 7.6 Hz, 2H), 2.60 – 
2.62 (m, 2H), 3.04 – 3.13 (m, 2H), 4.74 – 
4.79 (m, 1H), 6.09 (d, J = 7.8 Hz, 1H), 7.14 
– 7.27 (m, 5H), 7.66 – 7.69 (m, 2H), 8.04 – 
8.07 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.3, 26.3, 28.0, 36.1, 38.2, 53.5, 
82.4, 126.3, 126.4, 127.0, 128.4 (2 x C), 
129.5 (2 x C), 132.21, 132.26, 133.4, 
133.5, 136.3, 144.0, 146.4, 170.9, 171.8, 
184.8, 185.3 
[α]D20:     +36.24º (c 0.91, CHCl3) 
IR Vmax:   3420 (N-H), 2978, 1732 (C=O), 1658 
(C=O), 1595, 1525, 1367, 1329, 1294, 
1257, 1226, 1155, 700 cm-1 
O
O
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HRMS [M+Na]:  For C28H31N1O5Na, predicted 484.2100, 
found 484.2110 
(S)-tert-Butyl-1-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanoyl)pyrrolidine-2-carboxylate (62) 
 
62 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (197 mg, 0.7623 mmol) and L-proline t-
butyl ester.HCl (140 mg, 0.6716 mmol) and the product purified by flash 
chromatography (60 % ethyl acetate/hexanes) to give 62 as yellow oil in 53 
% yield (146 mg, 0.3543 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.44 (s, 9H), 1.82 – 1.88 (m, 2H), 1.90 – 
1.96 (m, 2H), 2.04 – 2.13 (m, 2H), 2.21 (s, 
3H), 2.36 – 2.48 (m, 2H), 2.67 – 2.71 (m, 
2H), 3.47 – 3.52 (m, 1H), 3.59 – 3.64 (m, 
1H), 4.37 (dd, J = 8.5, 3.9 Hz, 1H), 7.66 – 
7.68 (m, 2H), 8.03 – 8.07 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 23.7, 24.7, 26.5, 28.0, 29.3, 34.1, 
47.1, 59.5, 81.2, 126.2 (2 x C), 132.23, 
132.26, 133.3 (2 x C), 144.0, 146.7, 171.0, 
171.6, 184.7, 185.3  
[α]D20:     +48.70 º (c 0.97, CHCl3) 
IR Vmax:  2976, 2935, 1735 (C=O), 1654 (C=O), 
1618, 1595, 1456, 1425, 1367, 1294, 1153, 
719 cm-1 
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(S)-tert-Butyl-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido) 
pentanoate (63) 
 
63 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (209 mg, 0.8096 mmol) and L-norvaline t-
butyl ester.HCl (159 mg, 0.7587 mmol) and the product purified by flash 
chromatography (50 % ethyl acetate/hexanes) to give 63 as yellow oil in 44 
% yield (140 mg, 0.3376 mmol). 
1H NMR δ (CDCl3, 400 MHz):  0.90 (t, J = 7.3 Hz, 3H), 1.29 – 1.33 (m, 
2H), 1.43 (s, 9H), 1.58 – 1.65 (m, 2H), 1.77 
-1.84 (m, 2H), 2.17 (s, 3H), 2.31 (t, J = 7.2 
Hz, 2H), 2.64 – 2.68 (m, 2H), 4.45 – 4.50 
(m, 1H), 6.27, d, J = 8.0 Hz, 1H), 7.64 – 
7.67 (m, 2H), 8.01 – 8.03 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 13.9, 18.6, 24.4, 26.4, 28.1, 34.9, 
36.2, 52.6, 82.0, 126.40, 126.45, 132.23, 
132.29, 133.51, 133.55, 144.1, 146.4, 
171.9, 172.2, 184.9, 185.3 
[α]D20:     -3.43º (c 0.17, CHCl3) 
IR Vmax:  3354 (N-H), 3296, 2962, 1734 (C=O), 1660 
(C=O), 1595, 1521, 1458, 1367, 1329, 
1294, 1149, 717 cm-1 
tert-Butyl 2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)acetate 
(64) 
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64 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (165 mg, 0.6381 mmol) and glycine t-
butyl ester (148 mg, 0.8852 mmol) and the product purified by flash 
chromatography (50 % ethyl acetate/hexanes) to give 64 as yellow viscous 
oil in 36 % yield (85 mg, 0.2294 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.41 (s, 9H), 1.79 (quin, J = 7.2 Hz, 2H), 
2.15 (s, 3H), 2.31 (t, J = 7.2 Hz, 2H), 2.62 – 
2.62 (m, 2H), 3.89 (d, J = 5.1 Hz, 2H), 6.27 
– 6.29 (m, 1H), 7.60 – 7.65 (m, 2H), 7.98 – 
8.01 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.3, 26.3, 28.0, 35.8, 42.0, 82.2, 
126.25, 126.29, 132.13, 132.17, 133.3, 
133.4, 144.0, 146.3, 169.2, 172.4, 184.7, 
185.1 
IR Vmax:  3369 (N-H), 2978, 1743 (C=O), 1660 
(C=O), 1595, 1521, 1369, 1329, 1294, 
1224, 1157, 717 cm-1 
(S)-tert-butyl-4-methyl-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)pentanoate (65) 
 
65 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (194 mg, 0.7496 mmol) and L-Leucine t-
butyl ester.HCl (168 mg, 0.7509 mmol) and the product purified by flash 
chromatography (40 % ethyl acetate/hexanes) to give 65 as yellow oil in 39 
% yield (124 mg, 0.2898 mmol). 
1H NMR δ (CDCl3, 400 MHz):  0.90 (d, J = 6.5 Hz, 6H), 1.42 (s, 9H), 1.46 
– 1.65 (m, 2H), 1.79 (quin, J = 7.4 Hz, 2H), 
2.16 (s, 3H), 2.29 (t, J = 7.4 Hz, 2H), 2.62 – 
O
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2.66 (m, 2H), 4.49 (td, J = 8.6, 5.3 Hz, 1H), 
6.16 (d, J = 8.3 Hz, 1H), 7.62 – 7.66 (m, 
2H), 7.98 – 8.03 (m, 2H)  
13C NMR δ (CDCl3, 100 MHz):  12.7, 22.1, 22.8, 24.3, 25.0, 26.4, 28.07, 
36.1, 41.9, 51.4, 81.8, 126.2, 126.3, 132.1, 
132.2, 133.40, 133.43, 144.0, 146.4, 171.9, 
172.5, 184.8, 185.2 
[α]D20:     -2.62 º (c 1.06, CHCl3) 
IR Vmax:  3354 (N-H), 2958, 2870, 1734 (C=O), 1718 
(C=O), 1660 (C=O), 1595, 1541, 1521, 
1456, 1367, 1329, 1294, 1149, 717 cm-1 
(S)-tert-butyl-3-(4-hydroxyphenyl)-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)propanoate and (S)-4-(3-(tert-butoxy)-2-(4-(3-methyl-1,4-
naphthoquinone-2-yl)butanamido)-3-oxopropyl)phenyl-4-(3-methyl-1,4-
naphthoquinone-2-yl)butanoate (66 and 68)  
 
66 were prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (225 mg, 0.8727 mmol) and L-tyrosine t-
butyl ester.HCl (188 mg, 0.7902 mmol). Purification by flash chromatography 
(60 % ethyl acetate/ hexanes) resulted in the identification of 66 and 68. 
Compounds were combined and dissolved in 10 mL methanol, excess 
potassium carbonate added and the reaction left stirring at r.t for 1hour. The 
mixture was extracted with dichloromethane 3x 30 mL and the organic layer 
dried over MgSO4, filtered and the solvent removed under reduced pressure 
to give crude 66 which was purified by flash chromatography (50 % ethyl 
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acetate/ hexanes) to give 66 as yellow oil in 20 % yield (42 mg, 0.0871 
mmol). 
Note: 68 (14.9 mg, 0.0208 mmol) was kept for analysis (yellow viscous oil).  
(S)-tert-butyl-3-(4-hydroxyphenyl)-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)propanoate     
1H NMR δ (CDCl3, 400 MHz):  1.42 (s, 9H), 1.78 (quin, J = 7.5 Hz, 2H), 
2.17 (s, 3H), 2.27 (t, J = 7.5 Hz, 2H), 2.61 – 
2.65 (m, 2H), 2.98 (dd, J = 14.1, 6.1 Hz, 
1H), 3.05 (dd, J = 14.1 Hz, 6.1 Hz, 1H), 
4.72 – 4.76 (m, 1H), 6.09 (d, J = 8.0 Hz, 
1H), 6.72 (d, J = 8.2 Hz, 2H), 7.01 (d, J = 
8.2 Hz, 2H), 7.67 – 7.72 (m, 2H), 8.05 – 
8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.3, 26.4, 28.1, 36.2, 37.4, 77.3, 
82.5, 115.4 (2 x C), 126.42, 126.47, 130.7 
(2 x C), 132.3, 133.5, 144.2, 146.5, 154.9, 
171.1, 171.9, 184.9, 185.3 
[α]D20:     +14.86. º (c 0.18, CHCl3) 
IR Vmax:  3367 (N-H), 2987, 2931, 1732 (C=O), 1654 
(C=O), 1616, 1695, 1516, 1506, 1369, 
1330, 1294, 1259, 1153, 734 cm-1 
(S)-4-(3-(tert-butoxy)-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)-3-oxopropyl)phenyl 4-(3-methyl-1,4-naphthoquinone-2-
yl)butanoate 
1H NMR δ (CDCl3, 400 MHz):  1.40 (s, 9H), 1.78 (quin, J = 7.8 Hz, 2H), 
1.90 (quin, J = 7.8 Hz, 2H), 2.18 (s, 3H), 
2.22 (s 3H), 2.28 (t, J = 7.8 Hz, 2H), 2.61 – 
2.65 (m, 4H), 2.73 – 2.77 (m, 2H), 3.09 (d, 
J = 6.1 Hz, 2H), 4.73 – 4.78 (m, 1H), 6.10 
(d, J = 7.7 Hz, 1H), 7.00 (d, J = 8.4 Hz, 
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2H), 7.17 (d, J = 8.4 Hz, 2H), 7.66 – 7.71 
(m, 4H), 8.04 – 8.09 (m, 4H) 
13C NMR δ (CDCl3, 100 MHz):  12.84, 12.87, 23.7, 24.3, 26.3, 26.4, 28.1, 
34.1, 36.1, 37.6, 53.5, 82.6, 121.5, 126.3, 
126.43, 126.45, 126.47, 130.5 (2 x C), 
132.23, 132.25, 132.29, 132.3, 133.51, 
133.52, 133.59 (2 x C), 134.0, 144.1, 
146.2, 146.4, 149.7, 170.8, 171.6, 172.8, 
184.7, 184.9, 185.31, 185.35 
[α]D20:     +17.91º (c 0.34, CHCl3) 
IR Vmax:  3366 (N-H), 2978, 2933, 1734 (C=O), 1654 
(C=O), 1595, 1506, 1456, 1369,1296, 
1259, 1201, 1153, 734 cm-1 
 (S)-2-(4-(3-Methyl-1,4-naphthoquinone-2-yl)butanamido)-3-
phenylpropanoic acid (70) 
 
70 was prepared from the deprotection of 61 (317 mg, 0.6875 mmol), using 
general procedure C. The product was purified by flash chromatography (5 % 
methanol/ethyl acetate) to give 70 as brown viscous oil in 79 % yield (220 
mg, 0.542 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.72 – 1.79 (m, 2H), 2.14 (s, 3H), 2.29 (t, J 
= 7.2 Hz, 2H), 2.58 (t, J = 7.8 Hz, 2H), 3.12 
(dd, J = 14.0, 7.0 Hz, 1H), 3.26 (dd, J = 
14.0, 5.4 Hz, 1H), 4.90 (m, 1H), 6.54 (d, J 
= 7.7 Hz, 1H), 7.17 – 7.28 (m, 5H), 7.66 – 
7.69 (m, 2H), 8.02 – 8.05 (m, 2H), 8.92 (bs, 
1H) 
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13C NMR δ (CDCl3, 100 MHz):  12.8, 24.2, 26.2, 35.8, 37.3, 53.4, 126.4, 
127.2, 128.7 (2 x C), 129.4 (2 x C), 132.0, 
132.2, 133.5, 133.6, 135.9, 144.3, 146.2, 
173.5, 174.7, 185.1, 185.2 
[α]D20:     +35.83 º (c 0.24, CHCl3) 
IR Vmax:  3491 (N-H), 2931, 1716 (C=O), 1660 
(C=O), 1616, 1595, 1521, 1456, 1332, 
1296, 1267, 1217, 702 cm-1 
HRMS [M+Na]:  For C24H23N1O5Na, predicted 428.1474, 
found 428.1484 
 (S)-1-(4-(3-Methyl-1,4-naphthoquinone-2-yl)butanoyl)pyrrolidine-2-
carboxylic acid (71) 
 
71 was prepared from the deprotection of 62 (114 mg, 0.2766 mmol), using 
general procedure C. The product was purified by flash chromatography (3 % 
methanol/ethyl acetate) to give 71 as brown viscous oil in 65 % yield (64 mg, 
0.1798 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.82 – 1.90 (m, 2H), 2.02 – 2.08 (m, 2H), 
2.21 (s, 3H), 2.13 – 2.33 (m, 2H), 2.45 – 
2.50 (m, 2H), .68 – 2.72 (m, 2H), 3.49 – 
3.53 (m, 1H), 3.60-3.63 (m, 1H), 4.55 – 
4.58 (m, 1H), 7.53 bs, 1H), 7.68 – 7.07 (m, 
2H), 8.04 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 23.3, 24.8, 26.4, 28.0, 34.1, 47.8, 
59.7, 126.34, 126.38, 132.1, 132.2, 133.51, 
133.56, 144.2, 146.3, 173.4, 173.9, 184.8, 
185.3  
O
O
O
N
OHO
Chapter	6:	Experimental	Details	
	156	
[α]D20:     -65.80º (c 1.69, CHCl3) 
IR Vmax:  2976, 2956, 1716 (C=O), 1658 (C=O), 
1616, 1595, 1456, 1329, 1294, 1188, 717 
cm-1 
 (S)-2-(4-(3-Methyl-1,4-naphthoquinone-2-yl)butanamido)pentanoic acid 
(72) 
 
72 was prepared from the deprotection of 63 (140 mg, 0.3376 mmol), using 
general procedure C. The product was purified by silica plug (gradient 5-10 
% methanol/ethyl acetate) to give 72 as yellow/brown viscous oil in 36 % 
yield (44 mg, 0.1223 mmol). 
1H NMR δ (CD3OD, 400 MHz):  0.92 (t, J = 7.3 Hz, 3H), 1.35 – 1.45 (m, 
2H), 1.61 – 1.70 (m, 2H), 1.78 (quin, J = 
7.4 Hz, 2H), 2.14 (s, 3H), 2.34 (t, J = 7.4, 
2H), 2.64 (m, 2H), 4.29 – 4.32 (m, 1H), 
7.68 – 7.72 (m, 2H), 7.94 – 7.98 (m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.7, 14.0, 20.1, 25.7, 27.3, 35.0, 36.6, 
54.6, 127.00, 127.08, 133.3, 134.5, 144.9, 
147.5, 175.3 (2 x C) 185.6, 186.2  
[α]D20:     -24.44 º (c 0.09, CHCl3) 
IR Vmax:  3336 (N-H), 3296, 2960, 2874, 1681 
(C=O), 1660 (C=O), 1595, 1558, 1456, 
1296, 1205, 1139, 1026, 721 cm-1 
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2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)acetic acid (73) 
 
73 was prepared from the deprotection of 64 (75 mg, 0.1952 mmol), using 
general procedure C. The product purified by precipitation from 
dichloromethane and the solvent was decanted to give 73 as brown solid in 
54 % yield (34 mg, 0.1062 mmol) with a melting point of 62 – 66 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.82 (quin, J = 7.2 Hz, 2H), 2.16 (s, 3H), 
2.41 (t, J = 7.2 Hz, 2H), 2.64 – 2.68 (m, 
2H), 4.09 (d, J = 5.2 Hz, 2H), 6.96 – 6.99 
(m, 1H), 7.65 – 7.68 (m, 2H), 7.99 – 8.04 
(m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.3, 26.3,35.7, 41.6, 126.45, 126.48, 
132.0, 132.2, 133.6, 133.7, 144.5, 146.0, 
172.6, 174.7, 185.2, 185.3 
IR Vmax:  3296 (N-H), 2939, 1734 (C=O), 1718 
(C=O), 1654 (C=O), 1595, 1533, 1330, 
1296, 1024, 717 cm-1 
(S)-4-methyl-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)pentanoic acid (74) 
 
74 was prepared from the deprotection of 65 (109 mg, 0.2559 mmol), using 
general procedure C. The product purified by flash chromatography (5 % 
methanol/ethyl acetate) to give 74 as a dark yellow viscous oil in 61 % yield 
(58 mg, 0.1612 mmol). 
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1H NMR δ (CDCl3, 400 MHz):  0.93 – 0.95 (m, 6H), 1.61 – 1.73 (m, 2H) 
1.82 (quin, J = 7.4 Hz, 2H), 2.17 (s, 3H), 
2.38 (t, J = 7.4 Hz, 2H), 2.64 – 2.68 (m, 
2H), 4.59 – 4.64 (m, 1H), 6.73 (d, J = 8.0 
Hz, 1H), 7.65 – 7.67 (m, 2H), 7.99 – 8.03 
(m, 2H) 
13C NMR δ (CDCl3, 100 MHz): 12.7, 21.8, 22.9, 24.3, 25.0, 26.3, 35.9, 
41.0, 51.0, 126.3 (2 x C), 132.0, 132.1, 
133.5, 133.6, 144.3, 146.2, 173.5, 176.2, 
185.1, 185.2 
[α]D20:     -5.35 º (c 0.93, CHCl3) 
IR Vmax:  3321 (N-H), 1716 (C=O), 1660 (C=O), 
1618, 1595, 1539, 1506, 1330, 1294, 1207, 
717 cm-1 
 (S)-3-(4-hydroxyphenyl)-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)propanoic acid (75) 
 
75 was prepared from the deprotection of 66 (30 mg, 0.06213 mmol), using 
general procedure C. The product purified by precipitation from 
dichloromethane and the solvent decanted to give 75 as a dark yellow 
viscous oil in 76 % yield (20 mg, 0.0479 mmol). 
1H NMR δ (CD3OD, 400 MHz):  1.67 (quin, J = 7.7 Hz, 2H), 2.08 (s, 3H), 
2.23 – 2.30 (m, 2H), 2.37 – 2.45 (m, 1H), 
2.52 – 2.59 (m, 1H), 2.82 (dd, J = 14.0, 9.5 
Hz, 1H), 3.12 (dd, J = 14.0, 4.9 Hz, 1H), 
4.60 – 4.64 (m,1H), 6.65 (d, J = 8.3 Hz, 
2H), 7.04 (d, J = 8.3 Hz, 2H), 7.71 – 7.73 
(m, 2H), 7.99 – 8.02 (m, 2H) 
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13C NMR δ (CD3OD, 100 MHz):  12.6, 25.6, 27.1, 36.5, 37.6, 55.2, 116.1 (2 
x C), 127.0, 127.1, 129.1, 131.2 (2 x C), 
133.4, 134.56, 134.57, 145.0, 147.5, 157.2, 
174.9, 175.3, 185.7, 186.3 
[α]D20:     +2.21 º (c 0.81, CHCl3) 
IR Vmax:  3365 (N-H), 2937, 1734 (C=O), 1716 
(C=O), 1647 (C=O), 1616, 1595, 1516, 
1456, 1296, 1232 cm-1 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-(3-methyl-1,4-
naphthyoquinone-2-yl)butanamide (76) 
 
76 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (134 mg, 5169 mmol) and L-phenyl 
analinol (76 mg, 0.5053 mmol) and the product purified by flash 
chromatography (100 % ethyl acetate) to give 76 as yellow/orange oil in 49 % 
yield (98 mg, 0.2496 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.70 – 1.78 (m, 2H), 2.15 (s, 3H), 2.25 (t, J 
= 7.2 Hz, 2H), 2.55 (t, J = 8.0 Hz, 2H), 2.83 
– 2.94 (m, 2H), 3.03 (bs, 1H), 3.59 (dd, J = 
11.2, 5.4 Hz, 1H), 3.71 (dd, J = 11.2, 3.8 
Hz, 1H), 4.21 – 4.29 (m, 1H), 6.31 (d, J = 
8.0 Hz, 1H), 7.15 – 7.27 (m, 5H), 7.64 – 
7.69 (m, 2H), 8.00 – 8.05 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.3, 26.2, 36.2, 37.0, 52.9, 64.1, 
126.35, 126.36, 126.6, 128.6 (2 x C), 129.2 
(2 x C), 132.0, 132.1, 133.5, 133.6, 137.9, 
144.2, 146.2, 173.1, 185.12, 185.13 
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[α]D20:     -21.33 º (c 1.57, CHCl3) 
IR Vmax:  3369 (N-H), 3296 (-OH), 2933, 1658 
(C=O), 1595, 1539, 1456, 1377, 1330, 
1296, 1043, 717, 702 cm-1 
HRMS [M+Na]:  For C24H25N1O4Na, predicted 414.1676, 
found 414.1667 
(S)-2-(4-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-oxobutyl)-3-methyl-1,4-
naphthoquinone (77) 
 
77 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (117 mg, 0.4522 mmol) and L-Prolinol 
(159 mg, 0.7587 mmol) and the product purified by flash chromatography 
(100 % ethyl acetate) to give 77 as yellow oil in 36 % yield (50 mg, 1459 
mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.60 (quin, J = 6.2 Hz, 2H), 1.82 – 2.02 (m, 
6H), 2.21 (s, 3H), 2.39 (t, J = 7.2 Hz, 2H), 
2.67 – 2.72 (m, 2H), 3.50 – 3.55 (m, 1H), 
3.66 (dd, J = 11.3, 2.8 Hz, 1H), 4.15 – 4.22 
(m, 1H), 7.66 – 7.68 (m, 2H), 8.03 – 8.07 
(m, 2H).  
13C NMR δ (CDCl3, 100 MHz):  12.8, 23.6, 24.5, 26.4, 28.3, 34.6, 48.1, 
61.2, 67.3, 126.33, 126.37, 132.1, 132.2, 
133.4, 133.5, 144.1, 146.6, 173.6, 184.9, 
185.3 
[α]D20:     -35.12 º (c 0.41, CHCl3) 
O
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IR Vmax:  3367 (N-H), 2953, 2877, 1695, 1654, 1616, 
1595, 1454, 1329, 1296, 1047, 732, 719 
cm-1 
(S)-N-(2-hydroxy-1-phenylethyl)-4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamide (78) 
 
78 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (187 mg, 0.7252 mmol) and L-phenyl 
glycinol (106 mg, 0.7690 mmol) and the product purified by dissolving in 
dichloromethane and adding hexanes dropwise until a precipitate was formed 
to give 78 as yellow crystaline solid in 69 % yield (188 mg, 0.4992 mmol) with 
a melting point of 140 – 144 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.80 – 1.90 (m, 2H), 2.19 (s, 3H), 2.37 (t, J 
= 7.1 Hz, 2H), 2.65 – 2.72 (m, 2H), 3.92 (d, 
J = 5.0 Hz, 2H), 5.09 – 5.14 (m, 1H), 6.53 
(d, J = 6.3 Hz, 1H), 7.27 – 7.38 (m, 5H), 
7.68 – 7.70 (m, 2H), 8.04 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  128, 24.4, 26.3, 36.1, 56.2, 66.7, 126.4, 
126.9, 128.0, 128.9 (2 x C), 132.1, 132.3, 
133.5, 133.7, 139.0, 144.4, 146.3, 173.0, 
185.2, 185.3 
[α]D20:     +18.01º (c 0.66, CHCl3) 
IR Vmax:  3294 (C=O), 2937, 1656 (C=O), 1595, 
1535, 1454, 1377, 1330, 1294, 1070, 700 
cm-1 
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N-(4-hydroxyphenethyl)-4-(3-methyl-1,4-naphthoquinone-2-yl) 
butanamide (79) 
 
79 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (236 mg, 0.9122 mmol) and tyramine 
(119 mg, 0.8675 mmol) and the product purified by flash chromatography (80 
% ethyl acetate/hexanes) to give 79 as yellow solid in 33 % yield (109 mg, 
0.2885 mmol) with a melting point of 116 – 118 °C.  
1H NMR δ (CDCl3, 400 MHz):  1.76 (quin, J = 7.5 Hz, 2H), 2.12 (s, 3H), 
2.24 (t, J = 7.2 Hz, 2H), 2.56 – 2.60 (m, 
2H), 2.71 (t, J = 7.0 Hz, 2H), 3.44 – 3. 49 
(m, 2H), 6.22 (t, J = 5.5 Hz, 1H), 6.75 (d, J 
= 8.4 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 
7.62 – 7.65 (m, 2H), 7.97 – 8.00 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.4, 16.3, 34.7, 36.1, 41.1, 115.7, 
126.3, 129.8 (2 x C), 129.9, 132.0, 132.1, 
133.53, 133.59, 144.2, 146.2, 155.3, 173.1, 
185.0, 185.2 
IR Vmax:  3365 (N-H), 3306 (-OH), 2935, 1654 
(C=O), 1616, 1595, 1541, 1516, 1375, 
1330, 1296, 715 cm-1 
HRMS [M+Na]:  For C23H23N1O4Na, predicted 400.1519, 
found 400.1510 
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N-(3,4-dimethoxyphenethyl)-4-(3-methyl-1,4-naphthoquinone-2-yl) 
butanamide (80) 
 
80 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (188 mg, 0.7260 mmol) and 3,4-
dimethoxyphenylethylamine (147 mg, 0.8088 mmol) and the product purified 
by flash chromatography (90 % ethyl acetate/hexanes) to give 80 as pale 
orange crystalline solid in 38 % yield (117 mg, 0.2776 mmol) with a melting 
point of 105 – 108 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.77 (quin, J = 7.2 Hz, 2H), 2.16 (S, 3H), 
2.22 (t, J = 7.2 Hz, 2H), 2.58 – 2.62 (m, 
2H), 2.74 (t, J = 7.2 Hz, 2H), 3.46 – 3.51 
(m, 2H), 3.79 (s, 3H), 3.81 (s, 3H), 5.94 (t, 
J = 5.6 Hz, 1H), 6.68 – 6.76 (m, 3H), 7.63 – 
7.66 (m, 2H), 7.98 – 8.02 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.3, 26.3, 35.2, 36.1, 40.7, 55.8, 
55.9, 111.4, 111.9, 120.7, 126.25, 126.29, 
131.4, 132.0, 132.1, 133.4, 133.5, 144.0, 
146.2, 147.7, 149.0, 172.3, 184.8, 185.1 
IR Vmax:  3377 N-H), 3296, 2935, 1656 (C=O), 1595, 
1516, 1462, 1329, 1294, 1261, 1236, 1157, 
1141, 1028, 717 cm-1 
HRMS [M+Na]:  For C25H27N1O5Na, predicted 444.1781, 
found 444.1773 
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4-(3-methyl-1,4-naphthoquinone-2-yl)-N-phenethylbutanamide (81) 
 
81 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (179 mg, 0.6942 mmol) and 
phenethylamine (98 mg, 0.8088 mmol) and the product purified by flash 
chromatography (70 % ethyl acetate/hexanes) to give 81 as yellow solid in 59 
% yield (148 mg, 0.4086 mmol) with a melting point of 106 – 107 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.80 (quin, J = 7.3 Hz, 2H), 2.20 (s, 3H), 
2.25 (t, J = 7.3 Hz, 2H), 2.62 – 2.66 (m, 
2H), 2.85 (t, J = 7.0 Hz, 2H), 3.53 – 3.58 
(m, 2H), 5.92 (bs, 1H),7.20 – 7.23 (m, 3H), 
7.28 – 7.32 (m, 2H), 7.67 (m, 2H), 7.71 (m, 
2H), 8.03 – 8.09 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.4, 26.4, 35.7, 36.1, 40.7, 126.3, 
126.4, 126.6, 128.7 (2 x C), 128.8 (2 x C), 
132.1, 132.2, 133.5, 133.6, 138.9, 144.2, 
146.3, 172.4, 185.0, 185.2 
IR Vmax:  3298 (N-H), 3064, 2933, 1714 (C=O), 1653 
(C=O), 1595, 1541, 1456, 1377, 1329, 
1294, 717 cm-1  
N-(2-(1H-indol-3-yl)ethyl)-4-(3-methyl-1,4-naphthoquinone-2-yl) 
butanamide (82) 
 
82 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (194 mg, 0.7507 mmol) and tryptamine 
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(124 mg, 0.7708 mmol) and the product purified by flash chromatography (80 
% ethyl acetate/hexanes) to give 82 as a brown viscous oil in 42 % yield (127 
mg, 0.3178 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.77 (quin, J = 7.4 Hz, 2H), 2.14 (s, 3H), 
2.22 (t, J = 7.4 Hz, 2H), 2.57 – 2.61 (m, 
2H), 2.97 (t, J = 6.8 Hz, 2H), 3.58 – 3.63 
(m, 2H), 6.13 (t, J = 5.2 Hz, 1H), 7.01 (bs, 
1H), 7.04 – 7.08 (m, 1H), 7.11 – 7.15 (m, 
1H), 7.32 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 
8.0 Hz, 1H), 7.64 – 7.67 (m, 2H), 7.99 – 
8.04 (m, 2H), 8.69 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.3, 25.2, 26.3, 36.1, 39.9, 111.4, 
112.7, 118.6, 119.3, 122.0, 122.2, 126.2 (2 
x C), 127.3, 132.02, 132.09, 133.42, 
133.47, 136.4, 143.9, 146.2, 172.6, 184.8, 
185.1 
IR Vmax:  3392 (N-H), 3294, 2935, 1705 (C=O), 1653 
(C=O), 1595, 1527, 1458, 1332, 1296, 740, 
715 cm-1 
(2S,4R)-methyl-4-hydroxy-1-(4-(3-methyl-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)butanoyl)pyrrolidine-2-carboxylate (83) 
 
83 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (143 mg, 0.5536 mmol) and trans-4-
Hydroxy-L-proline methyl ester.HCl (103 mg, 0.5693 mmol) and the product 
purified by flash chromatography (90 % ethyl acetate/hexanes) to give 83 as 
yellow viscous oil in 59 % yield (126 mg, 0.3256 mmol). 
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1H NMR δ (CDCl3, 400 MHz):  1.77 – 1.85 (m, 2H), 2.05 (ddd, J = 13.3, 
8.1, 5.0 Hz, 1H), 2.18 (s, 3H), 2.25 – 2.31 
(m, 1H), 2.41 (t, J = 7.2 Hz, 2H), 2.64 – 
2.68 (t, J = 7.9 Hz, 2H), 3.47 (bs, 1H), 3.54 
– 3.56 (m, 1H), 3.69 (s, 3H), 3.73 – 3.76 
(m, 1H), 4.56 (t, J = 8.0 Hz, 2H), 7.63 – 
7.67 (m, 2H), 7.99 – 8.04 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 23.5, 26.3, 34.0, 37.8, 52.4, 55.3, 
57.7, 70.3, 126.3 (2 x C, 132.1, 132.2, 
133.4, 133.5, 144.2, 146.5, 172.0, 172.8, 
184.9, 185.3 
[α]D20:     -58.57º (c 1.33, CHCl3) 
IR Vmax:  3396 (N-H), 2951, 1747 (C=O), 1716 
(C=O), 1653 (C=O), 1622, 1595, 1456, 
1437, 1327, 1296, 1199, 1084, 717 cm-1 
(S)-methyl-3-hydroxy-2-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)propanoate (84) 
 
84 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (149 mg, 0.5777 mmol) and L-serine 
methyl ester.HCl (98 mg, 0.6286 mmol) and the product purified by flash 
chromatography (100 % ethyl acetate) to give 84 as yellow crystalline 
needles in 53 % yield (110 mg, 0.3069 mmol) with a melting point of 94 – 98 
°C. 
1H NMR δ (CDCl3, 400 MHz):  1.78 – 1.94 (m, 2H), 2.21 (s, 3H), 2.37 (td, 
J = 7.0, 2.7 Hz, 2H), 2.46 (bs, 1H), 2.62 – 
2.77 (m, 2H), 3.79 (s, 3H), 4.02 (d, J = 3.5 
Hz, 2H), 4.70 (dt, J = 7.1, 3.5 Hz, 1H), 6.64 
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(d, J = 7.1 Hz, 1H), 7.68 – 7.70 (m, 2H), 
8.03 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.2, 26.1, 35.8, 53.9, 54.9, 63.4, 
126.4, 126.5, 132.0, 132.2, 133.6, 133.7, 
144.5, 146.3, 171.1, 172.7, 185.2, 185.3 
[α]D20:     +6.17 º (c 0.75, CHCl3) 
IR Vmax:   3280 (N-H), 2955, 1734 (C=O), 1716 
(C=O), 1645 (C=O), 1616, 1558, 1521, 
1506, 1456, 1338, 1296 cm-1 
(2S,3S)-methyl-3-hydroxy-2-(4-(3-methyl-naphthoquione-2-
yl)butanamido)butanoate (85) 
 
85 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (151 mg, 0.5827 mmol) and L-threonine 
methyl ester.HCl (103 mg, 0.6102 mmol) and the product purified by flash 
chromatography (90 % ethyl acetate/hexane) to give 85 as yellow crystalline 
solid in 39 % yield (84 mg, 0.2252 mmol) with a melting point of 50 – 52 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.25 (d, J = 6.5 Hz, 3H), 1.81 – 1.89 (m, 
2H), 2.20 (s, 3H), 2.39 (t, J = 7.1 Hz, 2H), 
2.67 – 2.72 (m, 2H), 3.76 (s, 3H), 4.36 (dq, 
J = 6.5, 2.5 Hz, 1H), 4.63 (dd, J = 8.8, 2.5 
Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 7.67 – 
7.70 (m, 2H), 8.02 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 20.2, 24.3, 26.3, 36.0, 52.6, 57.4, 
68.1, 126.3, 126.4, 132.0, 132.2, 133.5, 
133.6, 144.2, 146.3, 171.7, 173.0, 185.0, 
185.2  
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[α]D20:     -2.42º (c 1.60, CHCl3)  
IR Vmax:  3358 (N-H), 2974, 1743 (C=O), 1658 
(C=O), 1595, 1529, 1437, 1379, 1329, 
1294, 1209, 717 cm-1 
 N-butyl-4-(3-methyl-1,4-naphthoquione-2-yl)butanamide (86) 
 
86 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (149 mg, 0.5533 mmol) and butylamine 
(67 mg, 0.9106 mmol) and the product purified by flash chromatography (70 
% ethyl acetate/hexanes) to give 86 as yellow solid in 40 % yield (73 mg, 
0.2336 mmol) with a melting point of 136 – 138 °C. 
1H NMR δ (CDCl3, 400 MHz):  0.91 (t, J = 7.3 Hz, 3H), 1.35 (sextet, J = 
7.3 Hz, 2H), 1.49 (quin, J = 7.3 Hz, 2H), 
1.83 (quin, J = 7.3 Hz, 2H), 2.21 (s, 3H), 
2.27 (t, J = 7.3 Hz, 2H), 2.65 – 2.69 (m, 
2H), 3.24 – 3.29 (m, 2H), 5.78 (bs, 1H), 
7.67 – 7.69 (m, 2H), 8.04 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 13.8, 20.2, 24.5, 26.5, 31.8, 36.2, 
39.4, 126.40, 126.43, 132.2, 132.3, 133.5, 
133.6, 144.2, 146.4, 172.2, 185.1, 185.2 
IR Vmax:  3302 (N-H), 2931, 2862, 1660 (C=O), 
1639, 1595, 1554, 1458, 1323, 1296, 717 
cm-1 
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(S)-methy-2-hydroxy-4-(4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamido)butanoate (87) 
 
87 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (153 mg, 0.5905 mmol) and (R)-2-
hydroxy-4-aminobutyric acid methyl ester.HCl (103 mg, 0.6073 mmol) and 
the product purified by a Reveleris ® X2 automated flash chromatography 
system (Eluent: gradient 50 – 80% ethyl acetate/hexanes, Column: Reveleris 
® Silica 4 g, Flow rate: 18 mL/min) to give 87 as a bright yellow oil in 16 % 
yield (34 mg, 0.0921 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.74 – 1.81 (m, 2H), 2.16 (s, 3H), 2.28 (t, J 
= 7.2 Hz, 2H), 2.60 – 2.64 (m, 2H), 3.32 – 
3.39 (m, 2H), 3.47 – 3.53 (m, 2H), 3.73 (s, 
3H), 4.25 (dd, J = 8.8, 3.7 Hz, 1H), 6.54 (t, 
J = 5.7 Hz, 1H), 7.64 – 7.67 (m, 2H), 7.99 – 
8.03 (m, 2H)  
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.3, 26.4, 33.7, 36.0, 36.2, 52.6, 
69.0, 126.3 (2 x C), 132.0, 132.1, 133.5, 
133.6, 144.2, 146.2, 173.4, 174.0, 185.0, 
185.1 
[α]D20:     -2.47. º (c 0.97, CHCl3) 
IR Vmax:  3367 (N-H), 3306, 2953, 2929, 1739 
(C=O), 1658 (C=O), 1595, 1539, 1456, 
1437, 1329, 1294, 1215, 1122, 846, 717 
cm-1 
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3-(3-methyl-1,4-naphthoquinone-2-yl)propanoic acid (31) 
 
31 was prepared according to general procedure A from menadione (12) 
(1.995 g, 11.59 mmol) and succinic acid (2.757 g, 23.34 mmol) and the 
product purified by flash chromatography (100% dichloromethane followed by 
100% ethyl acetate) to give 31 as a crystalline yellow solid in 20 % yield 
(0.5607 g, 2.296 mmol) with a melting point of 68 – 72 °C. 
1H NMR δ (CDCl3, 400 MHz):  2.23 (s, 3H), 2.60 (t, J = 7.9 Hz, 2H), 2.98 
(t, J = 7.9 Hz, 2H), 7.69 – 7.71 (m, 2H), 
8.06 – 8.09 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.9, 22.7, 32.6, 126.5, 126.5, 132.2, 
132.3, 133.75, 133.76, 144.7, 144.9, 177.8, 
184.6, 185.2  
IR Vmax:  2932 (-OH), 1738 (C=O), 1706 (C=O), 
1658 1595, 1379, 1330, 1296, 716 
5-(3-methyl-1,4-naphthoquinone-2-yl)pentanoic acid (88) 
 
88 was prepared according to general procedure A from menadione (12) 
(2.164 g, 12.566 mmol) and adipic acid (3.724 g, 25.484 mmol) and the 
product purified by flash chromatography (100% dichloromethane followed by 
100% ethyl acetate) to give 88 as a crystalline yellow solid in 78 % yield 
(2.653 g, 9.7422 mmol) with a melting point of 66 – 70 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.49 – 1.57 (m, 2H), 1.70 – 1.77 (m, 2H), 
2.17 (s, 3H), 2.40 (t, J = 7.4 Hz, 2H), 2.64 
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(t, J = 7.9 Hz, 2H), 7.66 – 7.68 (m, 2H), 
8.03 – 8.05 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.9, 26.7, 28.1, 33.8, 126.3, 126.4, 
132.20, 132.21, 133.4, 133.5, 143.5, 146.8, 
179.6, 184.7, 185.3 
IR Vmax:  2939 (-OH), 1705 (C=O), 1658 (C=O), 
1618, 1595, 1379, 1327, 1294, 1261, 715 
cm-1 
6-(3-methyl-1,4-naphthoquinone-2-yl)hexanoic acid (89) 
 
89 was prepared according to general procedure A from menadione (12) 
(2.010 g, 11.676 mmol) and pimelic acid (3.720 g, 23.229 mmol) and the 
product purified by flash chromatography (100% dichl;oromethane followed 
by 100% ethyl acetate) to give 89 as a crystalline yellow solid in 57 % yield 
(1.921 mg, 6.710 mmol) with a melting point of 49 – 51 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.45 – 1.51 (m, 4H), 1.69 (quin, J = 7.4 Hz, 
2H), 2.18 (s, 3H), 2.36 (t, J = 7.4 Hz, 2H), 
2.63 (t, J = 7.4 Hz, 2H), 7.66 – 7.69 (m, 
2H), 8.05 – 8.07 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.5, 26.9, 28.4, 29.4, 33.9, 126.3, 
126.4 132.2, 132.3, 133.46, 133.49, 143.4, 
147.2, 179.6, 184.8, 185.4 
IR Vmax:  2937 (-OH), 1707 (C=O), 1658 (C=O), 
1595, 1327, 1294, 1259, 715 cm-1 
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(S)-tert-butyl-2-(3-(3-methyl-1,4-naphthoquinone-2-yl)propanamido)-3-
phenylpropanoate (90) 
 
90 was prepared according to general procedure B from 3-(3-Methyl-1,4-
naphthalen-2-yl)-propanoic acid (31) (119 mg, 0.4876 mmol) and L-
phenylalanine t-butyl ester.HCl (115 mg, 0.4462 mmol) and the product 
purified by flash chromatography (30 % ethyl acetate/hexanes) to give 90 as 
yellow oil in 22 % yield (45 mg, 0.0997 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.37 (s, 9H), 2.94 (s, 3H), 2.37 – 2.41 (m, 
2H), 2.92 (t, J = 7.8 Hz, 2H), 3.05 (d, J = 
6.1 Hz, 2H), 4.71 – 4.76 (m, 1H), 6.08 (d, J 
= 7.7 Hz, 1H), 7.09 – 7.21 (m, 5H), 7.66 – 
7.68 (m, 2H), 8.02 – 8.05 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 23.4, 28.0, 34.9, 38.1, 53.5, 82.4, 
126.33, 126.39, 127.0, 128.4 (2 x C), 129.5 
(2 x C), 132.1, 132.2, 133.50, 133.54, 
136.2, 144.5, 145.4, 170.7, 171.0, 184.7, 
185.0 
[α]D20:     +29.91º (c 0.54, CHCl3) 
IR Vmax:  3365 (N-H), 2978, 1732(C=O), 1718 
(C=O), 1660 (C=O), 1595, 1521, 1456, 
1367, 1294, 1153, 700  cm-1 
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(S)-2-(3-(3-methyl-1,4-naphthoquinone-2-yl)propanamido)-3-phenyl 
propanoic acid (91) 
 
91 was prepared from the deprotection of 90 (18 mg, 0.0407 mmol), using 
general procedure C. The product purified by flash chromatography (5 % 
methanol/ethyl acetate) to give 91 as a yellow oil in 80 % yield (13 mg, 
0.0327 mmol). 
1H NMR δ (CD3OD, 400 MHz):  2.08 (s, 3H), 2.37 (td, J = 7.6, 3.5 Hz, 2H), 
2.82 (t, J = 7.6 Hz, 2H), 2.89 (dd, J = 13.9, 
9.3 Hz, 1H), 3.17 (dd, J = 13.9, 4.9 Hz, 
1H), 4.64 (dd, J = 9.3, 5.0 Hz, 1H), 7.11 – 
7.17 (m, 5H), 7.72 – 7.75 (m, 2H), 8.00 – 
8.02 (m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.7, 24.3, 35.1, 38.4, 55.0, 127.0, 127.7, 
129.3 (2 x C), 130.1 (2 x C), 133.4, 
134.590, 134.598, 138.4, 145.5, 146.4, 
174.4, 185.6, 186.1 
[α]D20:     -3.95 º (c 0.45, CHCl3) 
IR Vmax:  3306 (N-H), 2926, 1732 (C=O), 1714 
(C=O), 1658 (C=O), 1595, 1454, 1330, 
1296, 1195, 734, 702 cm-1 
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(S)-tert-butyl-2-(5-(3-methyl-1,4-naphthoquinone-2-yl)pentanamido)-3-
phenylpropanoate (92) 
 
92 was prepared according to general procedure B from 5-(3-methyl-1,4-
naphthoquinone-2-yl)pentanoic acid (88) (205 mg, 0.7525 mmol) and L-
phenylalanine t-butyl ester.HCl (188 mg, 0.7308 mmol) and the product 
purified by flash chromatography (40 % ethyl acetate/hexanes) to give 92 as 
bright yellow oil in 69 % yield (240 mg, 0.5055 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.35 (s, 9H), 1.39 - 1.47 (m, 2H), 1.67 
(quin, J = 7.5 Hz, 2H), 2.11 (s, 3H), 2.20 (t, 
J = 7.5 Hz, 2H), 2.58 (t, J = 7.9 Hz, 2H), 
2.98 – 3.08 (m, 2H), 4.70 – 4.75 (m, 1H), 
6.09 (d, J = 7.6 Hz, 1H), 7.09 – 7.12 (m, 
5H), 7.60 – 7.64 (m, 2H), 7.98 – 8.02 (m, 
2H) 
13C NMR δ (CDCl3, 100 MHz):  12.6, 25.6, 26.5, 27.9 28.0, 36.0, 38.0, 
53.4, 82.2, 126.1, 126.2, 126.8, 128.3 (2 x 
C), 129.4 (2 x C), 132.11, 132.12, 133.3 (2 
x C), 136.2, 143.4, 146.8, 170.8, 172.1, 
184.6, 185.1 
[α]D20:     +37.83º (c 0.92, CHCl3) 
IR Vmax:  3306 (N-H), 2978, 2933, 1732 (C=O), 1658 
(C=O), 1595, 1531, 1367, 1329, 1257, 
1294, 1155, 715 cm-1 
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(S)-2-(5-(3-methyl-1,4-naphthoquinone-2-yl)pentanamido)-3-
phenylpropanoic acid (93) 
 
93 was prepared from the deprotection of 92 (215 mg, 0.4517 mmol), using 
general procedure C. The product purified by flash chromatography (35 % 
ethyl acetate/hexane) to give 93 as a brown oil in 85 % yield (161 mg, 0.3843 
mmol). 
1H NMR δ (CD3OD, 400 MHz):  1.26 – 1.40 (m, 2H), 1.58 (quin, J = 7.6 Hz, 
2H), 2.09 (s, 3H), 2.17 – 2.22 (m, 2H), 2.55 
(t, J = 7.9 Hz, 2H), 2.90 (dd, J = 14.0, 9.6 
Hz, 1H), 3.19 (dd, J = 14.0, 4.8 Hz, 1H), 
4.67 (dd, J = 9.6, 4.8 Hz, 2H), 7.14 – 7.21 
(m, 5H), 7.70 – 7.74 (m, 2H), 7.99 – 8.02 
(m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.7, 26.9, 27.4, 28.9, 36.4, 38.3, 54.8, 
127.0, 127.1, 127.6, 129.3 (2 x C), 130.1 (2 
x C), 133.40, 133.42, 134.5 (2 x C), 138.5, 
144.5, 148.0, 174.7, 175.7, 185.7, 186.3 
[α]D20:     +25.16º (c 1.06, CHCl3) 
IR Vmax:  3316 (N-H), 2939, 1734 (C=O), 1716 
(C=O), 1656  (C=O), 1595, 1525, 1456, 
1294, 1190, 736, 702 cm-1 
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(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-5-(3-methyl-1,4-naphthoquinone-
2-yl)pentanamide (94) 
 
94 was prepared according to general procedure B from 5-(3-methyl-1,4-
naphthoquinone-2-yl)pentanoic acid (88) (149 mg, 0.5483 mmol) and L-
phenylalaninol  (88 mg, 0.5800 mmol) and the product purified by flash 
chromatography (2 % methanol/ethyl acetate) to give 94 as bright 
yellow/brown oil in 59 % yield (131 mg, 0.3236 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.43 (quin, J = 7.7 Hz, 2H), 1.66 – 1.75 (m, 
2H), 2.17 (s, 3H), 2.24 – 2.28 (m, 2H), 2.56 
– 2.64 (m, 2H), 2.83 – 2.94 (m, 2H), 3.39 
(bs, 1H), 3.58 (dd, J = 11.2, 5.1 Hz, 1H), 
3.70 (dd, J = 11.2, 3.5 Hz, 2H), 4.19 – 4.23 
(m, 1H), 6.26 (d, J = 7.7 Hz, 1H),  7.15 – 
7.28 (m, 5H), 7.68 – 7.72 (m, 2H), 8.03 – 
8.09 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 25.8, 26.5, 27.7, 36.0, 37.0, 53.0, 
64.1, 126.32, 126.39, 126.6, 128.6 (2 x C), 
129.2 (2 x C), 132.1, 132.2, 133.5, 133.6, 
137.7, 143.7, 146.7, 173.7, 185.0, 185.2  
[α]D20:     -16.60º (c 2.12, CHCl3) 
IR Vmax:  3296 (N-H), 2935, 1656 (C=O), 1595, 
1531, 1456, 1377, 1329, 1294, 702 cm-1 
 
 
O
O
N
H
O
OH
Chapter	6:	Experimental	Details	
	177	
N-(4-hydroxyphenethyl)-5-(3-methyl-1,4-naphthoquinone-2-
yl)pentanamide (95) 
 
95 was prepared according to general procedure B from 5-(3-methyl-1,4-
naphthoquinone-2-yl)pentanoic acid (88) (159 mg, 0.5831 mmol) and 
tyramine (77 mg, 0.5628 mmol) and the product purified by flash 
chromatography (85 % ethyl acetate/hexanes) to give 95 as orange solid in 
20 % yield (45 mg, 0.1137 mmol) with a melting point of 136 – 138 °C. 
1H NMR δ (CD3OD, 400 MHz): 1.42 – 1.50 (m, 2H), 1.66 (quin, J = 7.5 Hz, 
2H), 2.15 (s, 3H), 2.19 (t, J = 7.3 Hz, 2H), 
2.62 – 2.68 (m, 4H), 3.33 (t, J = 7.2 Hz, 
2H), 6.67 (d, J = 8.5 Hz, 2H), 7.00 (d, J = 
8.5 Hz, 2H), 7.72 – 7.74 (m, 2H), 8.01 – 
8.04 (m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.7, 27.1, 27.4, 29.1, 35.6, 36.8, 42.2, 
116.1, 127.0, 127.1, 130.7 (2 x C), 131.2, 
133.4, 134.5 (2 x C), 144.6, 148.0, 156.8, 
175.8, 185.8, 186.3  
IR Vmax:  3369 (N-H), 3296, 2937, 1755 (C=O), 1693 
(C=O), 1653 (C=O), 1616, 1595, 1516, 
1329, 1294, 1197, 734, 715 cm-1 
N-(3,4-dimethoxyphenethyl)-5-(3-methyl-1,4-naphthoquinone-2-
yl)pentanamide (96) 
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96 was prepared according to general procedure B from 5-(3-methyl-1,4-
naphthoquinone-2-yl)pentanoic acid (88) (170 mg, 0.6243 mmol) and 3,4-
dimethoxyphenylethylamine (105 mg, 0.5777 mmol) and the product purified 
by flash chromatography (90 % ethyl acetate/hexanes) to give 96 as bright 
yellow solid in 35 % yield (95 mg, 0.2170 mmol) with a melting point of 106 – 
108 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.46 (quin, J = 7.5 Hz, 2H), 1.70 (quin, J = 
7.6 Hz, 2H), 2.14 (s, 3H), 2.18 (t, J = 7.5 
Hz, 2H), 2.58 – 2.62 (m, 2H), 2.73 (t, J = 
7.1 Hz, 2H), 3.44 – 3.49 (m, 2H), 3.80 (s, 
3H), 3.82 (s, 3H), 5.75 (t, J = 5.4 Hz, 1H), 
6.66 – 6.68 (m, 2H), 6.73 – 6.73 (m, 1H), 
7.64 – 7.67 (m, 2H), 7.99 – 8.04 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 25.8, 26.5, 28.0, 35.3, 36.3, 40.7, 
55.90, 55.94, 111.3, 111.8, 120.6, 126.25, 
126.29, 131.4, 132.14, 132.17, 133.43, 
133.47, 143.5, 146.8, 147.7, 149.0, 172.8, 
184.7, 185.2  
IR Vmax:  3381 (N-H), 3292, 2935, 1658 (C=O), 
1595, 1516, 1462, 1329, 1294, 1261, 1236, 
1157, 1141, 1028, 715 cm-1 
(S)-tert-butyl-2-(6-(3-methyl-1,4-naphthoquinone-2-yl)hexanamido)-3-
phenylpropanoate (97) 
 
97 was prepared according to general procedure B from 6-(3-methyl-1,4-
naphthoquinone-2-yl)hexanoic acid (89) (240 mg, 0.8396 mmol) and L-
phenylalanine t-butyl ester.HCl (180 mg, 0.7001 mmol) and the product 
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purified by flash chromatography (40 % ethyl acetate/hexanes) to give 97 as 
yellow oil in 48 % yield (166 mg, 0.3383 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.40 (s, 9H), 1.41 – 1.47 (m, 4H), 1.64 
(quin, J = 7.5 Hz, 2H), 2.16 (s, 3H), 2.18 – 
2.29 (m, 2H), 2.60 (t, J = 7.8 Hz, 2H), 3.02 
– 3.10 (m, 2H), 4.73 – 4.78 (m, 1H), 6.05 
(d, J = 7.7 Hz, 1H), 7.13 – 7.15 (m, 2H), 
7.21 – 7.28 (m, 3H), 7.65 – 768 (m, 2H), 
8.03 – 8.06 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.6, 25.2, 26.8, 27.9, 28.3, 29.4, 36.3, 
38.1, 53.3, 82.3, 126.20, 126.28, 126.9, 
128.3 (2 x C), 129.5 (2 x C), 132.17, 
132.19, 133.32, 133.35, 134.18, 136.3, 
143.2, 147.2, 170.9, 172.3, 184.6, 185.3 
[α]D20:     +23.33º (c 0.66, CHCl3) 
IR Vmax:  3290 (N-H), 2978, 2933, 1734 (C=O), 1718 
(C=O), 1695 (C=O), 1653, 1595, 1521, 
1456, 1369, 1294, 1155, 702 cm-1 
(S)-2-(6-(3-methyl-1,4-naphthoquinone-2-yl)hexanamido)-3-
phenylpropanoic acid (98) 
 
98 was prepared from the deprotection of 97 (166 mg, 0.3382 mmol), using 
general procedure C. The product purified by precipitation from 
dichloromethane and the solvent was decanted to give 98 as brown solid in 
84 % yield (124 mg, 0.2854 mmol) with a melting point of 72 – 76 °C. 
1H NMR δ (CD3OD, 400 MHz):  1.30 – 1.35 (m, 2H), 1.39 – 1.46 (m, 2H), 
1.56 (quin, J = 7.5 Hz, 2H), 2.16 (s, 3H), 
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2.17 – 2.20 (m, 2H), 2.58 – 2.62 (m, 2H), 
2.93 (dd, J = 14.0, 9.5 Hz, 1H), 3.22 (dd, J 
= 14.0, 4.9 Hz, 1H), 4.69 (dd, J = 9.5, 4.9 
Hz, 1H), 7.20 – 7.28 (m, 5H), 7.74 – 7.76 
(m, 2H), 8.03 – 8.05 (m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.7, 26.5, 27.6, 29.3, 30.2, 36.5, 38.4, 
54.8, 127.02, 127.09, 127.7, 129.4, 130.2, 
133.46, 133.49, 134.57, 134.58, 138.5, 
144.4, 148.3, 174.7, 175.9, 185.8, 186.3 
[α]D20:     +24.71 º (c 0.78, CHCl3) 
IR Vmax:  3288 (N-H), 2937, 1732 (C=O), 1716 
(C=O), 1660 (C=O), 1595, 1531, 1456, 
1377, 1330, 1294, 1172, 736, 702 cm-1 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-6-(3-methyl-1,4-naphthoquione-2-
yl)hexanamide (99) 
 
99 was prepared according to general procedure B from 6-(3-methyl-1,4-
naphthoquinone-2-yl)hexanoic acid (89) (148 mg, 0.5176 mmol) and L-
phenylalaninol (92 mg, 0.6071 mmol) and the product purified by flash 
chromatography (2 % methanol/ethyl acetate) to give 99 as yellow semi solid 
in 34 % yield (74 mg, 0.1759 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.34 – 1.48 (m, 4H), 1.62 (quin, J = 7.4 Hz, 
2H), 2.16 (s, 3H), 2.17 (t, J = 7.5 Hz, 2H), 
2.56 – 2.60 (m, 2H), 2.78 (bs, 1H), 2.81 – 
2.92 (m, 2H), 3.59 (dd, J = 11.1, 5.2 Hz, 
1H), 3,69 (dd, J = 11.1, 3.5 Hz, 1H), 4.16 – 
4.20 (m, 1H), 5.97 (d, J = 7.0 Hz, 1H), 7.19 
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– 7.23 (m, 3H), 7.27 -  7.31 (m, 2H), 7.67 – 
7.70 (m, 2H), 8.03 – 8.07 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz): 12.8, 25.4, 26.9, 28.3, 29.3, 36.4, 37.1, 
53.1, 64.4, 126.3, (2 x C), 126.8, 128.7, 
129.3, 132.26, 132.28, 133.51, 133.53, 
137.7, 143.4, 147.2, 174.1, 184.9, 185.4 
cm-1 
[α]D20:     +15.15º (c 2.31, CHCl3) 
IR Vmax:  3336 (N-H), 2935, 1695 (C=O), 1658 
(C=O), 1595, 1541, 1456, 1377, 1329, 
1296, 715, 702 cm-1 
N-(4-hydroxyphenethyl)-6-(3-methyl-1,4-naphthoquinone-2-yl) 
hexanamide (100) 
 
100 was prepared according to general procedure B from 6-(3-methyl-1,4-
naphthoquinone-2-yl)hexanoic acid (89) (1367 mg, 0.4778 mmol) and 
tyramine (74 mg, 0.5423 mmol) and the product purified by flash 
chromatography (90 % ethyl acetate/hexanes) to give 100 as orange 
crystalline solid in 39 % yield (75 mg, 0.1842 mmol) with a melting point of 90 
– 92 °C. 
1H NMR δ (CD3OD, 400 MHz):  1.33 – 1.42 (m, 2H), 1.45 – 1.54 (m, 2H), 
1.62 (quin, J = 7.4 Hz, 2H), 2.13 – 2.16 (m, 
2H), 2.17 (s, 3H), 2.62 – 2.69 (m, 2H), 3.34 
(t, J = 7.3 Hz, 2H), 6.68 – 6.70 (m, 2H), 
6.99 – 7.03 (m, 2H), 7.72 – 7.78 (m, 2H), 
8.02 – 8.05 M, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.6, 26.6, 27.6, 29.2, 30.3, 35.7, 36.9, 
42.0, 116.3, 127.00, 127.08, 130.6 (2 x C), 
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131.3, 133.55, 134.52, 134.54, 144.5, 
148.4, 156.8, 175.9, 185.9, 186.4 
IR Vmax:  3369 (N-H), 3296, 2935, 1695 (C=O), 1654 
(C=O), 1595, 1541, 1516, 1329, 1296, 734, 
713 cm-1 
N-(3,4-dimethoxyphenethyl)-6-(3-methyl-1,4-naphthoquinone-2-
yl)hexanamide (100) 
 
101 was prepared according to general procedure B from 6-(3-methyl-1,4-
naphthoquinone-2-yl)hexanoic acid (89) (165 mg, 0.5773 mmol) and 3,4-
dimethoxyphenyletheylamine (126 mg, 0.6932 mmol) and the product 
purified by flash chromatography (90 % ethyl acetate/hexanes) to give 101 as 
yellow solid in 60 % yield (155 mg, 0.3457 mmol) with a melting point of 98 – 
100 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.39 – 1.48 (m, 4H), 1.65 (quin, J = 7.4 Hz, 
2H), 2.14 (t, J = 7.7 Hz, 2H), 2.16 (s, 3H), 
2.57 – 2.61 (m, 2H), 2.74 (t, J = 7.0 Hz, 
2H), 3.46 – 3.51 (m, 2H), 3.83 (s, 3H), 3.84 
(s, 3H), 5.61 (bs, 1H), 6.70 – 6.72 (m, 2H), 
6.77 – 6.80 (m, 1H), 7.65 – 7.68 (m, 2H), 
8.02 – 8.06 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 25.4, 26.9, 28.3, 29.5, 35.3, 36.5, 
40.7, 55.9, 56.0, 111.4, 112.0, 120.7, 
126.31, 126.32, 131.4, 132.2, 133.44, 
133.45, 143.3, 147.2, 147.8, 149.1, 173.0, 
184.8, 185.3  
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IR Vmax:  3369 (N-H), 3304, 2935, 1656 (C=O), 
1595, 1516, 1456, 1329, 1294, 1261, 1236, 
1028, 715 cm-1 
(R)-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-3-
phenylpropanoic acid (105) 
 
4-(3-Methyl-1,4-naphthalen-2-yl)-butanoic acid (32) (200 mg, 0.7736 mmol) 
was added to anhydrous dichloromethane (10 mL) under an atmosphere of 
N2. Carbonyl diimidazole (145 mg, 0.8930 mmol) was added and the 
resulting mixture stirred for 3.5 h at room temperature. The reaction was 
quenched with H2O (20mL) and the organic layer washed with H2O (2 x 20 
mL). The organic layer was dried with MgSO4, filtered and the solvent 
removed under reduced pressure to give the crude intermediate 103 as a 
yellow oil (221.7 mg, 0.7190 mmol). To the crude intermediate in THF (5 mL) 
a solution of D-phenylalanine (650 mg, 3.937 mmol) and pyridine (0.28 mL, 
3.6084 mmol) in H2O (15 mL) was added and the reaction stirred under an 
atmosphere of nitrogen for 6 h. The reaction mixture was quenched with 20 
mL 2M HCl and extracted DCM (3 x 20 mL) and the organic layer was dried 
with MgSO4, filtered and the solvent removed under reduced pressure to give 
a crude product, which was purified by flash chromatography (7 % 
methanol/ethyl acetate) to give 105 as yellow oil in 14 % yield (44 mg, 0.1080 
mmol). 
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(2-(4-(1H-imidazol-1-yl)-4-oxobutyl)-3-methylnaphthalene-1,4-dione) 
Intermediate (103) 
1H NMR δ (CDCl3, 400 MHz): 1.90 (quin, J = 7.6 Hz, 2H), 2.13 (s, 3H), 
2.65 – 2.29 (m, 2H), 2.94 (t, J = 7.0 Hz, 
2H), 6.99 (s, 1H), 7.40 (s, 1H), 7.57 – 7.60 
(m, 2H), 7.90 – 7.93 (m, 2H), 8.10 (s, 1H) 
13C NMR δ (CDCl3, 100 MHz): 12.5, 22.4, 25.8, 34.6, 126.1, 130.9, 131.7, 
131.8, 133.3, 133.4, 144.0, 145.5, 168.9, 
184.4, 184.8  
IR Vmax: 1738 (C=O), 1695 (C=O), 1658, 1595, 
1472, 1390, 1295, 1222, 717 
(R)-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-3-
phenylpropanoic acid (105) 
1H NMR δ (CDCl3, 400 MHz):  1.72 – 1.79 (m, 2H), 2.15 (s, 3H), 2.30 (t, J 
= 7.3 Hz, 2H), 2.57 – 2.61 (m, 2H), 3.13 
(dd, J = 14.1, 7.0 Hz, 2H), 3.27 (dd, J = 
14.1, 5.5 Hz, 2H), 4.88 – 4.93 (m, 1H), 6.51 
(d, J = 7.5 Hz, 1H), 7.18 – 7.29 (m, 5H), 
7.67 – 7.71 (m 2H), 8.03 – 8.07 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.2, 26.2, 35.9, 37.4, 53.4, 126.4, 
127.2, 128.7 (2 x C), 129.4 (2 x C), 132.1, 
132.2, 133.5, 133.6, 135.9, 144.3, 146.2, 
173.3, 174.8, 185.0, 185.2 
[α]D20:     -38.75º (c 0.16, CHCl3) 
IR Vmax:  3370 (N-H), 2928, 1732 (C=O), 1716 
(C=O), 1658 (C=O), 1595, 1527, 1456, 
1330, 1294, 734, 717, 702 cm-1 
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(R)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-(3-methyl-1,4-naphthoquione-
2-yl)butanamide (106) 
 
106 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (180 mg, 0.6954 mmol) and D-
phenylalaninol (117 mg, 0.7731 mmol) and the product purified by flash 
chromatography (100 % ethyl acetate) to give 106 as a brown oil in 55 % 
yield (186 mg, 0.4300 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.72 – 1.78 (m, 2H), 2.17 (s, 3H), 2.25 (t, J 
= 6.9 Hz, 2H), 2.56 – 2.60 (m, 2H), 2.86 – 
2.91 (m, 2H), 3.60 (dd, J = 11.2, 5.2 Hz, 
1H), 3.74 (dd, J = 11.2, 3.5 Hz, 1H), 4.21 – 
4.25 (m, 1H), 6.09 (d, J = 7.7 Hz 1H), 7.19 
– 7.29 (m, 5H), 7.68 – 7.71 (m, 2H), 8.03 – 
8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.3, 26.2, 36.2, 37.1, 53.0, 64.4, 
126.45, 126.47, 126.7, 128.7, 129.3, 132.1, 
132.2, 133.5, 133.7, 137.8, 144.3, 146.3, 
173.0, 185.22, 185.27 
[α]D20:     -13.88º (c 0.25, CHCl3) 
IR Vmax:  3369, 3306, 3064, 2933, 1653, 1595, 1533, 
1456, 1377, 1330, 1294, 1041, 734, 702 
cm-1 
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(R)-N-(2-hydroxy-1-phenylethyl)-4-(3-methyl-1,4-naphthoquinone-2-
yl)butanamide (107) 
 
107 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (178 mg, 0.6877 mmol) and D-phenyl 
glycinol (109 mg, 0.7953 mmol) and the product purified by dissolving in 
dichloromethane and adding hexanes dropwise until a precipitate was formed 
to give 107 as yellow crystaline solid in 62 % yield (161 mg, 0.4266 mmol) 
with a melting point of 150 – 154 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.80 – 1.90 (m, 2H) 2.29 (s, 3H), 2.36 (t, J 
= 7.1 Hz, 2H), 2.65 – 2.73 (m, 2H), 3.92 (d, 
J = 5.0 Hz, 2H), 5.10 – 5.14 (m, 1H), 6.50 
(d, J = 6.8 Hz, 1H), 7.27 – 7.38 (m, 5H), 
7.67 – 7.72 (m, 2H), 8.03 – 8.10 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.8, 24.4, 26.3, 36.2, 56.1, 66.8, 126.4, 
126.9, 128.0, 129.0 (2 x C), 132.1, 132.3, 
133.5, 133.7, 139.0, 144.4, 146.3, 172.9, 
185.2, 185.3 
[α]D20:     -31.81º (c 0.64, CHCl3) 
IR Vmax:  3296 (N-H), 2935, 1658 (C=O), 1595, 
1541, 1456, 1377, 1330, 1294, 719, 700 
cm-1 
 (S)-methyl-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-2-
phenylacetate (108) 
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108 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (209 mg, 0.8100 mmol) and S-(+)-phenyl 
glycine methyl ester.HCl (169 mg, 0.8396 mmol) and the product purified by 
flash chromatography (45 % ethyl acetate/hexanes) to give 108 as yellow 
solid in 72 % yield (236 mg, 0.5826 mmol) with a melting point of 100 – 102 
°C. 
1H NMR δ (CDCl3, 400 MHz):  1.78 – 1.85 (m, 2H), 2.13 (s, 3H), 2.35 (td, 
J = 7.3, 3.2 Hz, 2H), 2.63 – 2.67 (m, 2H), 
3.70 (s, 3H), 5.59 (d, J = 7.2 Hz, 1H), 6.87 
(d, J = 7.2 Hz, 1H), 7.28 – 7.37 (m, 5H), 
7.63 – 7.66 (m, 2H), 7.99 – 8.03 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.2, 26.3, 35.8, 52.8, 56.5, 126.3, 
126.4, 127.4, 128.6, 129.1, 132.1, 132.2, 
133.4, 133.5, 136.5, 144.1, 146.3, 171.5, 
171.7, 184.9, 185.2 
[α]D20:     +99.11º (c 1.13, CHCl3) 
IR Vmax:  3306 (N-H), 3030, 2953, 1743 (C=O), 1647 
(C=O), 1597, 1597, 1537, 1456, 1379, 
1330, 1296, 1213, 1127, 754, 717, 698 cm-
1 
 (R)-methyl-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-2-
phenylacetate (109) 
 
109 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (202 mg, 0.7810 mmol) and R-(-)-phenyl 
glycine methyl ester.HCl (161 mg, 0.8396 mmol) and the product purified by 
flash chromatography (45 % ethyl acetate/hexanes) to give 109 as yellow 
solid in 69 % yield (219 mg, 0.5394 mmol) with a melting point of 90 – 92 °C. 
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1H NMR δ (CDCl3, 400 MHz):  1.78 – 1.86 (m, 2H), 2.15 (s, 3H), 2.35 (td, 
J = 7.3, 3.0 Hz, 2H), 2.46 – 2.68 (m, 2H), 
3.71 (s, 3H), 5.60 (d, J = 7.2 Hz, 1H), 6.79 
(d, J = 7.2 Hz, 1H), 7.30 – 7.36 (m, 5H), 
7.64 – 7.69 (m, 2H), 8.00 – 8.06 (m, 2H)  
13C NMR δ (CDCl3, 100 MHz):  12.7, 24.3, 26.3, 35.9, 52.9, 56.5, 126.3, 
126.4, 127.4 (2 x C), 128.7, 129.1 (2 x C), 
132.20, 132.27, 133.50, 133.54, 136.6, 
144.1, 146.4, 171.5, 171.7, 184.9, 185.3 
[α]D20:     -93.58º (c 0.78, CHCl3) 
IR Vmax:  3304 (N-H), 3032, 2953, 1743 (C=O), 1656 
(C=O), 1647, 1597, 1521, 1456, 1435, 
1379, 1323, 1296, 1259, 1213, 1172, 754, 
717, 696 cm-1 
(S)-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-2-phenylacetic 
acid (110) 
 
108 (76 mg, 0.1877 mmol) was added to 6M HCl (4 mL) with a catalytic 
amount of glacial acetic acid. Solution was refluxed for 2h and reaction 
quenched with the addition of H2O (20 mL) and dichloromethane (20 mL), 
and the aqueous layer extracted with a further 2 x 20 mL dichloromethane. 
The organic layer dried with MgSO4 and the solvent removed under reduced 
pressure to give a crude product, which was purified by precipitation from 
dichloromethane and the solvent decanted to give 110 as pale yellow solid in 
46 % yield (34 mg, 0.0869 mmol) with a melting point of 168 – 170 °C. 
1H NMR δ (CD3OD, 400 MHz):  1.81 (quin, J = 7.6 Hz, 2H), 2.14 (s, 3H), 
2.35 – 2.40 (m, 2H), 2.65 – 2.70 (m, 2H), 
O
O
H
N
O
OH
O
Chapter	6:	Experimental	Details	
	189	
5.42 (s, 1H), 7.31 – 7.42 (m, 5H), 7.72 – 
7.75 (m, 2H), 8.02 – 8.04 (m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  12.7, 25.6, 27.2, 36.2, 58.2, 127.0, 127.1, 
128.8 (2 x C), 129.3, 129.7 (2 x C), 133.50, 
133.51, 134.5, 134.6, 138.1, 145.9, 147.5, 
175.1, 185.8, 186.3 (Note: one carbon 
signal missing or overlapped) 
[α]D20:     +90.34º (c 0.74, CHCl3) 
IR Vmax:  3350 (N-H), 3030, 2933, 1732 (C=O), 1658 
(C=O), 1647, 1597, 1533, 1456, 1379, 
1330, 1296, 1259, 1219, 754, 717, 698 cm-
1 
(R)-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-2-phenylacetic 
acid (111) 
 
109 (49 mg, 0.1208 mmol) was added to 6M HCl (4 mL) with a catalytic 
amount of glacial acetic acid. Solution was refluxed for 2h and reaction 
quenched with the addition of H2O (20 mL) and dichlormethane (20 mL), and 
the aqueous layer extracted with a further 2 x 20 mL dichloromethane. The 
organic layer dried with MgSO4 and the solvent removed under reduced 
pressure to give a crude product, which was purified by precipitation from 
dichloromethane and the solvent decanted to give 111 as pale yellow solid in 
14 % yield (7 mg, 0.0169 mmol) with a melting point of 128 – 130 °C. 
1H NMR δ (CD3OD, 400 MHz):  1.81 (quin, J = 7.5 Hz, 2H), 2.14 (s, 3H), 
2.35 – 2.40 (m, 2H), 2.65 – 2.70 (m, 2H), 
5.42 (s, 1H), 7.31 – 7.42 (m, 5H), 7.73 – 
7.75 (m, 2H), 8.02 – 8.04 (m, 2H) 
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13C NMR δ (CD3OD, 100 MHz):  12.7, 25.6, 27.2, 36.2, 58.3, 127.0, 127.1, 
128.8 (2 x C), 129.3, 129.7 (2 x C), 133.50, 
133.52, 134.57, 134.59, 138.2, 145.0, 
147.5, 175.1, 185.8, 186.3 (Note: one 
carbon signal missing or overlapped) 
[α]D20:     -127.41º (c 0.14, CHCl3) 
IR Vmax:  3348 (N-H), 3066, 2928, 1732 (C=O), 1658 
(C=O), 1647, 1597, 1496, 1456, 1379, 
1330, 1296, 1259, 1217, 1178, 754, 717, 
698 cm-1 
3-((3-Methyl-1,4-naphthoquinone-2-yl)thio)propanoic acid (113) 
 
Mercapto-propanoic acid (112) (1.4 mL, 10.829 mmol) was added to a 
solution of menadione (12) (536 mg, 3.1119 mmol) in methanol (50 mL) and 
isopropanol (40 mL) and the reaction mixture stirred at room temperature for 
24 h. The solvent was removed under reduced pressure and re-dissolved in 
dichloromethane and washed with 10% copper sulfate solution (2 x 25 mL) 
and H2O (3 x 25 mL) The organic layer was dried with MgSO4, filtered and 
the solvent removed under reduced pressure to give a crude product which 
was purified by flash chromatography (30 % ethyl acetate/hexanes) to give 
113 as red solid oil in 48 % yield (387 mg, 1.4021 mmol). 
1H NMR δ (CDCl3, 400 MHz):  2.34 (s, 3H), 2.75 (t, J = 7.0 Hz, 2H), 3.42 
(t, J = 7.0 Hz, 2H), 7.69 – 7.71 (m, 2H), 
8.06 – 8.09 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  15.4, 28.9, 35.4, 126.7, 126.9, 132.1, 
132.9, 133.5, 133.8, 145.8, 147.6, 176.2, 
181.3, 182.2 
Spectral data consistent with data reported in the literature.64  
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4-((1,4-naphthoquinone-2-yl)amino)butanoic acid (115) 
 
A solution of gamma amino butyric acid (170 mg, 1.6466 mmol) in H2O (5 
mL) was added to a hot solution of 1,4-naphthoquinone (4) (525 mg, 3.317 
mmol) in ethanol (50 mL) and the mixture stirred at room temperature for 16 
h. The solvent removed under reduced pressure and the product purified by 
a Reveleris ® X2 automated flash chromatography system (Eluent: gradient 
0 – 10 % methanol in dichloromethane, Column: Reveleris ® Silica 4 g, Flow 
rate: 18 mL/min) to give 115 as a burgundy red solid in 22 % yield (92 mg, 
0.3560 mmol). 
1H NMR δ (CDCl3, 400 MHz):  2.04 (quin, J = 7.0 Hz, 2H), 2.50 (t, J = 7.0 
Hz, 2H), 3.29 (q, J = 7.0 Hz, 2H), 5.78 (s, 
1H), 6.07 – 6.10 (m, 1H), 7.61 (td, J = 7.5, 
1.3 Hz, 1H), 7.72 (td, J = 7.5, 1.3 Hz, 1H), 
8.03 (dd, J = 7.7, 1.0 Hz, 1H), 8.09 (dd, J = 
7.7, 1.0 Hz, 1H)  
13C NMR δ (d6-DMSO, 100 MHz): 22.6, 30.9, 41.22, 99.3, 125.2, 125.8, 
130.4, 132.0, 133.1, 134.7, 148.5, 174.1, 
181.2, 181.5 
Spectral data consistent with data reported in the literature.90 
(S)-methyl-2-(4-((1,4-naphthoquinone-2-yl)amino)butanamido)-3-
phenylpropanoate (117) 
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117 was prepared according to general procedure B from 4-((1,4-
naphthoquinone-2-yl)amino)butanoic acid (115) (63  mg, 0.2416 mmol) and 
L-phenylalanine methyl ester.HCl (60 mg, 0.2791 mmol) in DMF. The 
reaction was quenched with H2O (20mL) and the aqueous layer was 
extracted with 1:1 ethyl acetate/hexanes. The organic layer was combined 
and washed with 2x 25 mL H2O, dried with MgSO4, filtered and the solvent 
removed under reduced pressure to give a crude product. The product was 
purified by flash chromatography (90 % ethyl acetate/hexanes) to give 117 as 
bright red solid in 18 % yield (19 mg, 0.0445 mmol) with a melting point of 
105 – 107 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.97 – 2.04 (m, 2H), 2.29 – 2.33 (m, 2H), 
3.08 (dd, J = 14.0, 6.2 Hz, 1H), 3.18 (dd, J 
= 14.0, 5.8 Hz, 1H), 3.19 – 3.23 (m, 2H), 
3.73 (s, 3H), 4.90 – 4.95 (m, 1H), 5.82 (s, 
1H), 5.96 (d, J = 7.6 Hz, 1H), 6.51 (bs, 1H), 
7.07 – 7.09 (m, 2H), 7.22 – 7.29 (m, 3H), 
7.61 (td, J = 7.6, 1.3 Hz, 1H), 7.72 (td, J = 
7.6, 1.3 Hz), 8.05 (dd, J = 7.7, 1.0 Hz, 1H), 
8.09 (dd, J = 7.7, 1.0 Hz, 1H)  
13C NMR δ (CDCl3, 100 MHz):  23.4, 33.6, 37.9, 42.4, 52.5, 53.2, 100.5, 
126.4, 126.6, 127.3, 128.7 (2 x C), 129.3 (2 
x C), 130.6, 132.2, 133.5, 134.9, 135.8, 
148.6, 171.6, 172.1,181.6, 182.8 
[α]D20:     -46.67º (c 0.06, CHCl3) 
IR Vmax:  3290 (N-H), 3061, 2953, 1743 (C=O), 1676 
(C=O), 1604, 1570, 1510, 1456, 1336, 
1305, 1253, 1213, 779 cm-1 
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(S)-1-((S)-2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)-3-
phenylpropanoyl)pyrrolidine-2-carboxylic acid (119) 
 
120 was prepared according to general procedure B from 70 (112 mg, 
0.2752 mmol) and L-Proline t-butyl ester.HCl (75 mg, 0.3625 mmol) and the 
product purified by flash chromatography (80 % ethyl acetate/hexanes) to 
give the t-butyl ester as a yellow viscous oil in 35 % yield (53.4 mg, 0.0956 
mmol). Deprotection of the t-butyl ester (44.1 mg, 0.0789) was performed 
using general procedure C. The product was purified by flash 
chromatography (7 % methanol/ethyl acetate) to give 120 as a yellow oil in 
49 % yield (20 mg, 0.0390 mmol). 
HR ESI MS:  For C29H30N2Na06, predicted 525.2002, 
found 525.1990 
[α]D20:     -28.31 º (c 0.45, CHCl3) 
IR Vmax:  3293 (N-H), 3064, 2929, 1716 (C=O), 1732 
(C=O), 1658, 1622, 1539, 1454, 1330, 
1294, 1188, 734, 702 cm-1 
N-(2-(benzylamino)-2-oxoethyl)-2-((S)-3-(4-hydroxy-2,6-dimethylphenyl)-
2-(4-(3-methyl-1,4-naphthoquinone-2-yl)butanamido)propanoyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide 
 
O
O
O
NH
O
N
O
OH
OH
O
N
O N
H
H
N
O
O
O
NH
O
Chapter	6:	Experimental	Details	
	194	
122 was prepared according to general procedure B from 4-(3-Methyl-1,4-
naphthalen-2-yl)-butanoic acid (32) (31 mg, 01181 mmol) and DMT-Tic-Gly-
Bnz.HCl (49 mg, 0.0785 mmol) and the product purified by flash 
chromatography (95:5:1 methanol/ethyl acetate/H2O) to give 122 as an 
opaque yellow semi-solid in 27 % yield (15 mg, 0.0196 mmol). 
MS m/z  (ES+):    777 (M+Na, 45), 755 (M+, 48), 591 (100) 
[α]D20:     -26.67 º (c 0.05, CHCl3) 
IR Vmax:  3306 (N-H), 1653 (C=O), 1595, 1539, 
1456, 1437, 1379, 1294, 1267, 1143, 1030, 
734 cm-1 
6.2.3 Solid Phase Peptide Synthesis 
SPPS procedure A: Preparation of Resin 
Solid phase peptide synthesis was conducted manually in a sinter-fitted 
polypropylene syringe. 2-Chlorotrityl resin (100 – 200 mesh, 1.63 mmol/g 
resin loading) was agitated in CH2Cl2 for 30 mins and then drained. A 
solution containing fmoc-amino acid (3 eq. relative to maximum resin loading) 
in 0.4M DIPEA (diisopropylethylamine)/CH2Cl2 was added and the mixture 
agitated for 3 h. The resin was drained and washed with 17:2:1 
CH2Cl2/MeOH/DIPEA (3 x 1 min), CH2Cl2 (2 x 1 min), DMF (2 x 1 min) 
CH2Cl2 (2 x 1 min) and DMF (2 x 1 min). 
SPPS procedure B: Fmoc Deprotection 
Resin was agitated with 10 % piperidine in DMF (2 x 2 mL x 3 min) then 
drained and washed with DMF (3 x 1 min), CH2Cl2 (3 x 1 min) and DMF (3 x 
1 min). 
SPPS procedure C: Peptide Coupling 
A solution of the desired fmoc-amino acid (3 eq. relative to the maximum 
resin loading) and PyBOP (2.9 eq. relative to resin loading) in minimal 
amount of DMF was prepared. DIPEA (6 eq. relative to resin loading) was 
added to the solution and the mixture immediately added to the resin and 
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agitated for 1.5 h. The resin was drained and washed with DMF (3 x 1 min), 
CH2Cl2 (3 x 1 min) and DMF (3 x 1 min). 
SPPS Proceedure D: Cleavage 
After last fmoc deprotection was resin with CH2Cl2 (3 x 1 min) again and 
drained. Resin was agitated with 10 % 222,333-hexaflouro-isopropanol in 
CH2Cl2 (2 x 30 min). Cleavage solutions were combined and the solvent 
removed under reduced pressure to give a thin film. Diethyl ether (3 x) was 
added and decanted to give the desired peptide. 
SPPS procedure E: Deprotection of additional protecting groups after 
resin cleavage  
Minimal TFA (2 mL) was added to the peptides and the mixture stirred for 16 
h. The reaction mixture was the solvent removed under reduced pressure to 
give a thin film, diethyl ether (3 x) was added and decanted to give the pure 
peptide as a TFA salt.  
Quin-N-Arg-Tyr-Lys-Phen-OH (123) 
 
123 was prepared on a 0.086 mmol scale according to SPPS procedures A – 
E. The product was obtained as a TFA salt as a yellow viscous oil in 88 % 
yield according to the initial resin loading (82.0 mg, 0.0758 mmol). Further 
purification was not required.  
[α]D20:     -18.00º (c 0.10, DMSO) 
HRMS [M2+]:  For C45H58N8O9, predicted 427.2158, found 
427.2175 
 
O
O
H
N
O
N
H
H
N
N
H
OH
O
O
O
O
NH
NH3+NH+H3N
OH
Chapter	6:	Experimental	Details	
	196	
Quin-N-Phen-Lys-Tyr-Arg-OH (124) 
 
124 was prepared on a 0.086 mmol scale according to SPPS procedures A – 
E. The product was obtained as a TFA salt as a yellow viscous oil in 
quantitative yield according to the initial resin loading (90.1 mg, 0.0834 
mmol). Further purification was not required.  
 [α]D20:     -16.93º (c 0.68, MeOH) 
HRMS [M2+]:  For C45H58N8O9, predicted 427.2158, 
found 427.2173 
Quin-Lys-Phen-Lys-Phen-OH (125) 
 
125 was prepared on a 0.17 mmol scale according to SPPS procedures A – 
D. The protected product was obtained as a yellow soild in 91 % yield 
according to the initial resin loading (155.2 mg, 1.555 mmol). Further 
purification was not required. Deprotection of the protected product (26.9 mg, 
0.0269 mmol) using SPPS procedure E resulted in 125 as a TFA salt in 
quantitative yield (27.3 mg, 0.0263 mmol). 
[α]D20:     -27.39º (c 0.46, MeOH) 
HRMS [M2+]:  For C55H72N6O12, predicted 405.2153, 
found 405.2151 
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Quin-N-Lys-Phen-Phen-Lys-OH (126) 
 
126 was prepared on a 0.086 mmol scale according to SPPS procedures A – 
E. The product was obtained as a TFA salt as a yellow viscous oil in 73 % 
yield according to the initial resin loading (65.5 mg, 0.0632 mmol). Further 
purification was not required.  
[α]D20:     -21.46º (c 2.33, MeOH) 
HRMS [M2+]:  For C30H46N8O6, predicted 405.2153, found 
405.2153 
Quin-N-Lys-Lys-Phen-Phen-OH (127) 
 
127 was prepared on a 0.086 mmol scale according to SPPS procedures A – 
E. The product was obtained as a TFA salt as a yellow viscous oil in 92 % 
yield according to the initial resin loading (82.2 mg, 0.0792 mmol). Further 
purification was not required.  
[α]D20:     -15.24º (c 1.47, MeOH) 
HRMS [M2+]:  For C45H58N6O8, predicted 405.2153, found 
405.2147 
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Quin-N-His-Phen-His-Phen-OH (128) 
 
128 was prepared on a 0.086 mmol scale according to SPPS procedures A – 
E. The product was obtained as a TFA salt as a cream coloured soild in 86 % 
yield according to the initial resin loading (78.9 mg, 0.0748 mmol). Further 
purification was not required.  
[α]D20:     -10.20º (c 0.49, MeOH) 
HRMS [M2+]:  For C45H48N8O8, predicted 414.1792, found 
414.1787 
Quin-N-Lys-Trp-Lys-Trp-OH (129) 
 
129 was prepared on a 0.086 mmol scale according to SPPS procedures A – 
E. The product was obtained as a TFA salt as a brown soild in 76 % yield 
according to the initial resin loading (71.8 mg, 0.0643 mmol). Further 
purification was not required.  
[α]D20:     -41.71º (c 1.64, MeOH) 
HRMS [M2+]:  For C49H60N8O8, predicted 444.2262, found 
444.2256 
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6.3 Chapter 3 Experimental Details 
6.3.1 Synthesis of non-methyl naphthoquinone analogues 
4-(1,4-naphthoquinone-2-yl)butanoic acid (130) and 4,4'-(1,4-dioxo-1,4-
dihydronaphthalene-2,3-diyl)dibutanoic acid (131) 
 
130 was prepared according to general procedure A from naphthoquinone 
(4) (1.999 g, 12.64 mmol) and glutaric acid (0.8354 mg, 6.323 mmol) and the 
product purified by a Reveleris ® X2 automated flash chromatography 
system (Eluent: gradient 0 – 80 % ethyl acetate in hexane, Column: 
Reveleris ® Silica 24 g, Flow rate: 18 mL/min) to give 130 as a brown solid in 
42 % yield (0.655 g, 2.680 mmol) and 131 as a crystalline yellow solid in 9 % 
yield (185 mg, 0.5607 mmol). 
4-(1,4-naphthoquinone-2-yl)butanoic acid (130) 
Melting point:   120 – 122 °C. 
1H NMR δ (CD3OD, 400 MHz):  1.90 (quin, J = 7.6 Hz, 2H), 2.39 (t, J = 7.6 
Hz, 2H), 2.62 (td, J = 7.6, 1.1 Hz, 2H), 6.85 
(t, J = 1.1 Hz, 1H), 7.78 – 7.80 (m, 2H), 
8.02 – 8.04 (m, 1H), 8.07 – 8.10 (m, 1H) 
13C NMR δ (CD3OD, 150 MHz):  24.4, 30.0, 34.2, 126.8, 127.4, 133.4, 
133.7, 134.8, 134.9, 136.0, 152.4, 176.8, 
186.1, 186.3  
IR Vmax:  2956 (-OH), 1699 (C=O), 1660 (C=O), 
1620, 1953, 1417, 1327, 1303, 1265, 1143, 
783, 661 cm-1 
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4,4'-(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)dibutanoic acid (131) 
Melting point:   146 – 149 °C 
1H NMR δ (CD3OD, 400 MHz):  1.80 (quin, J = 7.4 Hz, 4H), 2.42 (t, J = 7.4 
Hz, 4H), 2.69 – 2.73 (m, 4H), 7.74 – 7.76 
(m, 2H), 8.03 – 8.05 (m, 2H) 
13C NMR δ (CD3OD, 100 MHz):  25.7, 27.2, 34.7, 127.1, 133.5, 134.6, 
148.0, 176.9, 186.1  
IR Vmax:  2932 (-OH), 1697 (C=O), 1656 (C=O), 
1595, 1406, 1294, 1240, 935, 721 cm-1 
(S)-tert-butyl-2-(4-(1,4-naphthoquinone-2-yl)butanamido)-3-
phenylpropanoate (132) 
 
132 was prepared according to general procedure B from 4-(1,4-naphthalen-
2-yl)-butanoic acid (130) (351 mg, 1.437 mmol) and L-phenylalanine t-butyl 
ester.HCl (496 mg, 1.925 mmol) and the product purified by flash 
chromatography (50 % ethyl acetate/hexanes) to give 132 as yellow viscous 
oil in 67 % yield (432 mg, 0.9660 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.43 (s, 9H), 1.91 (quin, J = 7.5 Hz, 2H), 
2.29 (td, J = 7.5, 2.9 Hz, 2H), 2.56 – 2.60 
(m, 2H), 3.10 – 3.14 (m, 2H), 4.76 – 4.81 
(m, 1H), 6.03 (d, J = 7.3 Hz, 1H), 7.16 -6 
7.31 (m, 5H), 7.74 – 7.76 (m, 2H), 8.07 – 
8.12 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  23.9, 28.1, 29.1, 35.8, 38.2, 53.5, 82.5, 
126.2, 126.7, 127.1, 128.5 (2 x C), 129.6 (2 
x C), 132.2, 132.3, 133.7, 133.8, 135.3, 
136.3, 150.9, 170.9, 172.5, 185.1, 185.2 
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[α]D20:     +38.46º (c 0.39, CHCl3) 
IR Vmax:  3309 (N-H), 2978, 2931, 1732 (C=O), 1662 
(C=O), 1595, 1525, 1456, 1367, 1301, 
1259, 1153, 700 cm-1 
(S)-2-(4-(1,4-naphthoquinone-2-yl)butanamido)-3-phenylpropanoic acid 
(133) 
 
133 was prepared from the deprotection of 132 (428 mg, 0.9563 mmol), 
using general procedure C. The product was purified by flash 
chromatography (5 % methanol/ethyl acetate) to give 133 as brown solid in 
92 % yield (345 mg, 0.8811 mmol) with a melting point of 110 – 112 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.86 (quin, J = 7.4 Hz, 2H), 2.40 (t, J = 7.3 
Hz, 2H), 2.45 – 2.54 (m, 2H), 3.12 (dd, J = 
14.0, 7.4 Hz, 1H), 3.28 (dd, J = 14.0, 5.2 
Hz, 1H), 4.97 – 5.02 (m, 1H), 6.74 (s, 1H), 
7.04 (d, J = 7.9 Hz, 1H), 7.17 – 7.21 (m, 
3H), 7.24 – 7.28 (m, 2H), 7.71 – 7.73 (m, 
2H), 7.99 – 8.06 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  24.0, 28.8, 35.3, 37.3, 53.5, 126.2, 126.7, 
127.4, 128.8, 129.3, 131.9, 132.1, 134.0, 
135.3, 135.53, 135.55, 150.7, 174.82, 
174.88, 185.2, 185.6 
[α]D20: +7.87º (c 0.33, MeOH)  
IR Vmax:  3301 (N-H), 2929, 1708 (C=O), 1661 
(C=O), 1554, 1454, 1369, 1302, 1260, 697 
cm-1 
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(S)-4-(1,4-naphthoquinone-2-yl)-N-(1-hydroxy-3-phenylpropan-2-yl) 
butanamide (134) 
 
134 was prepared according to general procedure B from 4-(1,4-naphthalen-
2-yl)-butanoic acid (130) (140 mg, 0.5728 mmol) and L-phenylalaninol (96 
mg, 0.6349 mmol) and the product purified by flash chromatography (4 % 
methanol/ ethyl acetate) to give 134 as a dark brown semi solid in 53 % yield 
(115 mg, 0.3034 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.86 (quin, J = 7.3 Hz, 2H), 2.25 (t, J = 7.3 
Hz, 2H), 2.49 – 2.53 (m, 2H), 2.89 (t, J = 
7.0 Hz, 2H), 3,04 (bs, 1H), 3.59 (dd, J = 
11.1, 5.1 Hz, 1H), 3.70 (dd, J = 11.1, 3.6 
Hz, 1H), 4.21 – 4.25 (m, 1H), 6.17 (d, J = 
7.9 Hz, 1H), 6.76 (s, 1H), 7.19 – 7.29 (m, 
5H), 7.71 – 7.73 (m, 2H), 8.02 – 8.07 (m, 
2H) 
13C NMR δ (CDCl3, 100 MHz):  24.9, 28.9, 35.9, 37.1, 52.8, 64.0, 126.1, 
126.7, 128.6 (2 x C), 129.3 (2 x C), 132.1, 
132.2, 133.8, 135.3, 137.8, 150.9, 172.7, 
185.1, 185.3 
[α]D20:     -23.09º (c 0.97, CHCl3) 
IR Vmax:  3350 (N-H), 2947, 1733 (C=O), 1645 
(C=O), 1611, 1456, 1266, 1204, 1153, 
1055, 735, 702 cm-1 
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4-(1,4-naphthoquinone-2-yl)-N-(4-hydroxyphenethyl)butanamide (135) 
 
135 was prepared according to general procedure B from 4-(1,4-naphthalen-
2-yl)-butanoic acid (130) (150 mg, 0.6149 mmol) and tyramine (89 mg, 
0.6502 mmol) and the product purified by flash chromatography (80 % ethyl 
acetate/hexanes) to give 135 as a brown viscous oil in 33 % yield (109 mg, 
0.2885 mmol).  
1H NMR δ (CDCl3, 400 MHz):  1.85 (quin, J = 7.4 Hz, 2H), 2.22 (t, J = 7.4 
Hz, 2H) 2.49 – 2.53 (m, 2H), 2.72 (t, J = 
6.8 Hz, 2H), 3.46 – 3.50 (m, 2H), 5.89 (t, J 
= 5.27 Hz, 1H), 6.71 (s, 1H), 6.77 (d, J = 
8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 7.68 
– 7.71 (m, 2H), 7.99 – 8.05 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  24.0, 29.0, 34.7, 35.9, 40.9, 115.7, 121.7, 
126.1, 126.7, 129.9, 132.1, 132.2, 133.8, 
133.9, 150.9, 155.1, 172.6, 185.1, 185.24, 
185.28 
IR Vmax:  3312 (N-H), 2932, 1661 (C=O), 1594, 
1539, 1455, 1302, 1265, 1042, 733, 702 
cm-1 
N-(3,4-dimethoxyphenethyl)-4-(1,4-dioxo-1,4-naphthoquinone-2-yl) 
butanamide (136) 
 
136 was prepared according to general procedure B from 4-(1,4-naphthalen-
2-yl)-butanoic acid (130) (140 mg, 0.5748 mmol) and 3,4-
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dimethoxyphenethylamine (129 mg, 0.7111 mmol) and the product purified 
by flash chromatography (90 % ethyl acetate/hexanes) to give 136 as brown 
semi solid in 36 % yield (84 mg, 0.2059 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.90 (quin, J = 7.4 Hz, 2H), 2.21 (t, J = 7.4 
Hz, 2H), 2.54 – 2.58 (m, 2H), 7.26 (t, J = 
7.1 Hz, 2H), 3.47 – 3.52 (m, 2H), 3.83 (s, 
3H), 3.85 (s, 3H), 5.63 (t, J = 5.5 Hz, 2H), 
6.71 (s, 1H), 6.77 – 6.80 (m, 3H), 7.76 – 
7.74 (m, 2H), 8.03 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  24.0, 29.1, 35.3, 35.9, 40.7, 56.00, 56.03, 
111.5, 112.0, 120.7, 126.2, 126.7, 131.4, 
132.2, 132.3, 133.7, 133.8, 135.2, 147.8, 
149.2, 150.9, 172.0, 185.0, 185.2 
IR Vmax:  3311 (n-H), 2935, 1644 (C=O), 1593, 1516, 
1328, 1302, 1263, 1236, 1157, 1141, 1028, 
732 cm-1 
6.3.2 Synthesis of hydroxy-naphthoquinone derivatives 
2-hydroxy-3-methylnaphthalene-1,4-dione (138) 
 
Menadione (12) (100 mg, 0.5825 mmol) was dissolved in methanol (1 mL) 
and cooled to 0 °C. A solution containing anhydrous Na2CO3 (26.3 mg, 
0.2481 mmol) and 0.15 mL of 30% H2O2 in 0.5 mL H2O was added dropwise 
at 0 °C. Mixture was left for 5 mins before the addition of 10 mL chilled H2O 
resulting in the precipitation of 2-methyl-naphthoquinone oxide which was 
collected by filtration as a pale yellow solid. The solid was treated with 0.5 mL 
conc. H2SO4 and left to stand for 10 mins before the reaction mixture was 
diluted with 10 mL H2O which resulted in a the precipitation of a purple solid. 
The product was purified by flash chromatography (25 % ethyl 
O
O
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acetate/hexanes) to give 138 as yellow solid in 33 % yield (36 mg, 0.1918 
mmol) with a melting point of 132 – 133°C. 
1H NMR δ (CDCl3, 400 MHz):  2.11 (s, 3H), 7.29 (s, 1H), 7.67 (t, J = 7.5 
Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 8.07 (d, J 
= 7.6 Hz, 1H), 8.12 (d, J = 7.6 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  8.8, 120.6, 126.2, 126.8, 129.5, 133.05, 
133.07, 134.9, 153.2, 181.3, 185.1 
IR Vmax:  3368 (-OH), 1651 (C=O), 1645 (C=O), 
1590, 1458, 1381, 1348, 1338, 1270, 1072, 
726 cm-1 
Ethyl 4-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)oxy)butanoate (143) 
 
Lawsone (139) (516 mg, 2.963 mmol) in DMF (2 mL) was added to a solution 
of lithium carbonate (232 mg, 3.142 mmol) in DMF (10 mL) and stirred at 
room temperature for 0.25 h. A solution of ethyl bromobutyrate (0.8 mL, 
1.090 g, 5.590 mmol) in DMF (2 mL) was added dropwise over a 5 min 
period before the reaction mixture was stirred for 1 hour. Reaction mixture 
was then refluxed for 3 hours before cooling and quenching with H2O (50 
mL), extracted with dichloromethane (3 x 20 mL) and washed with H2O (3 x 
20 mL). The organic extract was dried with Na2SO4, filtered and the product 
purified by flash chromatography (50 % ethyl acetate/hexanes) to give 143 as 
brown crystalline solid in 46 % yield (393 mg, 1.364 mmol) with a melting 
point of 60 – 61 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.25 (t, J = 7.2 Hz, 3H), 2.17 – 2.24 (m, 
2H), 2.53 (t, J = 7.1 Hz, 2H), 4.05 (t, J = 6.2 
Hz, 2H), 4.14 (q, J = 7.2 Hz, 2H), 6.14 (s, 
1H), 7.66 – 7.74 (m, 2H), 8.04 – 8.06 (m, 
1H), 8.08 – 8.10 (m, 1H) 
O
O
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13C NMR δ (CDCl3, 100 MHz):  14.3, 23.7, 30.4, 60.7, 68.3, 110.4, 126.2, 
126.7, 131.2, 132.0, 133.4, 134.3, 159.7, 
172.7, 180.0, 185.0 
IR Vmax:  2981, 2940, 1731 (C=O), 1685 (C=O), 
1653 (C=O), 1608, 1577, 1330, 1244, 
1209, 1181, 1043, 1022, 782, 725 cm-1 
4-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)butanoic acid (149) 
 
To a suspension of glutaric anhydride (6.979 g, 61.17 mmol) in H2O (8 mL), 
30 % H2O2 (10 mL) was added and stirred at room temperature for 1 h. The 
reaction mixture was cooled to 0 °C before a white precipitate was formed 
and the solid filtered producing digluteroylperoxide. This solid was slowly 
added to a hot solution (100 °C) of Lawsone (139) (2.844 g, 16.33 mmol) in t-
butanol (20 mL). The reaction mixture was refluxed for 3 mins before being 
cooled to room temperature and quenched with H2O (50 mL). The reaction 
mixture was extracted with CH2Cl2 (4 x 50 mL) and the organic extract was 
dried over MgSO4, filtered and the solvent removed under reduced pressure 
to give the crude product 149 (4.570 g) as a yellow solid, which was unable 
to be purified by flash column chromatography and used in subsequent 
reactions as a crude mixture. 
1H NMR δ (CDCl3, 400 MHz):  1.84 (quin, J = 7.5 Hz, 2H), 2.33 (t, J = 7.5 
Hz, 2H), 2.61 – 2.65 (m, 2H), 7.69 – 7.79 
(m, 2H), 8.01 – 8.08 (m, 2H) 
13C NMR δ (CDCl3, 150 MHz):  23.4, 24.6, 34.7, 124.5, 126.8, 127.1, 
131.6, 134.0, 135.4, 157.0, 177.3, 182.3, 
186.4 
IR Vmax:  3352, 1705 (C-O), 1642 (C=O), 1590, 
1374, 1348, 1274, 1216, 727 cm-1 
O
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Note: Crude Mixture of 149 was used for synthesis of analogues 150, 153 
and 154 without purification 
(S)-tert-butyl-2-(4-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)butanamido)-3-phenylpropanoate (150) 
 
150 was prepared according to general procedure B from crude 149 (627 
mg) and L-phenylalanine t-butyl ester.HCl (582 mg, 2.264 mmol) and the 
product purified by flash chromatography (45 % ethyl acetate/hexanes) to 
give 150 as yellow viscous oil in 9 % yield (88 mg, 0.1903 mmol). 
* Yield calculated as if acid 149 was a pure compound 
1H NMR δ (CDCl3, 400 MHz):  1.39 (s, 9H), 1.86 (quin, J = 7.3 Hz, 2H), 
2.22 (t, J = 7.3 Hz, 2H), 2.63 (t, J = 7.3 Hz, 
2H), 3.09 (d, J = 6.10 Hz, 2H), 4.75 – 4.80 
(m, 1H), 6.23 (d, J = 7.7 Hz, 1H), 7.15 – 
7.28 (m, 5H), 7.66 (dt, J = 7.5, 1.2 Hz, 1H), 
7.73 (dt, J = 7.5, 1.2 Hz, 1H), 8.05 – 8.10 
(m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  22.5, 24.1, 28.0, 35.7, 38.2, 53.6, 82.4, 
123.4, 126.2, 126.8, 127.0, 128.4, 129.6, 
129.8, 132.8, 133.0, 134.8, 136.3, 154.1, 
170.9, 172.5, 181.3, 184.8 
[α]D20:     +61.82º (c 0.33, CHCl3) 
IR Vmax:  3314 (N-H), 2978, 2931, 1731 (C=O), 1713 
(C=O), 1647 (C=O), 1594, 1457, 1368, 
1274, 1217, 1155, 726 cm-1 
 
O
O
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(S)-2-(4-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)butanamido)-
3-phenylpropanoic acid (151) 
 
151 was prepared from the deprotection of 150 (58 mg, 0.1252 mmol), using 
general procedure C. The product was purified by flash chromatography (100 
% ethyl acetate) to give 151 as a pale yellow solid in 74 % yield (38 mg, 
0.0930 mmol) with a melting point of 110 – 112 °C. 
1H NMR δ (MeOD, 400 MHz):  169 – 1.76 (m, 2H), 2.20 (t, J = 7.78 Hz, 
2H), 2.53 (t, J = 7.5 Hz, 2H), 2.94 (dd, J = 
14.0, 9.1 Hz, 1H), 3.19 (dd, J = 14.0, 5.2 
Hz, 1H), 4.65 (dd, J = 9.1, 5.2 Hz, 1H) 7.12 
– 7.25 (m, 5H), 7.70 (dt, J = 7.4, 1.2 Hz, 
1H), 7.75 (dt, J = 7.4, 1.2 Hz, 1H), 8.00 – 
8.03 (m, 2H) 
13C NMR δ (MeOD, 100 MHz):  23.5, 25.5, 36.7, 38.4, 54.9, 124.5, 126.7, 
127.1, 127.7, 129.3, 130.2, 131.6, 133.9, 
134.0, 135.4, 138.4, 156.9, 174.7, 175.7, 
182.2, 186.4 
[α]D20:     +23.11º (c 0.45, MeOH) 
IR Vmax:  3328 (N-H), 2930, 1733 (C=O), 1713 
(C=O), 1668 (C=O), 1645, 1593, 1539, 
1369, 1274, 1217, 726, 701 cm-1 
4-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-
hydroxyphenethyl)butanamide (153) 
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153 was prepared according to general procedure B from crude 149 (587 
mg) and tyramine (292 mg, 2.129 mmol) and the product purified by flash 
chromatography (2 % methanol/ethyl acetate) to give 153 as yellow needles 
in a 4 % yield (33 mg, 0.08566 mmol) with a melting point of 122 – 123 °C. 
* Yield calculated as if acid 149 was a pure compound 
1H NMR δ (Acetone-D6, 400 MHz): 1.83 (quin, J = 7.4 Hz, 2H), 2.20 (t, J = 
7.4 Hz, 2H), 2.62 (t, J = 7.4 Hz, 2H), 2.68 
(t, J = 7.4 Hz, 2H), 3.34 – 3.39 (m, 2H), 
6.73 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 
Hz, 2H), 7.21 (bs, 1H), 7.75 – 7.84 (m, 2H), 
8.02 – 8.05 (m, 2H), 8.12 (bs, 1H), 
13C NMR δ (Acetone-D6, 100 MHz): 22.3, 24.2, 34.6, 35.1, 40.8, 115.0, 
123.2, 125.5, 125.9, 129.5, 130.1, 130.3, 
132.6, 132.8, 134.2, 155.2, 155.7, 172.5, 
180.9, 184.3 
IR Vmax:  3330 (N-H), 2932, 1662 (C=O), 1634 
(C=O), 1593, 1516, 1368, 1273, 1217, 725 
cm-1 
N-(3,4-dimethoxyphenethyl)-4-(3-hydroxy-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)butanamide (154) 
 
154 was prepared according to general procedure B from crude 149 (458 
mg) and 3,4-dimethoxyphenethylamine (322 mg, 1.778 mmol) and the 
product purified by flash chromatography (100 % ethyl acetate) to give 154 
as yellow solid in 5 % yield* (38 mg, 0.08879 mmol) with a melting point of 
145 – 147 °C. 
* Yield calculated as if acid 149 was a pure compound 
H
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1H NMR δ (CDCl3, 400 MHz):  1.86 (quin, J = 7.2 Hz, 2H), 2.18 (t, J = 7.2 
Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H), 2.77 (t, J 
= 7.0 Hz, 2H), 3.49 – 3.54 (m, 2H), 3.840 
(s, 3H), 3.847 (s, 3H), 5.91 (t, J = 5.91 Hz, 
1H), 6.71 – 6.74 (m, 2H), 6.78 – 6.80 (m, 
1H), 7.66 (dt, J = 7.5, 1.2 Hz, 1H), 7.73 (dt, 
J = 7.5, 1.2 Hz, 1H), 8.05  - 8.08 (m, 2H), 
8.30 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  22.5, 24.3, 35.3, 35.9, 40.8, 56.00, 56.03, 
111.4, 112.0, 120.8, 123.4, 126.3, 126.7, 
129.8, 131.4, 132.8, 133.1, 134.8, 147.8, 
149.1, 154.2, 173.1, 181.3, 185.0 
IR Vmax: 3274 (N-H), 2933, 1635 (C=O), 1592, 
1516, 1349, 1262, 1235, 1157, 1140, 1026, 
726 cm-1 
6.3.3 Synthesis of plastiquinone core and analogues 
Trimethyl-p-benzoquinone (5) 
 
To a solution of trimethyl-p-hydroquinone (157) (518 mg, 3.405 mmol) in 
methanol (10 mL), iodine (47 mg, 0.1860 mmol) was added followed by 30% 
hydrogen peroxide (0.13 mL) and concentrated sulfuric acid (0.10 mL) and 
the mixture stirred at room temperature for 3 h before being diluted with 
diethyl ether (50 mL). The organic layer was washed with H2O (3x 20 mL), 
sat. sodium thiosulfate (2x 40 mL), and brine (30 mL). The organic layer was 
dried over MgSO4, filtered and the solvent removed under reduced pressure 
to afford the product 5 as a bright yellow crystalline solid in 80 % yield (411 
mg, 2.738 mmol). Used without further purification. 
O
O
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1H NMR δ (CDCl3, 400 MHz):  1.91 (s, 3H), 1.93 (s, 3H), 1.95 (s, 3H), 
6.46 (s, 1H) 
13C NMR δ (CDCl3, 100 MHz):  11.9, 12.3, 15.8, 133.0, 140.6, 140.8, 1 
     45.2, 187.3, 187.7 
Note: Spectral data consistent with that reported in the literature.18 
4-(2,3,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid (158) 
 
158 was prepared according to general procedure A from trimethyl-p-
benzoquinone (5) (411 mg, 2.738 mmol) and glutaric acid (728 mg, 5.512 
mmol) and the product purified by flash chromatography (100% 
dichloromethane followed by 100% ethyl acetate) to give 158 as a crystalline 
yellow solid in 33 % yield (216 mg, 0.9136 mmol) with a melting point of 56 – 
57 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.69 (quin, J = 7.4 Hz, 2H), 1.95 (s, 6H), 
1.98 (s, 3H), 2.36 (t, J = 7.4 Hz, 2H), 2.47 – 
2.51 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.1, 12.35, 12.38, 23.5, 25.8, 33.7, 140.5, 
140.6, 140.9, 143.1, 179.2, 187.0, 187.6 
IR Vmax:  2940, 1707 (C=O), 1642 (C=O), 1457, 
1375, 1260, 1158, 717 cm-1 
(S)-tert-butyl-3-phenyl-2-(4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-
1-yl)butanamido)propanoate (159) 
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159 was prepared according to general procedure B from 4-(2,3,5-trimethyl-
1,4-benzoquinone-1-yl)butanoic acid (158) (253 mg, 1.072 mmol) and L-
phenylalanine t-butyl ester.HCl (284 mg, 1.105 mmol) and the product 
purified by flash chromatography (40 % ethyl acetate/hexane) to give 159 as 
yellow viscous oil in 24 % yield (111 mg, 0.2531 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.41 (s, 9H), 1.71 (quin, J = 7.4 Hz, 2H), 
2.01 (s, 6H), 2.02 (s, 3H), 2.22 (t, J = 7.4 
Hz, 2H), 2.48 (t, J = 8.4 Hz, 2H), 3.09 – 
3.11 (m, 2H), 4.77 (q, J = 6.7 Hz, 1H), 6.07 
(d, J = 7.6 Hz, 1H), 7.15 – 7.29 (m, 5H) 
13C NMR δ (CDCl3, 100 MHz):  12.2, 12.3, 12.4 24.3, 25.9, 28.0, 36.0, 
38.1, 53.5, 82.3, 126.9, 128.4, 129.5, 
136.3, 140.4, 140.6, 140.9, 143.4, 170.9, 
171.7, 187.2, 187.7  
[α]D20:     +47.24º (c 0.58, CHCl3) 
IR Vmax:  3303 (N-H), 2978, 2933, 1738 (C=O), 1717 
(C=O), 1645 (C=O), 1538, 1456, 1368, 
1155, 701 cm-1 
(S)-3-phenyl-2-(4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-
yl)butanamido)propanoic acid (160) 
 
160 was prepared from the deprotection of 159 (87 mg, 0.1976 mmol), using 
general procedure C. The product was purified by flash chromatography (5 % 
methanol/ethyl acetate) to give 160 as brown solid in a quantitative yield with 
a melting point of 72 – 74°C. 
1H NMR δ (CDCl3, 600 MHz):  1.54 – 1.60 (m, 2H), 1.89 (s, 3H), 1.90 (s, 
3H), 1.91 (s, 3H), 2.16 (t, J = 7.1 Hz, 2H), 
O
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2.31 – 2.34 (m, 2H), 3.03 (dd, J = 14.0, 7.2 
Hz, 1H), 3.18 (dd, J = 14.0, 5.1 Hz, 1H), 
4.77 4.81 (m, 1H), 6.51 (d, J = 7.3 Hz, 1H), 
7.08 – 7.09 (m, 2H), 7.13 – 7.20 (m, 3H)  
13C NMR δ (CDCl3, 150 MHz):  12.2, 12.4, 12.5, 24.3, 25.7, 35.7, 37.2, 
53.6, 127.4, 128.8, 129.3, 135.7, 140.5, 
141.0, 141.4, 143.0, 174.2, 174.6, 187.6, 
187.7  
[α]D20:     +32.78º (c 1.88, CHCl3) 
IR Vmax:  3355 (N-H), 2934, 1738 (C=O), 1717 
(C=O), 1642 (C=O), 1539, 1456, 1375, 
1206, 1172, 702 cm-1 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-(2,4,5-trimethyl-3,6-
dioxocyclohexa-1,4-dien-1-yl)butanamide (161) 
 
161 was prepared according to general procedure B from 4-(2,3,5-trimethyl-
1,4-benzoquinone-1-yl)butanoic acid (158) (182 mg, 0.7692 mmol) and L-
phenylalaninol (193 mg, 1.277 mmol) and the product purified by flash 
chromatography (2 % methanol/ethyl acetate) to give 161 as yellow viscous 
oil in 11 % yield (52 mg, 0.1352 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.63 – 1.71 (m, 2H), 2.01 (s, 9H), 2.20 (t, J 
= 7.1 Hz, 2H), 2.24 (t, J = 7.8 Hz, 2H), 2.89 
(t, J = 7.0 Hz, 2H), 3.59 (dd, J = 11.0, 5.2 
Hz, 1H), 3.71 (dd, J = 11.0, 3.5 Hz, 1H), 
4.19 – 4.27 (m, 1H), 6.14 (d, J = 7.8 Hz, 
1H), 7.18 – 7.29 (m, 5H) 
O
O
H
N
O
OH
Chapter	6:	Experimental	Details	
	214	
13C NMR δ (CDCl3, 100 MHz):  12.2, 12.41, 12.49, 24.4, 25.8, 36.2, 37.1, 
52.9, 64.3, 126.6, 128.6, 129.2, 137.8, 
140.4, 140.9, 141.1, 143.3, 173.0, 187.62, 
187.63 
[α]D20:     -26.91º (c 0.54, CHCl3) 
IR Vmax:  3374 (N-H), 3299, 2936, 1642 (C=O), 
1538, 1455, 1374, 1042, 845, 702 cm-1 
N-(4-hydroxyphenethyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-
1-yl)butanamide (162) 
 
162 was prepared according to general procedure B from 4-(2,3,5-trimethyl-
1,4-benzoquinone-1-yl)butanoic acid (158) (100 mg, 0.4240 mmol) and 
tyramine (66 mg, 0.4818 mmol) and the product purified by flash 
chromatography (90 % ethyl acetate/hexane) to give 162 as yellow viscous 
oil in 51 % yield (77 mg, 0.2158 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.68 (quin, J = 7.4 Hz, 2H), 1.97 (s, 9H), 
2.18 (t, J = 7.4 Hz, 2H), 2.41 – 2.45 (m, 
2H), 2.72 (t, J = 7.0 Hz, 2H), 3.45 – 3.50 
(m, 2H), 6.08 (t, J = 5.7 Hz, 1H), 6.75 (d, J 
= 8.3 Hz, 2H), 6.97 (d, J = 8.4 Hz, 2H), 
7.54 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.2, 12.42, 12.48, 24.5, 25.9, 34.7, 36.2, 
41.0, 115.6, 129.7, 129.9, 140.4, 140.8, 
141.1, 143.3, 155.3, 173.1, 187.5, 187.7  
IR Vmax:  3362 (N-H), 2937, 1641 (C=O), 1516, 
1456, 1374, 1262, 832, 716 cm-1 
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N-(3,4-dimethoxyphenethyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-
dien-1-yl)butanamide (163) 
 
163 was prepared according to general procedure B from 4-(2,3,5-trimethyl-
1,4-benzoquinone-1-yl)butanoic acid (158) (96 mg, 0.4053 mmol) and 3,4-
dimethoxyphenethylamine (107 mg, 0.5926 mmol) and the product purified 
by flash chromatography (90 % ethyl acetate/hexane) to give 163 as yellow 
semi solid in 42 % yield (69 mg, 0.1717 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.67 (quin, J = 7.7 Hz, 2H), 1.95 (s, 3H), 
1.96 (s, 3H), 1.99 (s, 3H), 2.15 (t, J = 7.2 
Hz, 2H), 2.41 – 2.45 (m, 2H), 2.73 (t, J = 
7.0 Hz, 2H), 3.45 – 3.50 (m, 2H), 3.80 (s, 
3H), 3.81 (s, 3H), 5.84 (t, J = 5.1 Hz, 1H), 
6.68 – 6.70 (m, 2H), 6.75 (d, 8.6 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.2, 12.3, 12.4, 24.4, 25.9, 35.5, 36.1, 
40.7, 55.8, 55.9, 111.4, 111.9, 120.6, 
131.4, 140.3, 140.6, 140.9, 143.3, 147.7, 
149.0, 172.3, 187.3, 187.6 
IR Vmax:  3375 (N-H), 3300, 2936, 1642 (C=O), 
1455, 1374, 1261, 1236, 1157, 1140, 1028, 
846, 717 cm-1 
6.3.4 Synthesis of benzoquinone core and derivatives 
2,6-dibromo-4-methylphenol (169) 
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Bromine (9.5 mL, 29.63 g, 0.1854 mol) was added dropwise over 0.5 h to a 
solution of p-Cresol (168) (9.997 g, 0.0924 mol) in CH2Cl2 (30 mL) at 0 oC. 
The mixture was the stirred at room temperature for 5 h before quenching 
with sat. sodium metabisulfate (50 mL) and CH2Cl2 (50 mL). The organic 
layer was washed with sat. sodium metabisulfate (2 x 50 mL) and H2O (3 x 
50 mL). The organic layer was dried over MgSO4, filtered and the solvent 
removed under reduced pressure to give the product 169 (24.86 g, 0.0935 
mol) as a pale yellow coloured solid in a quantitative yield which required no 
further purification. 
1H NMR δ (CDCl3, 400 MHz):  2.21 (s, 3H), 5.70 (s, 1H), 7.20 (s, 2H) 
Spectral data consistent with data reported in the literature.107 
3,5-dibromo-4-methoxytoluene (170) 
 
2,6-dibromo-4-methylphenol (169) (20.16 g, 0.0758 mol) was added to 
anhydrous DMF (150 mL) at room temperature under an atmosphere of N2. 
To this solution, potassium carbonate (20.91 g, 0.1512 mol) and methyl 
iodide (5.62, 12.81 g, 0.0903 mol) was added successively and the mixture 
left stirring for 48 h before quenching with 100 mL H2O. The mixture was 
extracted with 1:1 ethyl acetate/hexanes (3 x 100 mL) and the organic extract 
was washed with sat. NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The 
organic layer was dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the crude product which was filtered through a plug 
of silica (50 % ethyl acetate/ hexanes) to give the pure product 170 as a pale 
yellow oil in 90 % yield (19.21 g, 0.0686 mol) 
1H NMR δ (CDCl3, 400 MHz):  2.24 (s, 3H), 3.83 (s, 3H), 7.27 (s, 2H) 
Spectral data consistent with data reported in the literature.154 
 
CH3
OMe
Br Br
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3,4,5-Trimethoxytoluene (167) 
 
Sodium metal (15.76 g, 0.6854 mol) was added to methanol (150 mL) at 
room temperature, after complete formation of sodium methoxide, copper 
iodide (39.28 g, 0.2062 mol) was added followed by a solution of 3,5-
dibromo-4-methoxytoluene (170) (19.21 g, 0.0686 mol) in DMF (50 mL) and 
the mixture heated to 110oC o/n. The reaction mixture was quenched with 
saturated ammonium chloride (100 mL) and the mixture extracted with 1:1 
ethyl acetate/hexanes (4 x 50 mL). The organic extract was washed with sat. 
NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The organic layer was dried over 
MgSO4, filtered and the solvent removed under reduced pressure to give the 
crude product which was purified by flash column chromatography (20 % 
ethyl acetate/hexanes) to give a mixture of 3,4,5-trimethoxytoluene (167) and 
3,4-dimethoxytoluene (171) in a 3:2 ratio as a pale yellow oil in 71 % yield 
(8.897 g, 0.0488 mol). 
1H NMR δ (CDCl3, 400 MHz):  2.30 (s, 3H), 3.81 (s, 3H), 3.83 (s, 3H), 
6.38 (s, 3H) 
13C NMR δ (CDCl3, 100 MHz):  21.9, 56.1, 60.9, 106.0, 133.6, 135.9, 153.1 
Spectral data consistent with that reported in the literature.155 
2,3-Dimethoxy-5-methyl-p-benzoquinone (6) 
 
Trimethoxytoluene (167) (1.0548 g, 5.789 mmol) was added to 1.4 mL formic 
acid and 0.7 mL acetic acid. 35 % Hydrogen peroxide (2.1 mL) was added 
dropwise and the solution heated to 35 oC for 2 h. The reaction mixture was 
cooled and diluted with H2O (15 mL) and extracted with 3 x 20 mL CH2Cl2. 
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The organic extract was washed with sat. NaHCO3 (3 x 20 mL) and H2O (3 x 
20 mL). The organic layer was dried over MgSO4, filtered and the solvent 
removed under reduced pressure to give the crude product which was 
purified by flash column chromatography (30 % ethyl acetate/hexanes) to 
give the pure product 6 as a bright yellow solid in 55 % yield (0.585 g, 3.212 
mmol). 
1H NMR δ (CDCl3, 400 MHz):  2.03 (d, J = 1.6 Hz, 3H), 3.99 (s, 3H), 4.01 
(s, 3H), 6.42 (q, J = 1.6 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):   15.5, 61.2, 61.3, 131.3, 144.1, 144.9, 
145.1, 184.2, 184.4  
Spectral data consistent with that reported in the literature.109 
4-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic 
acid (166) 
 
166 was prepared according to general procedure A from 2,3-dimethoxy-1,4-
benzoquinone (6) (478 mg, 2.622 mmol) and glutaric acid (756 mg, 5.724 
mmol) and the product purified by flash chromatography (30 % ethyl 
acetate/hexanes followed by 100% ethyl acetate) to give 166 as a yellow oil 
in 25 % yield (177 mg, 0.6598 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.70 (quin, J = 7.7 Hz, 2H), 1.99 (s, 3H), 
2.37 (t, J = 7.1 Hz, 2H), 2.47 – 2.51 (m, 
2H), 3.94 (s, 6H) 
13C NMR δ (CDCl3, 100 MHz):  11.9, 23.4, 25.6, 33.5, 61.21, 61.22, 139.6, 
141.7, 144.41, 144.47, 178.5, 184.0, 184.5  
IR Vmax:  3340 (-OH), 2950, 1706 (C=O), 1649 
(C=O), 1611, 1456, 1266, 1206, 1154, 
1105, 1059, 745 cm-1 
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(S)-tert-butyl-2-(4-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-
1-yl)butanamido)-3-phenylpropanoate (172) 
 
172 was prepared according to general procedure B from 4,5-dimethoxy-2-
methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid 166 (101 mg, 0.3761 
mmol) and L-phenylalanine t-butyl ester.HCl (108 mg, 0.4190 mmol) and the 
product purified by flash chromatography (40 % ethyl acetate/hexane) to give 
172 as yellow viscous oil in 12 % yield (21 mg, 0.0437 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.40 (s, 9H), 1.70 (quin, J = 7.5 Hz, 2H), 
2.00 (s, 3H), 2.21 (t, J = 7.5 Hz, 2H), 2.43 – 
2.47 (m, 2H), 3.08 (d, J = 6.0 Hz, 2H), 3.98 
(s, 6H), 4.72 – 4.77 (m, 1H), 5.96 (d, J = 
7.6 Hz, 1H), 7.13 – 7.28 (m, 5H) 
13C NMR δ (CDCl3, 100 MHz):  12.0, 24.3, 25.7, 28.0, 36.0, 38.2, 53.5, 
61.2 (2 x C), 82.5, 127.0, 128.5, 129.5, 
136.3, 139.6, 142.0, 144.50, 144.57, 170.9, 
171.7, 184.2, 184.6 
[α]D20:     +40.78º (c 0.25, CHCl3) 
IR Vmax:  3369 (N-H), 2978, 2940, 1729 (C=O), 1652 
(C=O), 1647, 1611, 1456, 1368, 1266, 
1205, 1153, 1055, 701 cm-1 
(S)-2-(4-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-
yl)butanamido)-3-phenylpropanoic acid (173) 
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173 was prepared from the deprotection of 172 (11 mg, 0.0231 mmol), using 
general procedure C. The product was purified by flash chromatography (5 % 
methanol/ethyl acetate) to give 173 as yellow viscous oil in 84 % yield (8 mg, 
0.0195 mmol). 
1H NMR δ (MeOD, 400 MHz):  1.59 (quin, J = 7.7 Hz, 2H), 1.93 (s, 3H), 
2.13 – 2.25 (m, 2H), 2.28 – 2.44 (m, 2H), 
2.92 (dd, J = 14.0, 9.4 Hz, 1H), 3.22 (dd, J 
= 14.0, 5.0 Hz, 1H), 3.952 (s, 3H), 3.955 (s, 
3H), 4.67 (dd, J = 9.4, 5.0 Hz, 1H), 7.15 – 
7.27 (m, 5H) 
13C NMR δ (MeOD, 150 MHz):  12.2, 25.9, 26.8, 36.6, 38.7, 55.3, 61.8, 
61.9, 128.0, 129.7, 130.5, 138.9, 140.9, 
143.4, 146.1, 146.2, 175.1, 175.5, 185.7, 
186.2 
[α]D20:     +57.27º (c 0.22, CHCl3) 
IR Vmax:  3350 (N-H), 2947, 1733 (C=O), 1652 
(C=O), 1645 (C=O), 1611, 1456, 1266, 
1204, 1153, 1055, 735, 702 cm-1 
 (S)-4-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-N-(1-
hydroxy-3-phenylpropan-2-yl)butanamide (174) 
 
174 was prepared according to general procedure B from 4,5-dimethoxy-2-
methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid (166) (77 mg, 0.2818 
mmol) and L-phenylalaninol (102 mg, 0.6779 mmol) and the product purified 
by flash chromatography (2 % methanol/ethyl acetate) to give 174 as yellow 
oil in 17 % yield (19 mg, 0.0483 mmol). 
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1H NMR δ (CDCl3, 400 MHz):  1.68 (quin, J = 7.4 Hz, 2H), 1.99 (s, 3H), 
2.17 (t, J = 7.4 Hz, 2H), 2.39 – 2.43 (m, 
2H), 2.87 (t, J = 6.5 Hz, 2H), 3.58 (dd, J = 
11.0, 5.1 Hz, 1H), 3.71 (dd, J = 11.0, 3.5 
Hz, 1H), 3.97 (s, 3H), 3.98 (s, 3H), 4.18 – 
4.22 (m, 1H), 5.91 (d, J = 7.5 Hz, 1H), 7.18 
– 7.21 (m, 3H), 7.27 – 7.29 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.0, 24.3, 25.5, 36.0, 37.1, 53.0, 61.3 (2 x 
C), 64.3, 126.7, 128.7, 129.3, 137.8, 139.8, 
141.9, 144.4, 144.6, 172.8, 184.55, 184.56 
[α]D20:     -42.76º (c 0.29, CHCl3) 
IR Vmax:  3356 (N-H), 3293, 2942, 1645 (C=O), 
1610, 1456, 1265, 1205, 1045, 702 cm-1 
4-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-N-(4-
hydroxyphenethyl) butanamide (175) 
 
175 was prepared according to general procedure B from 4,5-dimethoxy-2-
methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid 166 (85 mg, 0.3161 
mmol) and tyramine (48 mg, 0.3477 mmol) and the product purified by flash 
chromatography (2 % methanol/ethyl acetate) to give 175 as yellow viscous 
oil in 13 % yield (16 mg, 0.0413 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.70 (quin, J = 7.4 Hz, 2H), 2.01 (s, 3H), 
2.17 (t, J = 7.4 Hz, 2H), 2.43 – 2.47 (m, 
2H), 2.75 (t, J = 7.0 Hz, 2H), 3.47 – 3.52 
(m, 2H), 3.987 (s, 3H), 3.988 (s, 3H), 5.26 
(bs, 1H), 5.62 (d, J = 4.9 Hz, 1H), 6.76 (d, J 
= 8.5 Hz, 2H), 7.04 (d, J = 8.5 Hz, 2H),  
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13C NMR δ (CDCl3, 150 MHz):  12.1, 24.4, 25.7, 34.7, 35.9, 41.1, 61.3 (2 x 
C), 115.6, 129.9, 130.4, 139.9, 141.8, 
144.4, 144.6, 154.8, 172.9, 184.58, 184.59 
IR Vmax:  3348 (N-H), 3281, 2944, 1652 (C=O), 1645 
(C=O), 1611, 1516, 1456, 1265, 1204, 
1053, 844, 737 cm-1 
4-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-N-(3,4-
dimethoxyphenethyl) butanamide (176) 
 
176 was prepared according to general procedure B from 4,5-dimethoxy-2-
methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid 166 (96 mg, 0.3590 
mmol) and 3,4-dimethoxyphenethylamine (107 mg, 0.5926 mmol) and the 
product purified by flash chromatography (90 % ethyl acetate/hexane) to give 
176 as yellow viscous oil in 16 % yield (25 mg, 0.0586 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.71 (quin, J = 7.4 Hz, 2H), 2.02 (s, 3H), 
2.17 (t, J = 7.4 Hz, 2H), 2.44 – 2.68 (m, 
2H), 2.77 (t, J = 7.0 Hz, 2H), 3.49 – 3.53 
(m, 2H), 3.85 (s, 3H), 3.86 (s, 3H), 3.98 (s, 
6H), 5.61 (t, J = 5.1 Hz, 1H), 6.72 – 6.74 
(m, 2H), 6.79 – 6.81 (m, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.1, 24.4, 25.7, 35.3, 36.1, 40.8, 56.01, 
56.05, 61.2, 61.3, 111.5, 112.0, 120.7, 
131.4, 139.7, 141.9, 144.4, 144.5, 147.8, 
149.2, 172.2, 184.4, 184.5 
IR Vmax:  3371 (N-H), 3302, 2938, 1652 (C=O), 1645 
(C=O), 1645, 1516, 1455, 1263, 1237, 
1156, 1028, 846 cm-1 
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(S)-tert-butyl 3-phenyl-2-(4-phenylbutanamido)propanoate (178) 
 
178 was prepared according to general procedure B from phenybutyric acid 
177 (122 mg, 0.7442 mmol) and L-phenylalanine t-butyl ester.HCl (166 mg, 
0.6452 mmol) to give 178 as clear oil in 81 % yield (192 mg, 0.5211 mmol) 
with no further purification required. 
1H NMR δ (CDCl3, 400 MHz):  1.44 (s, 9H), 1.96 (quin, J = 7.5 Hz, 2H), 
2.19 – 2.23 (m, 2H), 2.63 (t, J = 7.5 Hz, 
2H), 3.06 – 3.16 (m, 2H), 4.80 – 4.85 (m, 
1H), 6.13 (d, J = 7.8 Hz, 1H), 7.16 – 7.31 
(m, 10H) 
13C NMR δ (CDCl3, 100 MHz):  26.9, 27.9, 35.0, 35.6, 38.1, 53.3, 82.2, 
125.8, 126.8, 128.3 (2 x C), 128.4, 129.4, 
136.2, 141.4, 170.9, 172.1 
[α]D20:     +55.74º (c 1.83, CHCl3) 
IR Vmax:  3299 (N-H), 2978, 2931, 1735 (C=O), 1649 
(C=O), 1534, 1496, 1454, 1367, 1225, 
1154, 743, 699 cm-1 
6.3.5 Synthesis of indoloquinone core and derivatives 
2-Bromohydroquinone (194) 
 
Bromine (2.85 mL, 0.0553 mol) was added to a solution of hydroquinone 
(193) (5.088 g, 0.0462 mmol) in diethyl ether (40 mL) at –13 °C and 
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maintained under these conditions for 2 h. The reaction quenched with H2O 
(20 mL) and the organic layer washed with sat. sodium thiosulfate (4 x 20 
mL) and H2O (3 x 20  mL). The organic layer was dried over MgSO4, filtered 
and the solvent removed under reduced pressure to give the product 194 as 
a light brown solid in 98% yield (8.516 g, 0.0451 mol), which was deemed 
pure by 1H NMR and 13C NMR and used without further purification. 
1H NMR δ (CDCl3, 400 MHz):  6.70 (dd, J = 8.7, 2.9 Hz, 1H), 6.84 (d, J = 
8.7 Hz, 1H), 6.99 (d, J = 2.9 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  109.2, 115.3, 116.7, 119.0, 146.8, 150.8 
Spectral data consistent with data reported in the literature.114 
2-Bromo-1,4-dimethoxybenzene (195) 
 
2-Bromohydroquinone (194) was added to NaH (60% suspension in mineral 
oil, 7.444 g, 0.1861 mol) in DMF (120 mL) and stirred at room temperature 
for 10 mins before cooling to 0 °C. Methyl Iodide (8.0 mL, 18.25 g, 0.1285 
mol) was added dropwise and the mixture maintained at 0 °C for 0.5 h before 
warming to room temperature for 3 h. The mixture was diluted with H2O and 
extracted with ethyl acetate/hexanes (1:1 v/v) and the organic extract washed 
with H2O (2 x 30 mL). The organic layer was dried over MgSO4, filtered and 
the solvent removed under reduced pressure to give the 195 as white 
crystals in a pale brown oil (12.24 g, 0.0564 mol). The product was taken 
through to the next step without purification. 
1H NMR δ (CDCl3, 400 MHz):  3.73 (s, 3H), 3.82 (s, 3H), 6.77 – 6.83 (m, 
2H), 7.11 (d, J = 2.5 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  55.9, 56.8, 112.0, 112.9, 113.6, 119.0, 
150.3, 154.0 
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Spectral data consistent with data reported in the literature.156 
2,5-Dimethoxybenzaldehyde (183) 
 
Without purification 2-Bromo-1,4-dimethoxybenzene (195) (11.03 g, 0.0508 
mol) and butyl lithium (51 mL, 0.068 mol, 1.33 M) were combined in dry THF 
(60 mL) at – 78 °C under an N2 atmosphere. DMF (17 mL) was added 
dropwise and the mixture warmed to room temperature and stirred for 3 h 
before quenching with H2O (50 mL). The mixture was extracted with diethyl 
ether (3 x 50 mL) and the organic layer was washed with sat. NaHCO3 (3 x 
50 mL) and brine (2 x 50 mL). The organic layer was dried over MgSO4, 
filtered and the solvent removed under reduced pressure to give the crude 
product, which was purified by flash chromatography (20 % ethyl 
acetate/hexanes) to give 183 as a pale yellow solid in 63 % yield (5.341 g, 
0.0321 mol). 
1H NMR δ (CDCl3, 400 MHz):  3.80 (s, 3H), 3.89 (s, 3H), 6.94 (d, J = 9.1 
Hz, 1H), 7.13 (dd, J = 9.0, 3.3 Hz, 1H), 
7.33 (d, J = 3.3 Hz, 1H), 10.44 (s, 1H) 
13C NMR δ (CDCl3, 100 MHz):  55.9, 56.3, 110.5, 113.5, 123.6, 125.1, 
153.7, 156.8, 189.7 
Spectral data consistent with data reported in the literature.118 
Methyl-2-azidoacetate (184) 
 
Sodium azide (10.988 g, 0.1690 mol) was added to methyl 2-bromoacetate 
(8.0 mL, 12.93 g, 0.0841 mol) in acetone:water (3:1, 160 mL).  The solution 
was stirred at room temperature for 1 h before being diluted with water (100 
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mL), and extracted with diethyl ether (3 x 40 mL).  The combined organic 
fractions were dried with MgSO4, filtered and concentrated in vacuo to 
produce 184 as a colourless oil in 93 % yield (9.053 g, 0.0787 mol) and used 
without further purification.   
1H NMR δ (CDCl3, 400 MHz):  3.80 (S, 3H), 3.88 (S, 2H) 
13C NMR δ (CDCl3, 100 MHz):  50.4, 52.7, 168.8 
2-Azido-3-(2,5-dimethoxyphenyl)-2-methyl propanoate (185) 
     
2,5-Dimethoxybenzaldehyde (183) (3.027 g, 18.22 mmol) was added to a 
solution of methyl-2-azidoacetate (184) (5.201 g, 45.19 mmol) in dry 
methanol (20 mL).  The mixture was cooled to -8oC and a solution of sodium 
methoxide (sodium metal (1.046 g, 45.37 mmol) in 20 mL of methanol) was 
added and stirred for 10 min before minimal THF was added until all starting 
material had dissolved.  The mixture was stirred at –8 oC for 1.5 h and then 
left at 2 oC for 16 h without stirring.  The yellow suspension was poured into 
ice-cold ammonium chloride (100 mL) and the precipitate formed was filtered 
and washed with ice cold H2O (3 x 30 mL). The solid was dissolved in 
CH2Cl2, dried with MgSO4, filtered filtered and the solvent removed under 
reduced pressure to give 185 as a yellow crystals in 59 % yield (2.836 g, 
10.77 mmol) which was determined to be pure by HNMR and CNMR.    
1H NMR δ (CDCl3, 400 MHz):  3.81 (s, 3H), 3.82 (s, 3H), 3.90 (s, 3H), 
6.81 (d, J = 9.0 Hz, 1H), 6.87 (dd, J = 9.0, 
3.0 Hz, 1H), 7.36 (s, 1H), 7.81 (d, J = 3.0 
Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  52.9, 55.9, 56.3, 111.6, 115.9, 116.3, 
119.4, 122.7, 125.3, 152.3, 153.2, 164.3 
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4,7-Dimethyoxy-1H-indole-2-methyl methanoate (186) 
 
2-Azido-3-(2,5-Dimethoxyphenyl)-2-methyl propanoate (185) (5.923 g, 22.49 
mmol) was heated in toluene (100 mL) at reflux for 5 h.  The product was 
concentrated in vacuo to produce the crude yellow product which was 
washed with acetonitrile to produce 186 as a white powdery solid in 94% 
yield  (4.968 g, 21.12 mmol). 
1H NMR δ (CDCl3, 400 MHz):  3.90 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 
6.35 (d, J = 8.3 Hz, 1H), 6.58 (d, J = 8.3 H, 
1H), 7.30 (d, J = 2.0 Hz, 1H), 9.10 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  52.0, 55.7, 55.8, 99.1, 104.4, 106.9, 120.2, 
126.0, 129.2, 141.1, 148.7, 162.2 
4,7-dimethoxy-1H-indole-2-carboxylic acid (187) 
 
4,7-dimethyoxy-1H-indole-2-methyl methanoate (186) (832 mg, 3.560 mmol) 
was added to an aqueous solution of 10% sodium hydroxide (20 mL).  The 
mixture was refluxed for 1 h and cooled in an ice-bath at 0oC and neutralised 
with 6 M HCl.  The mixture was filtered and the solid washed with H2O and 
collected by dissolution in ethyl acetate.  The mixture was dried with MgSO4 
and concentrated in vacuo to produce 187 as an off white solid in 60 % yield 
(470 mg, 2.124 mmol). Used without further purification.        
1H NMR δ (CDCl3, 400 MHz):  3.91 (s, 3H), 3.93 (s, 3H), 6.36 (d, J = 8.3 
Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 7.44 (d, J 
= 2.3 Hz, 1H), 9.06 (bs, 1H) 
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13C NMR δ (CDCl3, 150 MHz):  55.7, 55.9, 99.2, 105.0, 108.8, 120.4, 
125.1, 129.8, 141.1, 148.1, 166.1 
Spectral data consistent with data reported in the literature.121 
4,7-Dimethoxy-1H-indole (182) 
 
4,7-Dimethoxy-1H-indole-2-carboxylic acid (187) (470 g, 2.124 mmol) was 
added to quinoline (1.3 mL, 11.23 mmol) and copper (779 mg) and heated 
under nitrogen at 200oC for 4.5 h.  The reaction mixture was quenched with 
sat. KHSO4 (40 mL) and extracted with diethyl ether (3 x 40 mL), the organic 
extract was washed with sat. KHSO4 (3x 40 mL) and dried over MgSO4, 
filtered and the solvent removed under reduced pressure to give the product 
which was purified by flash chromatography (100 % dichloromethane) to give 
182 as white cubic crystals in 61 % yield (229 mg, 1.290 mmol). 
1H NMR δ (CDCl3, 400 MHz):  3.92 (s, 6H), 6.39 (d, J = 8.3 Hz, 1H), 6.51 
(d, J = 8.3 Hz, 1H), 6.63 (t, J = 2.6 Hz, 1H) 
7.11 (t, J = 2.6 Hz, 1H), 8.37 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  55.7 (2 x C), 98.9, 100.4, 101.6, 120.0, 
122.6, 127.7, 141.2, 147.8 
Spectral data consistent with data reported in the literature.121 
4,7-Dimethoxy-1H-indole-3-carbaldehyde (188) 
 
Phosphporous oxychloride (690 mg, 4.506 mmol) was added dropwise to 
DMF (2.5 mL) at room temperature and stirred for 0.25 h. This mixture was 
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diluted with DMF (5 mL) before 4,7-dimethoxyindole (182) (406 mg, 2.293 
mmol) was added and the reaction mixture left stirring for 15h before 
quenching slowly with sat. NaHCO3 solution (90 mL). The aqueous reaction 
mixture was cooled to 2 oC for 16 h resulting in crystallization of the product 
as large pale yellow crystalline needles which were filtered and washed with 
chilled H2O yielding 188 as a pure solid in 70 % yield (329 mg, 1.601 mmol) 
1H NMR δ (DMSO – D6, 600 MHz): 3.87 (s, 3H), 3.88 (s, 3H), 6.62 (d, J = 8.4 
Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H), 7.89 (s, 
1H), 10.30 (s, 1H), 12.39 (s, 1H) 
13C NMR δ (DMSO – D6, 150 MHz): 55.5, 55.6, 101.7, 102.9, 117.1, 118.6, 
127.6, 129.0, 141.2, 147.8, 186.3 
Spectral data consistent with data reported in the literature.124 
(E)-Ethyl 3-(4,7-dimethoxy-1H-indol-3-yl)acrylate (189) 
 
Triethyl phosphonoacetate (316 mg, 1.411 mmol) was added dropwise to a 
solution of sodium hydride (60 mg, 2.505 mmol) in anhydrous THF (5 mL) at 
0°C before warming to room temperature for 0.25 h. The reaction mixture 
was then cooled to 0°C and 4,7-dimethoxyindole-3-aldehyde (188) (206 mg, 
0.9921 mmol) was added and the reaction mixture stirred at room 
temperature for 16 h. The mixture was quenched with brine (30 mL) and 
extracted with ethyl acetate (3x 20 mL). The organic layer was dried over 
MgSO4, filtered and the solvent removed under reduced pressure to give the 
product which was purified by flash chromatography (20 % ethyl 
acetate/hexanes) to give 189 as cream coloured needles in 27 % yield (73 
mg, 0.2662 mmol). 
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1H NMR δ (CDCl3, 400 MHz):  1.33 (t, J = 7.2 Hz, 3H), 3.89 (s, 3H), 3.91 
(s, 3H), 4.26 (q, J = 7.1 Hz, 2H), 6.41 (d, J 
= 16.0 Hz, 1H), 6.44 (d, J = 8.4 Hz, 1H), 
6.53 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 2.3 
Hz, 1H), 8.30 (d, J = 16.0 Hz, 1H), 8.79 
(bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  14.5, 55.6, 55.8, 60.0, 100.6, 102.6, 114.0, 
114.6, 117.4, 123.9, 128.5, 139.4, 141.0, 
149.0, 168.3  
Methyl 4,7-dioxo-4,7-dihydro-1H-indole-2-carboxylate (196) 
 
[Bis(trifluoroacetoxy)iodo]benzene (281.2 mg, 0.6539 mmol) was added to a 
solution of 186 (95.6 mg, 0.4064 mmol) in H2O (2 mL) and MeOH (25µL) and 
stirred at r.t for 1 h. The reaction mixture was diluted with H2O (10 mL) and 
extracted with CH2Cl2 (3 x 15 mL) and the organic extract washed with H2O 
(3 x 10 mL), dried over MgSO4, filtered and the solvent removed under 
reduced pressure. The product was purified by flash chromatography (20 % 
ethyl acetate/ dichloromethane) to give 196 as yellow viscous oil in 45 % 
yield (37.4 mg, 0.2662 mmol). 
1H NMR δ (CDCl3, 400 MHz):  3.95 (s, 3H), 6.72 (d, J = 3.7 Hz, 2H), 7.23 
(d, J = 1.7 Hz, 1H) 
13C NMR δ (CDCl3, 150 MHz):  52.7, 112.4, 125.6, 128.2, 132.5, 136.4, 
139.1, 160.6, 177.7, 182.3 
IR Vmax:  3254 (N-H), 1708 (C=O), 1658 (C=O), 
1442, 1318, 1214, 840, 761 cm-1 
Spectral data consistent with data reported in the literature.128 
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Dimethyl-4,4',7,7'-tetraoxo-4,4',7,7'-tetrahydro-1H,1'H-[3,3'-biindole]-2,2'-
dicarboxylate (201) 
 
Cerric ammonium nitrate (CAN) (367 mg, 0.6610 mmol) in H2O (1 mL) was 
added to a solution of Indole ester 186 (66 mg, 0.2801 mmol) in 1:1 
acetonitrile/H2O (2 mL) and stirred at room temperature for 3 h. The reaction 
mixture was diluted with H2O (10 mL) and extracted with CH2Cl2 (3 x 20 mL) 
and dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The product was purified by flash chromatography (80 % ethyl 
acetate/ hexanes) to give 201 as yellow viscous oil in 74 % yield (42 mg, 
0.1038 mmol). 
1H NMR δ (CD3OD, 600 MHz): 3.71 (s, 3H), 6.57 (d, J = 10.3 Hz, 1H), 6.69 
(d, J = 10.3 Hz, 1H) 
13C NMR δ (CD3OD, 150 MHz): 52.3, 120.5, 124.4, 127.6, 133.4, 137.4, 
139.9, 162.0, 179.1, 184.2 
HRESIMS [M+Na]:  For C20H12N2O8Na, predicted 431.0486, 
found 431.0487 
(S)-tert-butyl-2-(4,7-dimethoxy-1H-indole-2-carboxamido)-3-
phenylpropanoate (206) 
 
206 was prepared according to general procedure B from 4,7-
dimethoxyindole-2-carboxylic acid 187 (98 mg, 0.4417 mmol) and L-
phenylalanine t-butyl ester.HCl (131 mg, 0.5084 mmol) and the product 
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purified by flash chromatography (40 % ethyl acetate/hexanes) to give 206 as 
clear viscous oil in 50 % yield (94 mg, 0.2219 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.43 (s, 9H), 3.19 – 3.28 (m, 2H), 3.89 (s, 
6H), 4.98 – 5.03 (m, 1H), 6.35 (d, J = 8.2 
Hz, 1H), 6.56 (d, J = 8.2 Hz, 1H), 6.77 (d, J 
= 7.7 Hz, 1H), 6.97 (d, J = 1.7 Hz, 1H), 
7.19 – 7.29 (m, 5H), 9.53 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  28.0, 38.3, 53.6, 55.6, 55.8, 82.6, 98.9, 
100.8, 103.8, 120.1, 127.0, 128.4, 128.6, 
129.2, 129.7, 136.1, 141.3, 148.3, 160.7, 
170.5  
[α]D20:     +61.05º (c 0.66, CHCl3) 
IR Vmax:  3277 (N-H), 2934, 1727 (C=O), 1643 
(C=O), 1527, 1367, 1262, 1225, 1153, 
1096, 740 cm-1 
 (S)-tert-Butyl-2-(4,7-dioxo-4,7-dihydro-1H-indole-2-carboxamido)-3-
phenylpropanoate (207) 
 
[Bis(trifluoroacetoxy)iodo]benzene (61 mg, 0.1411 mmol) was added to a 
solution of 206 (33 mg, 0.0773 mmol) in H2O (1 mL) and MeOH (25µL) and 
stirred at r.t for 1 h. The reaction mixture was diluted with H2O (10 mL) and 
extracted with CH2Cl2 (3 x 15 mL) and the organic extract washed with H2O 
(3 x 10 mL), dried over MgSO4, filtered and the solvent removed under 
reduced pressure. The product was purified by flash chromatography (45 % 
ethyl acetate/dichloromethane) to give 207 as yellow viscous oil in 25 % yield 
(8 mg, 0.0195 mmol). 
N
H
O
O
H
N
O
O
O
Chapter	6:	Experimental	Details	
	233	
1H NMR δ (CDCl3, 400 MHz):  1.44 (s, 9H), 3.25 (d, J = 5.6 Hz, 2H), 5.00 
– 5.05 (m, 1H), 6.61 (s, 2H), 6.81 (d, J = 
7.5 Hz, 1H), 6.93 (s, 1H), 7.17 – 7.29 (m, 
5H), 10.91 (bs, 1H) 
13C NMR δ (CDCl3, 150 MHz):  28.1, 38.1, 53.8, 83.2, 106.9, 125.7, 127.4, 
128.7, 129.6, 131.1, 132.0, 135.8, 136.5, 
138.7, 158.9, 170.2, 177.4, 182.6 
 [α]D20:     +144.76º (c 0.10, CHCl3) 
IR Vmax:  3166 (N-H), 2977, 1717 (C=O), 1653 
(C=O), 1646 (C=O), 1558, 1484, 1367, 
1274, 1154, 839, 700 cm-1 
(S)-2-(4,7-Dioxo-4,7-dihydro-1H-indole-2-carboxamido)-3-
phenylpropanoic acid (198) 
 
198 was prepared from the deprotection of 207 (8 mg, 0.0195 mmol), using 
general procedure C. The product was purified by flash chromatography (10 
% methanol/ethyl acetate) to give 198 as yellow oil in 56 % yield (4 mg, 
0.0109 mmol). 
1H NMR δ (Acetone-D6, 600 MHz): 3.14 (dd, J = 14.0, 9.5 Hz, 1H), 3.33, (dd, 
J = 14.0, 4.9 Hz, 1H), 4.89 – 4.92 (m, 1H), 
6.68 (d, J = 0.5 Hz, 2H), 7.18 – 7.35 (m, 
6H), 8.14 (d, J = 6.7 Hz, 1H), 12.0 (bs, 1H), 
13C NMR δ (Acetone- D6, 150 MHz): 37.9, 54.7, 108.5, 126.2, 127.5, 129.2, 
130.1, 130.2, 133.0, 137.6, 138.4, 138.8, 
160.0, 172.7, 178.0, 183.3 
 [α]D20:     -78.46º (c 0.13, CHCl3) 
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IR Vmax:  3120, 2927, 1661, 1652, 1558, 1486, 1282, 
1222, 839, 701 cm-1 
6.4 Chapter 4 Experimental Details 
6.4.1 Synthesis of quinone acids 
6-hydroxy-4,4,5,7,8-pentamethylchroman-2-one (214) 
 
Concentrated sulfuric acid (1 mL) was added to a solution of 2,3,5-
trimethylhydroquinone (1.009 g, 6.631 mmol) and 3,3-dimethylacrylic acid 
(0.711 g, 7.102 mmol) in toluene (20 mL) and the solution refluxed for 1h. 
The mixture was cooled to room temperature and quenched dropwise with 
sat. NaHCO3. The organic layer was separated and washed with sat. 
NaHCO3 (3x 20 mL) and H2O (3x 20 mL). The organic layer was dried over 
MgSO4, filtered and the solvent removed under reduced pressure and the 
product purified by flash chromatography (40 % ethyl acetate/hexanes) to 
give 214 as white crystalline solid in 38 % yield (588 mg, 2.512 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.45 (s, 6H), 2.18 (s, 3H), 2.21 (s, 3H), 
2.35 (s, 3H), 2.54 (s, 2H), 4.66 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.4, 12.7, 14.5, 27.8, 35.6, 46.22, 119.0, 
121.9, 123.5, 128.3, 143.6, 148.9, 168.9 
Spectral data consistent with data reported in the literature.135 
2,2-dimethyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-
yl)propanoic acid (216) 
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N-Bromosuccinimide (359 mg, 2.014 mmol) in acetonitrile (5 mL) was added 
dropwise to a solution of 214 (456.6 mg, 1.949 mmol) in 10% aqueous 
acetonitrile (25 mL) and the mixture left stirring at room temperature for 1 h. 
The mixture was extracted with ethyl acetate (3 x 20 mL) and the organic 
extract washed with brine (3 x 20 mL) and H2O (3 x 20 mL). The organic 
layer was dried over MgSO4, filtered and the solvent removed under reduced 
pressure and the product recrystallized from acetone/hexane to give 216 as a 
bright yellow crystalline solid in 98 % yield (476 mg, 1.901 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.36 (s, 6H), 1.85 (s, 3H), 1.87 (s, 3H), 
2.06 (s, 3H), 2.94 (s, 2H), 10.90 (bs, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.0, 12.4, 14.2, 28.7, 37.9, 47.2, 138.3, 
138.9, 142.9, 152.0, 178.8, 187.4, 190.8 
Spectral data consistent with data reported in the literature.135 
2-Methyl-1,4-dihydronaphthalene-1,4-diol (217) 
  
To a solution of menadione (12) (204 mg, 1.187 mmol) in diethyl ether (20 
mL) under an atmosphere of nitrogen, 10 % w/v aqueous solution of sodium 
dithionite (20 mL) was added and the reaction mixture stirred vigorously for 2 
h. The reaction mixture was separated and extracted with ethyl acetate (3 x 
20 mL) and the organic extracts were combined and washed with brine (3x 
20 mL). The organic layer was dried over MgSO4, filtered and the solvent 
removed under reduced pressure to give the pure product 217 as a purple 
solid in quantitative yield (205 mg, 1.164 mmol). 
1H NMR δ (MeOD, 400 MHz):  2.33 (s, 3H), 6.63 (s, 1H), 7.31 – 7.34 (m, 
1H), 7.39 (dt, J = 8.3, 1.2 Hz, 1H), 8.08 (t, J 
= 7.2 Hz, 2H) 
13C NMR δ (MeOD, 100 MHz):  16.5, 112.0, 120.4, 122.4, 122.9, 124.7, 
125.6, 128.3, 143.1, 147.5 
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Spectral data consistent with data reported in the literature.137,157 
4-ethoxy-2,2-dimethyl-4-oxobutanoic acid (220) 
 
A solution of 2,2-Dimethylsuccinic anhydride (219) (605 mg, 4.713 mmol) in 
ethanol (5 mL) was heated at 50 °C for 16 h. The solvent was removed under 
reduced pressure to give the pure product 220 as a clear crystalline solid in 
96 % yield (792 mg, 4.547 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.16 (t, J = 7.2 Hz, 3H), 1.22 (s, 6H), 2.53 
(s, 2H), 4.05 (q, J = 7.2 Hz, 2H) 
13C NMR δ (CDCl3, 100 MHz):  14.0, 25.1, 40.4, 44.1, 60.5,171.2, 183.3 
2,3-Dimethoxy-5-methyl-p-hydroquinone (222) 
 
To a solution of 2,3-Dimethoxy-5-methyl-p-benzoquinone (6) (290 mg, 1.593 
mmol) in diethyl ether (3 mL) was added a solution of sodium borohydride 
(323.9 mg, 8.562 mmol) in H2O (6 mL). The bi-phasic mixture was stirred 
vigorously for 10min before diluting with H2O (10 mL) and extracted with 
diethyl ether (3 x 10 mL). The organic extract was washed with H2O (3 x 10 
mL) and the organic layer was dried over MgSO4, filtered and the solvent 
removed under reduced pressure to give the crude product which was 
purified by flash chromatography (30 % ethyl acetate/hexanes) to give 222 as 
a white solid in 54 % yield (157 g, 0.8529 mol). 
1H NMR δ (CDCl3, 400 MHz):  2.17 (s, 3H), 3.87 (s, 3H), 3.90 (s, 3H), 
5.44 (s, 1H), 5.51 (s, 1H), 6.48 (s, 1H) 
13C NMR δ (CDCl3, 100 MHz):  15.4, 60.8, 60.9, 111.5, 119.5, 137.6, 
139.2, 140.4, 141.6 
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Spectral data consistent with data reported in the literature.140 
6-hydroxy-7,8-dimethoxy-4,4,5-trimethylchroman-2-one (223) 
 
Concentrated sulfuric acid (0.5 mL) was added to a solution of 2,3,-
dimethoxy-5-methylhydroquinone (222) (298 mg, 1.598 mmol) and 3,3-
dimethylacrylic acid (243 mg, 2.431 mmol) in toluene (5 mL) and the solution 
refluxed for 1h. The mixture was cooled to room temperature and quenched 
dropwise with sat. NaHCO3. The organic layer was separated and washed 
with sat. NaHCO3 (3x 10 mL) and H2O (3x 10 mL). The organic layer was 
dried over MgSO4, filtered and the solvent removed under reduced pressure 
and the product purified by flash chromatography (40 % ethyl 
acetate/hexanes) followed by recrystallizationfrom 5% ethyl acetate/hexanes 
to give 223 as white crystalline solid in 20 % yield (83 mg, 0.3124 mmol) with 
a melting point of 109 – 111 °C. 
1H NMR δ (CDCl3, 400 MHz):  1.44 (s, 6H), 2.32 (s, 3H), 2.56 (s, 2H), 
3.89 (s, 3H), 3.96 (s, 3H), 5.75 (s, 1H) 
13C NMR δ (CDCl3, 100 MHz):  13.8, 27.8, 35.9, 46.0, 61.3, 61.6, 116.4, 
126.5, 138.4, 138.5, 138.7, 144.0, 167.8 
IR Vmax:  3419 (-OH), 2969, 2945, 1767 (C=O), 
1489, 1418, 1357, 1238, 1113, 1083, 1028, 
681 cm-1 
3-(4,5-Dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-3-
methylbutanoic acid (224) 
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N-Bromosuccinimide (149 mg, 0.8394 mmol) in acetonitrile (2 mL) was 
added dropwise to a solution of 223 (141 mg, 0.5287 mmol) in 10% aqueous 
acetonitrile (10 mL) and the mixture immediately quenched with ethyl acetate 
(20 mL) and H2O (20 mL). The mixture was separated and the aqueous 
extracted with ethyl acetate (2x 20 mL) and the organic extract washed with 
brine (3x 20 mL) and H2O (3x 20 mL). The organic layer was dried over 
MgSO4, filtered and the solvent removed under reduced pressure and the 
product recrystallized from acetone/hexane to give 224 as a bright yellow oil 
in 18 % yield (27 mg, 0.0956 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.44 (s, 6H), 2.14 (s, 3H), 3.05 (s, 2H), 
3.89 (s, 3H), 3.96 (s, 3H) 
13C NMR δ (CDCl3, 100 MHz):  14.1, 29.0, 38.32, 47.31, 60.5, 60.9, 137.7, 
142.5, 145.4, 149.9, 177.8, 184.5, 186.4 
IR Vmax:  3404 (-OH), 2969, 2955, 1711 (C=O), 1684 
(C=O), 1596, 1457, 1309, 1233, 1197, 
1112, 1026, 736 cm-1 
Spectral data consistent with data reported in the literature.84 
 (S)-N-(1-hydroxy-3-phenylpropan-2-yl)-3-methyl-3-(2,4,5-trimethyl-3,6-
dioxocyclohexa-1,4-dien-1-yl)butanamide (231) 
 
231 was prepared according to general procedure B from 216 (75 mg, 
0.2993 mmol) and L-phenylalaninol (298 mg, 1.971 mmol) and the product 
purified by flash chromatography (70 % ethyl acetate/hexane) to give 231 as 
yellow oil in 35 % yield (40 mg, 0.1037 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.32 (s, 3H), 1.38 (s, 3H), 1.94 (6H), 2.09 
(s, 3H), 2.72 – 2.86 (m, 4H), 3.51 (dd, J = 
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11.0, 5.0 Hz, 1H), 3.59 (dd, J = 11.0, 3.6 
Hz, 1H), 4.05 – 4.10 (m, 1H), 5.63 (d, J = 
7.7 Hz, 1H), 7.14 – 7.22 (m, 3H), 7.27 – 
7.29 (m, 2H) 
13C NMR δ (CDCl3, 100 MHz):  12.2, 12.8, 14.2, 29.0, 37.0, 38.3, 49.3, 
52.6, 64.4, 126.8, 128.7, 129.2, 137.6, 
138.1, 138.2, 143.5, 153.1, 172.6, 187.6, 
191.4 
[α]D20:     +15.87º (c 0.31, CHCl3) 
IR Vmax:  3367 (N-H), 2926, 1639 (C=O), 1538,1454, 
1372, 1280, 1222, 1041, 736, 701 cm-1 
 (S)-N-(2-hydroxy-1-phenylethyl)-3-methyl-3-(2,4,5-trimethyl-3,6-
dioxocyclohexa-1,4-dien-1-yl)butanamide (230) 
 
230 was prepared according to general procedure B from 216 (126 mg, 
0.5030 mmol) and S-phenyl glycinol (100 mg, 0.7261 mmol) and the product 
purified by flash chromatography (70 % ethyl acetate/hexane) to give 230 as 
yellow oil in 38 % yield (70 mg, 0.1905 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.39 (s, 3H), 1.44 (s, 3H), 1.83 (d, J = 1.1 
Hz, 3H), 1.89 (d, J = 1.1 Hz, 3H), 2.08 (s, 
3H), 2.60 (bs, 1H), 2.83 (d, J = 15.1 Hz, 
1H), 2.94 (d, J = 15.1 Hz, 1H), 3.77 (d, J = 
4.9 Hz, 2H), 4.90 – 4.95 (m, 1H), 6.15 (d, J 
= 7.2 Hz, 1H), 7.18 – 7.31 (m, 5H) 
13C NMR δ (CDCl3, 100 MHz):  12.2, 12.6, 14.2, 29.3, 38.6, 49.3, 55.5, 
66.4, 126.7, 127.8, 128.8, 138.2, 138.3, 
139.0, 143.3, 152.9, 172.4, 187.6, 191.5 
O
O
N
H
O
OH
Chapter	6:	Experimental	Details	
	240	
[α]D20:     +106.10º (c 1.64, CHCl3) 
IR Vmax:  3366 (N-H), 2925, 1708 (C=O), 1641 
(C=O), 1530, 1372, 1281, 1222, 1044, 701 
cm-1 
2-(4-(1H-imidazol-1-yl)-2-methyl-4-oxobutan-2-yl)-3,5,6-
trimethylcyclohexa-2,5-diene-1,4-dione 
 
Carbonyl diimidazole (101 mg, 0.6223 mmol) was added to a solution of 216 
(116 mg, 0.4647 mmol) in CH2Cl2 (3 mL) under an atmosphere of N2. The 
mixture was stirred for 0.5 h at room temperature before being diluted with 
CH2Cl2 (20 mL). The organic layer was washed with H2O (3 x 20 mL) and the 
organic layer was dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the pure product 237 as a yellow solid in 
quantitative yield (135 mg, 0.4505 mmol) 
1H NMR δ (CDCl3, 400 MHz):  1.49 (s, 6H), 1.84 (s, 3H), 1.94 (s, 3H), 
2.17 (s, 3H), 3.57 (s, 2H), 7.03 (s, 1H), 
7.39 (s, 1H), 8.11 (s, 1H)  
6.4.2 Synthesis of dye fragments 
4-Azido-1,8-naphthalic Anhydride (227) 
 
Sodium azide (253 mg, 3.892 mmol) in H2O (0.5 mL) was added to a solution 
of 4-bromo-1,8-naphthalic anhydride (226) (798 mg, 2.8783 mmol) in DMF (5 
mL) and the mixture heated to 100 °C for 0.5 h. The reaction mixture was 
taken of the heat and solution poured into ice – cold water (75 mL) and a 
N
OO
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brown precipitate filtered and washed with H2O (3 x 30 mL). The brown solid 
was identified to be the pure product 227 in 72 % yield (496 mg, 2.072 
mmol). Used without further purification. 
1H NMR δ (CDCl3, 400 MHz):  7.53 (d, J = 8.0 Hz, 1H), 7.81 (t, J = 8.0 Hz, 
1H), 8.55 (d, J = 8.5 Hz, 1H), 8.61 (d, J = 
8.0 Hz, 1H), 8.66 (d, J = 7.4 Hz, 1H) 
4-Amino-1,8-naphthalic Anhydride (228) 
 
10% Pd/C was added to a solution of 4-Azido-1,8-naphthalic anhydride (227) 
(496 mg, 2.072 mmol) in anhydrous DMF (5 mL) under an atmosphere of 
hydrogen. The mixture was stirred at room temperature for 23 h and filtered 
through a bed of celite and the solution added to H2O (100 mL). The mixture 
was extracted with ethyl acetate (3 x 20 mL) and CH2Cl2 (3 x 20 mL) and the 
organic layer was dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the product 228 as a beige solid in 33 % yield (147 
mg, 0.6909 mmol). Used without further purification. 
1H NMR δ (Acetone-D6, 400 MHz): 7.04 (d, J = 8.0 Hz, 1H), 7.08 (bs, 2H), 
7.74 (dd, J = 8.2, 7.5 Hz, 1H), 8.28 (d, J = 
8.4 Hz, 1H), 8.51 (d, J = 7.4 Hz, 1H), 8.68 
(d, J = 8.3 Hz, 1H) 
6-Amino-2-butyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (229) 
 
OO O
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N-Butylamine (74 mL mg, 1.012 mmol) was added dropwise to a solution of 
4-amino-1,8-naphthalic anhydride 228 (68 mg, 0.3194 mmol) in ethanol (5 
mL) at reflux. The mixture was refluxed for 16 h and the solvent removed 
under reduced pressure to give the crude product, which was purified by 
flash chromatography (60 % ethyl acetate/hexanes) to give 229 as dark 
yellow solid in 82 % yield (70 mg, 0.2620 mmol). 
1H NMR δ (Acetone-D6, 400 MHz): 0.95 (t, J = 7.6 Hz, 3H), 1.40 (sextet, J = 
7.6 Hz, 2H), 1.66 (quin, J = 7.6 Hz, 2H), 
4.09 (t, J = 7.6 Hz, 2H), 6.70 (bs, 2H), 6.97 
(d, J = 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 7.3, 
Hz, 1H), 8.18 (d, J = 8.3 Hz, 1H), 8.49 (dd, 
J = 7.3, 1.0 Hz, 1H), 8.55 (dd, J = 8.3, 1.0 
Hz, 1H) 
1H NMR δ (Acetone-D6, 150 MHz): 14.2, 21.0, 31.1, 40.1, 109.4, 110.8, 
120.9, 123.8, 125.1, 129.1, 130.9, 131.7, 
134.5, 152.7, 164.2, 164.9 
Spectral data consistent with data reported in the literature.134,142 
6-Azido-2-butyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (232) 
 
Butylamine (74 mg, 1.012 mmol) was added dropwise to a solution of 4-
azido-1,8-naphthalic anhydride (227) (234 mg, 1.096 mmol) in ethanol (10 
mL) at reflux. The mixture was refluxed for 16 h and the solvent removed 
under reduced pressure to give the crude product, which was purified by 
flash chromatography (30 % ethyl acetate/hexanes) to give 232 as dark 
yellow solid in 22 % yield (72 mg, 0.2436 mmol). 
NO O
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1H NMR δ (CDCl3, 400 MHz):  0.97 (t, J = 7.5 Hz, 3H), 1.44 (sextet, J = 
7.5 Hz, 2H), 1.71 (quin, J = 7.5 Hz, 2H), 
4.16 (t, J = 7.5 Hz, 2H), 7.45 (d, J = 8.0 Hz, 
1H), 7.72 (dd, J = 8.4, 7.4 Hz, 1H), 8.41 
(dd, J = 8.4, 1.0 Hz, 1H), 8.56 (d, J = 8.0 
Hz, 1H), 8.61 (dd, J = 7.4, 1.0 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  13.9, 20.5, 30.3, 40.4, 114.7, 119.1, 122.8, 
124.4, 126.9, 128.8, 129.2, 131.7, 132.2, 
143.4, 163.7, 164.1 
IR Vmax:  2958, 2127 (-N3), 1699 (C=O), 1658 
(C=O), 1581, 1386, 1354, 1288, 1234, 781 
cm-1 
Spectral data consistent with data reported in the literature.144 
1,8-naphthalimide-based iminophosphorane (233) 
 
A solution of triphenylphosphine (24 mg, 0.0919 mmol) in dichloromethane 
(1.5 mL) was added dropwise to a solution of N-butyl-4-azido-1,8-
naphthalamide 232 (21 mg, 0.0724 mmol) and 2,2-dimethyl-3-(2,4,5-
trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)propanoic acid 216 (25 mg, 
0.0991 mmol) in dichloromethane (2 mL) at 0 °C under an atmosphere of 
nitrogen. The mixture was stirred at room temperature for 16 h and the 
solvent removed under reduced pressure to give the crude product, which 
was purified by flash chromatography (40 % ethyl acetate/hexanes) to give 
233 as dark yellow oil in 67 % yield (26 mg, 0.0486 mmol). 
NO O
N
P
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1H NMR δ (CDCl3, 400 MHz):  0.94 (t, J = 7.4 Hz, 3H), 1.42 (sextet, J = 
7.4 Hz, 2H), 1.67 (quin, J = 7.4 Hz, 2H), 
4.13 (t, J = 7.4 Hz, 2 H), 6.44 (d, J = 8.3 
Hz, 1H), 7.50 – 7.53 (m, 6H), 7,58 – 7.64 
(m, 4H), 7.78 – 7.83 (m, 6H), 8.08 (d, J = 
8.3 Hz, 1H), 8.56 (d, J = 7.3 Hz, 1H), 9.14 
(d, J = 8.3 Hz, 1H)  
Note: Spectral data consistent with data reported in the literature.145 
6-Bromo-2-butyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (235) 
 
N-Butylamine (148 mg, 2.023 mmol) was added dropwise to a solution of 4-
bromo-1,8-naphthalic anhydride (226) (303 mg, 1.095 mmol) in ethanol (10 
mL) at reflux. The mixture was refluxed for 16 h and the solvent removed 
under reduced pressure to give the crude product, which was purified by 
flash chromatography (20 % ethyl acetate/hexanes) to give 235 as white 
crystalline solid in 78 % yield (309 mg, 0.9314 mmol). 
1H NMR δ (CDCl3, 400 MHz):  1.00 (t, J = 7.5 Hz, 3H), 1.47 (sextet, J = 
7.5 Hz, 2H), 1.70 – 1.77 (m, 2H), 4.20 (t, J 
= 7.5 Hz, 2H), 7.87 (dd, J = 8.5, 7.4 Hz, 
1H), 8.06 (d, J = 7.8 Hz, 1H), 8.44 (d, J = 
7.8 Hz, 1H), 8.59 (dd, J = 8.5, 1.0 Hz, 1H), 
8.68 (dd, J = 7.4, 1.0 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  13.9, 20.5, 30.2, 40.5, 122.4, 123.2, 128.1, 
129.1, 130.3, 131.1, 131.2, 132.1, 133.2, 
163.70, 163.72 
NO O
Br
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Spectral data consistent with data reported in the literature.146 
6-((2-aminoethyl)amino)-2-butyl-1H-benzo[de]isoquinoline-1,3(2H)-dione 
(239) 
 
N-Butyl-4-bromo-1,8-naphthalamide 235 (124 mg, 0.3727 mmol), 
ethylenediamine (0.25 mL, 3.744 mmol) and CuSO45H2O (30 mg, 0.1201 
mmol) were refluxed in methoxyethanol (4 mL) for 1.5 h. The mixture was 
poured into cold water resulting in a yellow solid forming which was filtered 
and purified by flash chromatography (10 % (95:5 methanol:ammonia)/ethyl 
acetate) to give 239 as red solid in 52 % yield (60 mg, 0.1923 mmol). 
1H NMR δ (CDCl3, 400 MHz):  0.99 (t, J = 7.4 Hz, 3H), 1.46 (sextet, J = 
7.4 Hz, 2H), 1.73 (quin, J = 7.4 Hz, 2H), 
3.20 (t, J = 5.6 Hz, 2H), 3.55 (q, J = 5.6 Hz, 
2H), 4.18 (t, J = 7.4 Hz, 2H), 6.16 (bs, 1H), 
6.73 (d, J = 8.4 Hz, 1H), 7.64 (t, J = 7.8 Hz, 
1H), 8.19 (d, J = 8.4 Hz, 1H), 8.48 (d, J = 
8.4 Hz, 1H), 8.61 (d, J = 7.8 Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  13.9, 20.5, 30.4, 40.0, 40.2, 45.0, 104.3, 
110.1, 120.4, 122.9, 124.6, 126.3, 129.7, 
131.0, 134.4, 149.7, 164.2, 164.7 
Spectral data consistent with data reported in the literature.146 
 
 
NO O
NH
H2N
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6.4.3 Coupling of Dye to Quinone 
N-(2-((2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-
yl)amino)ethyl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-
1-yl)butanamide (238) 
 
238 was prepared according to general procedure B from 216 (47 mg, 
0.1870 mmol) and 239 (47 mg, 0.1522 mmol) and the product purified by 
flash chromatography (80 % ethyl acetate/hexane) to give 238 as yellow oil in 
86 % yield (71 mg, 0.1304 mmol). 
1H NMR δ (CDCl3, 400 MHz):  0.96 (t, J = 7.5 Hz, 3H), 1.39 – 1.48 (m, 
8H), 166 – 1.73 (m, 5H), 1.82 (s, 3H), 2.05 
(s, 3H), 2.92 (s, 2H), 3.36 (t, J = 5.6 Hz, 
2H), 3.65 (q, J = 5.6 Hz, 2H), 4.15 (t, J = 
7.5 Hz, 2H), 6.22 (t, J = 5.8 Hz, 1H), 6.45 
(d, J = 8.4 Hz, 1H), 7.03 (bs, 1H), 7.39 (t, J 
= 7.5 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 
8.38 (d, J = 8.4 Hz, 1H), 8.53 (d, J = 7.5 
Hz, 1H) 
13C NMR δ (CDCl3, 100 MHz):  12.1, 12.7, 14.0, 14.4, 20.5, 29.6, 30.4, 
38.90, 38.98, 40.1, 46.8, 49.6, 103.4, 
110.2, 120.3, 123.0, 124.8, 126.8, 128.9, 
131.3, 134.5, 138.7, 139.2, 142.8, 149.8, 
152.2, 164.4, 164.7, 175.5, 187.2, 191.1 
N
H
OO
O
NH
N OO
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IR Vmax:  3312 (N-H), 2935, 1678 (C=O), 1629, 
1582, 1398, 1362, 1274, 1243, 1126, 774 
cm-1 
HRESIMS [M+Na]:  For C32H37N3O5Na, predicted 566.2631, 
found 566.2646 
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Appendix I: Redox Properties 
 
reduction 
potential 
oxidation 
potential 
Δ oxid.-
reduc. 
Idebenone 11 -0.71 -0.64 -0.08 
Menadione 12 -0.74 -0.66 -0.08 
13 -0.85 -0.77 -0.08 
14 -0.85 -0.77 -0.08 
16 -0.85 -0.77 -0.08 
17 -0.84 -0.77 -0.07 
18 -0.87 -0.78 -0.09 
20 -0.81 -0.73 -0.08 
21 -0.82 -0.76 -0.06 
22 -0.76 -0.68 -0.08 
23 -0.83 -0.73 -0.10 
24 -0.84 -0.76 -0.08 
25 -0.86 -0.77 -0.08 
26 -0.77 -0.71 -0.07 
27 -0.86 -0.77 -0.09 
28 -0.83 -0.77 -0.06 
29 -0.80 -0.73 -0.08 
31 -0.79 -0.18 -0.61 
32 -0.69 -0.10 -0.59 
33 -0.81 -0.74 -0.07 
34 -0.84 -0.77 -0.06 
35 -0.83 -0.76 -0.07 
36 -0.80 -0.73 -0.07 
37 -0.81 -0.73 -0.08 
38 -0.81 -0.74 -0.07 
40 -0.77 -0.70 -0.07 
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Appendix II: Biological Experimental 
Protection against mitochondrial dysfunction 
Cytoprotection against mitochondrial dysfunction was measured as 
previously described [20]. Briefly, 5,000 cells per well were incubated with 
quinones (10 µM) in a 96 well plate for 2 days prior to being challenged by 
the mitochondrial complex I inhibitor rotenone (1 µM) for 6 hours. After post 
incubation with only quinones for 24h, cell viability was quantified by 
analysing ATP content per well using a luciferase-based reaction. 
Cytoprotection is displayed as a percentage of the untreated (no rotenone) 
control. Data represent the average of 3 independent experiments with n=6 
wells within each experiment. Error bars = SD.  
Acute rescue of ATP levels 
Acute rescue of ATP levels in the presence of a mitochondrial inhibitor was 
measured as previously described [Erb et al. 2012]. Briefly, 15,000 cells per 
well were seeded in a 96 well plate and allowed to attach overnight. After 
24h, cells were incubated with quinones (10 µM) along with the mitochondrial 
complex I inhibitor rotenone (10 µM) for 1 hour in glucose-free growth media 
before immediately measuring ATP levels using a luciferase-based reaction. 
Acute rescue of ATP levels is displayed as a percentage of the untreated (no 
rotenone) control. Data represent the average of 3 independent experiments 
with n=6 wells within each experiment. Error bars = SD. 
 
 
